Eventually    O
,    O
the    O
body    O
undergoes    O
physiological    O
changes    O
such    O
as    O
lower    O
lactate    O
production    O
(    O
because    O
reduced    O
glucose    O
breakdown    O
decreases    O
the    O
amount    O
of    O
lactate    O
formed    O
)    O
,    O
decreased    O
plasma    O
volume    O
,    O
increased    O
hematocrit    O
(    O
polycythemia    O
)    O
,    O
increased    O
RBC    O
mass    O
,    O
a    O
higher    O
concentration    O
of    O
capillaries    O
in    O
skeletal    O
muscle    O
tissue    O
,    O
increased    O
myoglobin    O
,    O
increased    O
mitochondria    O
,    O
increased    O
aerobic    O
enzyme    O
concentration    O
,    O
increase    O
in    O
2,3-BPG    B-Organophosphate114969994
,    O
hypoxic    O
pulmonary    O
vasoconstriction    O
,    O
and    O
right    O
ventricular    O
hypertrophy    O
.    O

2,3-bisphosphoglyceric    B-Organophosphate114969994
acid    I-Organophosphate114969994
(    O
adaptation    O
to    O
chronic    O
hypoxia    O
)    O

Since    O
the    O
discovery    O
of    O
its    O
activity    O
in    O
plants    O
,    O
it    O
has    O
been    O
purified    O
within    O
human    O
cells    O
and    O
implicated    O
in    O
2,3-DPG    B-Organophosphate114969994
regulation    O
.    O

The    O
implication    O
of    O
phosphoglycolate    O
phosphatase    O
â€™s    O
role    O
in    O
human    O
red    O
blood    O
cells    O
was    O
discovered    O
when    O
its    O
substrate    O
,    O
phosphoglycolate    O
,    O
was    O
shown    O
to    O
be    O
a    O
potent    O
activator    O
of    O
the    O
enzyme    O
2,3-bisphosphoglycerate    O
phosphatase(2,3-DPG    O
)    O
,    O
another    O
hydrolase    O
which    O
catalyzes    O
the    O
metabolic    O
reaction    O
of    O
2,3-bisphosphoglycerate    B-Organophosphate114969994
to    O
3-phosphoglycerate    O
.    O

Increased    O
affinity    O
for    O
oxygen    O
in    O
the    O
blood    O
caused    O
by    O
decreased    O
production    O
of    O
2,3-BPG    B-Organophosphate114969994
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
ATP    O
and    O
undecaprenol    O
,    O
whereas    O
its    O
two    O
products    O
are    O
ADP    O
and    O
undecaprenyl    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
UDP    O
-    O
galactose    O
and    O
undecaprenyl    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
,    O
whereas    O
its    O
two    O
products    O
are    O
UMP    O
and    O
alpha    O
-    O
D    O
-    O
galactosyl    O
-    O
diphosphoundecaprenol    O
.    O

inositol    B-Organophosphate114969994
pentakisphosphate    I-Organophosphate114969994

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl-CoA    B-Organophosphate114969994
and    O
monoterpenol    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    B-Organophosphate114969994
and    O
monoterpenol    O
acetate    O
ester    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl-CoA    B-Organophosphate114969994
and    O
N6-hydroxy    O
-    O
L    O
-    O
lysine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    B-Organophosphate114969994
and    O
N6-acetyl    O
-    O
N6-hydroxy    O
-    O
L    O
-    O
lysine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl-CoA    B-Organophosphate114969994
and    O
N    O
-    O
acetylneuraminate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    B-Organophosphate114969994
and    O
N    O
-    O
acetyl-4-O    O
-    O
acetylneuraminate    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl-CoA    B-Organophosphate114969994
and    O
N    O
-    O
acetylneuraminate    O
,    O
whereas    O
its    O
3    O
products    O
are    O
CoA    B-Organophosphate114969994
,    O
N    O
-    O
acetyl-7-O    O
-    O
acetylneuraminate    O
,    O
and    O
N    O
-    O
acetyl-9-O    O
-    O
acetylneuraminate    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl-CoA    B-Organophosphate114969994
and    O
N    O
-    O
hydroxyarylamine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    B-Organophosphate114969994
and    O
N    O
-    O
acetoxyarylamine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl-CoA    B-Organophosphate114969994
and    O
peptide    O
,    O
whereas    O
its    O
two    O
products    O
are    O
Nalpha    O
-    O
acetylpeptide    O
and    O
CoA    B-Organophosphate114969994

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl-CoA    B-Organophosphate114969994
and    O
L    O
-    O
phenylalanine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    B-Organophosphate114969994
and    O
N    O
-    O
acetyl    O
-    O
L    O
-    O
phenylalanine    O
.    O

The    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl-CoA    B-Organophosphate114969994
and    O
phosphate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    B-Organophosphate114969994
and    O
acetyl    O
phosphate    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl-CoA    B-Organophosphate114969994
and    O
alpha-2,8-linked    O
polymer    O
of    O
sialic    O
acid    O
,    O
whereas    O
its    O
3    O
products    O
are    O
CoA    B-Organophosphate114969994
,    O
polysialic    O
acid    O
acetylated    O
on    O
O-7    O
,    O
and    O
polysialic    O
acid    O
acetylated    O
on    O
O-9    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl-CoA    B-Organophosphate114969994
and    O
ribosomal    O
-    O
protein    O
L    O
-    O
alanine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    B-Organophosphate114969994
and    O
ribosomal    O
-    O
protein    O
N    O
-    O
acetyl    O
-    O
L    O
-    O
alanine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl-CoA    B-Organophosphate114969994
and    O
salutaridinol    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    B-Organophosphate114969994
and    O
7-O    O
-    O
acetylsalutaridinol    O
.    O

:    O
acetyl-CoA    B-Organophosphate114969994
+    O
L    O
-    O
serine    O
CoA    O
+    O
O    O
-    O
acetyl    O
-    O
L    O
-    O
serine    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl-CoA    B-Organophosphate114969994
and    O
L    O
-    O
serine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    B-Organophosphate114969994
and    O
O    O
-    O
acetyl    O
-    O
L    O
-    O
serine    O
.    O

More    O
specifically    O
,    O
its    O
role    O
is    O
to    O
catalyse    O
the    O
activation    O
of    O
L    O
-    O
serine    O
by    O
acetyl-CoA    B-Organophosphate114969994
entry    O
refers    O
to    O
the    O
N    O
-    O
terminus    O
of    O
the    O
protein    O
which    O
has    O
a    O
sequence    O
that    O
is    O
conserved    O
in    O
plants    O
and    O
bacteria    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl-CoA    B-Organophosphate114969994
and    O
taxa-4(20),11-dien-5alpha    O
-    O
ol    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    B-Organophosphate114969994
and    O
taxa-4(20),11-dien-5alpha    O
-    O
yl    O
acetate    O
.    O

The    O
3    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl-CoA    B-Organophosphate114969994
,    O
(    O
S)-2,3,4,5-tetrahydropyridine-2,6-dicarboxylate    O
,    O
and    O
H2O    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    B-Organophosphate114969994
and    O
L-2-acetamido-6-oxoheptanedioate    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl-CoA    B-Organophosphate114969994
and    O
2-aminoethanethiol    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    B-Organophosphate114969994
and    O
S-(2-aminoethyl)thioacetate    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl-CoA    B-Organophosphate114969994
and    O
16-epivellosimine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    B-Organophosphate114969994
and    O
vinorine    O
.    O

Arsenic    O
interferes    O
with    O
cellular    O
longevity    O
by    O
allosteric    O
inhibition    O
of    O
an    O
essential    O
metabolic    O
enzyme    O
pyruvate    O
dehydrogenase    O
(    O
PDH    O
)    O
complex    O
,    O
which    O
catalyzes    O
the    O
oxidation    O
of    O
pyruvate    O
to    O
acetyl-CoA    B-Organophosphate114969994
by    O
NAD+    O
.    O

PDH    O
is    O
a    O
precursor    O
of    O
acetyl-CoA    B-Organophosphate114969994
,    O
thus    O
the    O
inhibition    O
of    O
PDH    O
eventually    O
limits    O
the    O
production    O
of    O
ATP    O
in    O
electron    O
transport    O
chain    O
,    O
as    O
well    O
as    O
the    O
production    O
of    O
gluconeogenesis    O
intermediates    O
.    O

However    O
,    O
an    O
understanding    O
of    O
the    O
physiology    O
of    O
the    O
organism    O
would    O
have    O
revealed    O
that    O
due    O
to    O
an    O
incomplete    O
tricarboxylic    O
acid    O
pathway    O
,    O
"    O
Lactobacillus    O
plantarum    O
"    O
does    O
not    O
actually    O
produce    O
succinyl    O
-    O
CoA    O
,    O
and    O
the    O
correct    O
reactant    O
for    O
that    O
part    O
of    O
the    O
reaction    O
was    O
acetyl-CoA    B-Organophosphate114969994

In    O
contrast    O
the    O
"    O
Rhizobium    O
etli    O
"    O
,    O
tetramer    O
in    O
complex    O
with    O
ethyl    O
-    O
CoA    O
,    O
a    O
non    O
-    O
hydrolyzable    O
analog    O
of    O
acetyl-CoA    B-Organophosphate114969994
,    O
possesses    O
only    O
one    O
line    O
of    O
symmetry    O
.    O

In    O
most    O
species    O
,    O
this    O
reaction    O
requires    O
acetyl-CoA    B-Organophosphate114969994
as    O
an    O
allosteric    O
activator    O
binding    O
to    O
the    O
PT    O
domain    O
.    O

Next    O
,    O
a    O
series    O
of    O
condensation    O
reactions    O
of    O
three    O
acetate    O
units    O
from    O
malonyl    O
-    O
CoA    O
occurs    O
,    O
each    O
proceeding    O
through    O
an    O
acetyl-CoA    B-Organophosphate114969994
carbanion    O
derived    O
from    O
malonyl    O
-    O
CoA    O
decarboxylation    O
.    O

In    O
this    O
pathway    O
,    O
two    O
molecules    O
of    O
acetyl-CoA    B-Organophosphate114969994
undergo    O
a    O
condensation    O
reaction    O
to    O
give    O
acetoacetyl    O
-    O
CoA.    O
This    O
product    O
then    O
condenses    O
with    O
third    O
molecule    O
of    O
acetyl    O
-    O
CoA    O
in    O
a    O
stereospecific    O
fashion    O
to    O
form    O
3-hydroxy-3-methylglutaryl    O
-    O
CoA    O
(    O
HMG    O
-    O
CoA    O
)    O
which    O
then    O
is    O
reduced    O
to    O
mevalonic    O
acid    O
(    O
MVA    O
)    O
.    O

The    O
backbone    O
is    O
synthesized    O
through    O
the    O
addition    O
of    O
two    O
carbon    O
units    O
via    O
addition    O
of    O
acetate    O
units    O
from    O
acetyl-CoA    B-Organophosphate114969994
The    O
5    O
methyl    O
groups    O
are    O
added    O
via    O
S    O
-    O
adenosyl    O
methionine    O
(    O
SAM    O
)    O
methylation    O
,    O
as    O
opposed    O
to    O
incorporation    O
of    O
propionate    O
(    O
instead    O
of    O
acetate    O
)    O
to    O
the    O
growing    O
compound    O
during    O
biosynthesis    O
.    O

IPP    O
is    O
formed    O
from    O
acetyl-CoA    B-Organophosphate114969994
via    O
the    O
intermediacy    O
of    O
mevalonic    O
acid    O
in    O
the    O
HMG    O
-    O
CoA    O
reductase    O
pathway    O
.    O

The    O
pyruvate    O
is    O
then    O
converted    O
into    O
acetyl-CoA    B-Organophosphate114969994
so    O
that    O
it    O
can    O
enter    O
the    O
TCA    O
cycle    O
and    O
convert    O
the    O
original    O
pyruvate    O
molecules    O
into    O
ATP    O
,    O
or    O
usable    O
energy    O
for    O
the    O
organism    O
.    O

Each    O
pyruvate    O
goes    O
through    O
a    O
series    O
of    O
reactions    O
that    O
converts    O
it    O
to    O
acetyl    B-Organophosphate114969994
coenzyme    I-Organophosphate114969994
A    I-Organophosphate114969994

In    O
the    O
presence    O
of    O
air    O
and    O
various    O
cofactors    O
and    O
enzymes    O
,    O
fatty    O
acids    O
are    O
degraded    O
to    O
acetyl-CoA    B-Organophosphate114969994
The    O
pathway    O
is    O
called    O
beta    O
-    O
oxidation    O
.    O

Enoyl    O
-    O
CoA    O
hydratase    O
is    O
an    O
enzyme    O
that    O
hydrates    O
the    O
double    O
bond    O
between    O
the    O
second    O
and    O
third    O
carbons    O
on    O
acyl    O
-    O
CoA.    O
This    O
enzyme    O
,    O
also    O
known    O
as    O
crotonase    O
,    O
is    O
essential    O
to    O
metabolizing    O
fatty    O
acids    O
to    O
produce    O
both    O
acetyl    B-Organophosphate114969994
CoA    I-Organophosphate114969994
and    O
energy    O
.    O

ATP    O
citrate    O
lyase    O
is    O
the    O
primary    O
enzyme    O
responsible    O
for    O
the    O
synthesis    O
of    O
cytosolic    O
acetyl-CoA    B-Organophosphate114969994
in    O
many    O
tissues    O
.    O

ATP    O
-    O
citrate    O
lyase    O
is    O
responsible    O
for    O
catalyzing    O
the    O
conversion    O
of    O
citrate    O
and    O
CoA    B-Organophosphate114969994
into    O
acetyl-CoA    B-Organophosphate114969994
and    O
oxaloacetate    O
,    O
along    O
with    O
the    O
hydrolysis    O
of    O
ATP    O
.    O

In    O
the    O
presence    O
of    O
ATP    O
and    O
Coenzyme    B-Organophosphate114969994
A    I-Organophosphate114969994
,    O
citrate    O
lyase    O
catalyzes    O
the    O
cleavage    O
of    O
citrate    O
to    O
yield    O
acetyl    B-Organophosphate114969994
CoA    I-Organophosphate114969994
,    O
oxaloacetate    O
,    O
ADP    O
,    O
and    O
orthophosphate    O
:    O

:    O
citrate    O
+    O
ATP    O
+    O
CoA    O
+    O
H2O    O
â†’    O
oxaloacetate    O
+    O
Acetyl-CoA    B-Organophosphate114969994
+    O
ADP    O
+    O
Pi    O

The    O
first    O
three    O
steps    O
of    O
the    O
reaction    O
pathways    O
lead    O
from    O
ethanol    O
to    O
acetaldehyde    O
to    O
acetic    O
acid    O
to    O
acetyl-CoA    B-Organophosphate114969994
Once    O
acetyl    O
-    O
CoA    O
is    O
formed    O
,    O
it    O
is    O
free    O
to    O
enter    O
directly    O
into    O
the    O
citric    O
acid    O
cycle    O
.    O

Two    O
enzymes    O
are    O
associated    O
with    O
the    O
conversion    O
of    O
acetic    O
acid    O
to    O
acetyl-CoA    B-Organophosphate114969994
The    O
first    O
is    O
acyl    O
-    O
CoA    O
synthetase    O
short    O
-    O
chain    O
family    O
member    O
2    O
ACSS2    O
(    O
EC    O
6.2.1.1    O
)    O
.    O

It    O
is    O
created    O
from    O
acetyl-CoA    B-Organophosphate114969994
,    O
a    O
thioester    O
,    O
which    O
reacts    O
with    O
the    O
enolate    O
of    O
a    O
second    O
molecule    O
of    O
acetyl    O
-    O
CoA    O
in    O
a    O
Claisen    O
condensation    O
reaction    O
,    O
and    O
it    O
is    O
acted    O
upon    O
by    O
HMG    O
-    O
CoA    O
synthase    O
to    O
form    O
HMG    O
-    O
CoA.    O
During    O
the    O
metabolism    O
of    O
leucine    O
,    O
this    O
last    O
reaction    O
is    O
reversed    O
.    O

Thiolases    O
,    O
also    O
known    O
as    O
acetyl    O
-    O
coenzyme    O
A    O
acetyltransferases    O
(    O
ACAT    O
)    O
,    O
are    O
enzymes    O
which    O
convert    O
two    O
units    O
of    O
acetyl-CoA    B-Organophosphate114969994
to    O
acetoacetyl    O
CoA    O
in    O
the    O
mevalonate    O
pathway    O
.    O

This    O
gene    O
encodes    O
a    O
mitochondrially    O
localized    O
enzyme    O
that    O
catalyzes    O
the    O
reversible    O
formation    O
of    O
acetoacetyl    O
-    O
CoA    O
from    O
two    O
molecules    O
of    O
acetyl-CoA    B-Organophosphate114969994
The    O
ACAT1    O
enzyme    O
has    O
a    O
few    O
unique    O
properties    O
.    O

The    O
compound    O
undergoes    O
beta    O
oxidation    O
,    O
forming    O
one    O
or    O
more    O
molecules    O
of    O
acetyl-CoA    B-Organophosphate114969994
This    O
,    O
in    O
turn    O
,    O
enters    O
the    O
citric    O
acid    O
cycle    O
,    O
eventually    O
forming    O
several    O
molecules    O
of    O
ATP    O
.    O

Acetyl-CoA    B-Organophosphate114969994

The    O
complex    O
acts    O
to    O
convert    O
pyruvate    O
(    O
a    O
product    O
of    O
glycolysis    O
in    O
the    O
cytosol    O
)    O
to    O
acetyl-coA    B-Organophosphate114969994
,    O
which    O
is    O
then    O
oxidized    O
in    O
the    O
mitochondria    O
to    O
produce    O
energy    O
,    O
in    O
the    O
citric    O
acid    O
cycle    O
.    O

Pyruvate    O
dehydrogenase    O
kinase    O
is    O
activated    O
by    O
ATP    O
,    O
NADH    O
and    O
acetyl-CoA    B-Organophosphate114969994
It    O
is    O
inhibited    O
by    O
ADP    O
,    O
NAD+    O
,    O
CoA-SH    B-Organophosphate114969994
and    O
pyruvate    O
.    O

Processing    O
of    O
cholesterol    O
and    O
protein    O
gives    O
propionyl    O
-    O
CoA    O
that    O
is    O
converted    O
to    O
methylmalonyl-CoA    B-Organophosphate114969994
,    O
which    O
is    O
used    O
by    O
MUT    O
enzyme    O
to    O
make    O
succinyl-CoA    B-Organophosphate114969994
Vitamin    O
is    O
needed    O
to    O
prevent    O
anemia    O
,    O
since    O
making    O
porphyrin    O
and    O
heme    O
in    O
mitochondria    O
for    O
producing    O
hemoglobin    O
in    O
red    O
blood    O
cells    O
depends    O
on    O
succinyl-CoA    B-Organophosphate114969994
made    O
by    O
vitamin    O
.    O

The    O
4    O
substrates    O
of    O
this    O
enzyme    O
are    O
acyl    O
-    O
CoA    O
,    O
methylmalonyl-CoA    B-Organophosphate114969994
,    O
NADPH    O
,    O
and    O
H+    O
,    O
whereas    O
its    O
4    O
products    O
are    O
multi    O
-    O
methyl    O
-    O
branched    O
acyl    O
-    O
CoA    O
,    O
CoA    B-Organophosphate114969994
,    O
CO2    O
,    O
and    O
NADP+    O
.    O

D.    O
propionicus    O
"    O
uses    O
the    O
methylmalony-CoA    B-Organophosphate114969994
pathway    O
to    O
ferment    O
3    O
moles    O
of    O
pyruvate    O
to    O
2    O
moles    O
of    O
acetate    O
and    O
1    O
mole    O
of    O
propionate    O
.    O

PPT    O
attaches    O
the    O
4â€²-phosphopantetheine    B-Organophosphate114969994
prosthetic    I-Organophosphate114969994
group    I-Organophosphate114969994
of    O
CoA    O
to    O
the    O
acyl    O
carrier    O
protein    O
(    O
ACP    O
)    O
domain    O
,    O
which    O
is    O
found    O
in    O
the    O
N    O
terminus    O
of    O
the    O
Î±    O
subunit    O
.    O

Here    O
,    O
acetyltransferase    O
transfers    O
the    O
acetate    O
group    O
from    O
acetyl    O
-    O
CoA    O
onto    O
the    O
SH    O
group    O
of    O
the    O
4â€²-phosphopantetheine    B-Organophosphate114969994
prosthetic    O
group    O
of    O
ACP    O
,    O
which    O
had    O
been    O
attached    O
during    O
activation    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
ATP    O
and    O
4'-Phosphopantetheine    B-Organophosphate114969994
,    O
whereas    O
its    O
two    O
products    O
are    O
diphosphate    O
and    O
3'-dephospho    O
-    O
CoA.    O

PPADS    B-Organophosphate114969994
(    O
pyridoxalphosphate-6-azophenyl-2',4'-disulfonic    O
acid    O
)    O
is    O
a    O
selective    O
purinergic    O
P2X    O
antagonist    O
.    O

Colfosceril    B-Organophosphate114969994

Chlorfenvinfos    B-Organophosphate114969994

For    O
example    O
,    O
the    O
glycolytic    O
intermediate    O
1,3-bisphosphoglyceric    B-Organophosphate114969994
acid    I-Organophosphate114969994
has    O
a    O
half    O
-    O
life    O
of    O
27    O
minutes    O
"    O
in    O
vivo    O
"    O
.    O

1,3-Diphosphoglycerate    B-Organophosphate114969994

1,3-Diphosphoglyceric    B-Organophosphate114969994
acid    I-Organophosphate114969994

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
GTP    B-Organophosphate114969994
and    O
3-phospho-D-glycerate    B-Organophosphate114969994
,    O
whereas    O
its    O
two    O
products    O
are    O
GDP    B-Organophosphate114969994
and    O
3-phospho-D-glyceroyl    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
.    O

M    O
-    O
Ras    O
shares    O
a    O
similar    O
structure    O
with    O
H    O
-    O
Ras    O
and    O
Rap2A    O
with    O
the    O
exception    O
of    O
its    O
switch    O
1    O
conformation    O
when    O
bound    O
to    O
guanosine    O
5'-(beta    O
,    O
gamma    O
-    O
imido)triphosphate    O
(    O
Gpp(NH)p    B-Organophosphate114969994
)    O
.    O

Mannose-6    O
phosphate    O
isomerase    O
(    O
MPI    O
)    O
,    O
alternately    O
phosphomannose    O
isomerase    O
(    O
PMI    O
)    O
is    O
an    O
enzyme    O
which    O
facilitates    O
the    O
interconversion    O
of    O
fructose    B-Organophosphate114969994
6-phosphate    I-Organophosphate114969994
(    O
F6P    O
)    O
and    O
mannose-6-phosphate    B-Organophosphate114969994
(    O
M6P    O
)    O
.    O

The    O
heterotrophic    O
processing    O
of    O
carbohydrates    O
involves    O
isomerization    O
of    O
triose    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
and    O
interconversion    O
between    O
fructose-6-phosphate    B-Organophosphate114969994
and    O
glucose-6-phosphate    B-Organophosphate114969994
.    O

To    O
be    O
specific    O
,    O
glucosamine-6-phosphate    O
is    O
synthesized    O
from    O
fructose    B-Organophosphate114969994
6-phosphate    I-Organophosphate114969994
and    O
glutamine    O
as    O
the    O
first    O
step    O
of    O
the    O
hexosamine    O
biosynthesis    O
pathway    O
.    O

sedoheptulose    B-Organophosphate114969994
7-phosphate    I-Organophosphate114969994
+    O
glyceraldehyde    B-Organophosphate114969994
3-phosphate    I-Organophosphate114969994
erythrose    B-Organophosphate114969994
4-phosphate    I-Organophosphate114969994
+    O
fructose    B-Organophosphate114969994
6-phosphate    I-Organophosphate114969994

Then    O
transaldolase    O
catalyzes    O
the    O
condensation    O
of    O
glyceraldehyde-3-phosphate    B-Organophosphate114969994
with    O
the    O
Schiff    O
base    O
of    O
dihydroxyacetone    O
,    O
yielding    O
enzyme    O
-    O
bound    O
fructose    B-Organophosphate114969994
6-phosphate    I-Organophosphate114969994
.    O

Hydrolysis    O
of    O
the    O
Schiff    O
base    O
liberates    O
free    O
fructose    B-Organophosphate114969994
6-phosphate    I-Organophosphate114969994
,    O
one    O
of    O
the    O
products    O
of    O
the    O
pentose    O
phosphate    O
pathway    O
.    O

Ribulose    O
5-phosphate    O
can    O
alternatively    O
undergo    O
a    O
series    O
of    O
isomerizations    O
as    O
well    O
as    O
transaldolations    O
and    O
transketolations    O
that    O
result    O
in    O
the    O
production    O
of    O
other    O
pentose    O
phosphates    O
as    O
well    O
as    O
fructose    B-Organophosphate114969994
6-phosphate    I-Organophosphate114969994
and    O
glyceraldehyde    B-Organophosphate114969994
3-phosphate    I-Organophosphate114969994
(    O
both    O
intermediates    O
in    O
glycolysis    O
)    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
diisopropyl    O
fluorophosphate    O
and    O
H2O    O
,    O
whereas    O
its    O
two    O
products    O
are    O
diisopropyl    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
and    O
fluoride    O
.    O

In    O
the    O
first    O
step    O
of    O
galactose    O
metabolism    O
,    O
galactose    O
is    O
converted    O
to    O
galactose-1-phosphate    B-Organophosphate114969994
(    O
Gal-1-P    O
)    O
by    O
the    O
enzyme    O
galactokinase    O
.    O

Galactokinase    O
then    O
phosphorylates    O
Î±-D    O
-    O
galactose    O
at    O
the    O
1    O
'    O
hydroxyl    O
group    O
,    O
yielding    O
galactose-1-phosphate    B-Organophosphate114969994
.    O

"    O
Psilocybe    O
pelliculosa    O
"    O
contains    O
the    O
psychoactive    O
compounds    O
psilocybin    O
and    O
baeocystin    B-Organophosphate114969994
,    O
and    O
is    O
used    O
as    O
a    O
recreational    O
drug    O
.    O

Mildly    O
hallucinogenic    O
,    O
containing    O
psilocin    O
,    O
psilocybin    O
,    O
and    O
baeocystin    B-Organophosphate114969994
.    O

"    O
Pholiotina    O
cyanopus    O
"    O
is    O
hallucinogenic    O
,    O
containing    O
psilocin    O
,    O
psilocybin    O
,    O
baeocystin    B-Organophosphate114969994
,    O
norbaeocystin    B-Organophosphate114969994
and    O
aeruginascin    B-Organophosphate114969994
.    O

Protein    O
recognition    O
at    O
the    O
receptor    O
uses    O
cAMP    B-Organophosphate114969994
as    O
a    O
secondary    O
messenger    O
.    O

When    O
bound    O
,    O
the    O
receptor    O
couples    O
to    O
G    O
-    O
protein    O
alpha    O
subunit    O
,    O
activates    O
adenylyl    O
cyclase    O
,    O
and    O
increases    O
cAMP    B-Organophosphate114969994
production    O
.    O

During    O
ovulation    O
,    O
the    O
surge    O
in    O
luteinizing    O
hormone    O
increases    O
cAMP    B-Organophosphate114969994
which    O
increases    O
progesterone    O
and    O
PGF2Î±    O
production    O
.    O

Some    O
of    O
these    O
pathways    O
include    O
Rap    O
,    O
Erk1/2    O
,    O
MAPK    O
,    O
B    O
-    O
RAF    O
,    O
PI3-K    O
,    O
cAMP    B-Organophosphate114969994
,    O
PKA    O
,    O
and    O
TORC2    O
that    O
are    O
activated    O
to    O
initiate    O
exocytosis    O
,    O
proinsulin    O
gene    O
expression    O
and    O
translation    O
,    O
increase    O
insulin    O
biosynthesis    O
,    O
and    O
genetically    O
increase    O
beta    O
cell    O
proliferation    O
and    O
neogenesis    O
.    O

Prostaglandin    O
E1    O
(    O
PGE1    O
)    O
is    O
a    O
platelet    O
inhibitor    O
that    O
causes    O
an    O
increase    O
in    O
cyclic    B-Organophosphate114969994
adenosine    I-Organophosphate114969994
monophosphate    I-Organophosphate114969994
(    O
cAMP    O
)    O
in    O
platelets    O
by    O
stimulating    O
adenylyl    O
cyclase    O
activity    O
.    O

In    O
"    O
Dictyostelium    O
"    O
,    O
aggregation    O
is    O
signalled    O
by    O
cAMP    B-Organophosphate114969994
,    O
but    O
others    O
use    O
different    O
chemicals    O
.    O

The    O
mechanism    O
behind    O
the    O
aggregation    O
of    O
the    O
amoebae    O
relies    O
on    O
Cyclic    B-Organophosphate114969994
adenosine    I-Organophosphate114969994
monophosphate    I-Organophosphate114969994
(    O
cAMP    O
)    O
as    O
a    O
signal    O
molecule    O
.    O

By    O
comparison    O
,    O
"    O
N    O
"-    O
methyldopamine    O
also    O
had    O
no    O
effect    O
in    O
caudectomized    O
mice    O
at    O
â‰¤    O
150    O
mg    O
/    O
kg    O
,    O
and    O
only    O
a    O
weak    O
effect    O
in    O
nigral    O
-    O
lesioned    O
rats    O
at    O
25    O
mg    O
/    O
kg    O
,    O
although    O
it    O
was    O
as    O
effective    O
as    O
dopamine    O
in    O
stimulating    O
cAMP    B-Organophosphate114969994
in    O
the    O
adenylate    O
cyclase    O
assay    O
.    O

Upregulation    O
of    O
the    O
cyclic    B-Organophosphate114969994
adenosine    I-Organophosphate114969994
monophosphate    I-Organophosphate114969994
(    O
cAMP    O
)    O
signal    O
transduction    O
pathway    O
by    O
cAMP    O
response    O
element    O
binding    O
protein    O
(    O
CREB    O
)    O
,    O
a    O
gene    O
transcription    O
factor    O
,    O
in    O
the    O
nucleus    O
accumbens    O
is    O
a    O
common    O
mechanism    O
of    O
psychological    O
dependence    O
among    O
several    O
classes    O
of    O
drugs    O
of    O
abuse    O
.    O

When    O
stimulated    O
,    O
it    O
increases    O
cAMP    B-Organophosphate114969994
levels    O
,    O
in    O
turn    O
leading    O
to    O
CREB    O
activation    O
.    O

The    O
Î±    O
subunit    O
is    O
thought    O
to    O
be    O
the    O
effector    O
region    O
responsible    O
for    O
stimulation    O
of    O
adenylate    O
cyclase    O
(    O
involved    O
the    O
generation    O
of    O
cAMP    B-Organophosphate114969994
)    O
.    O

The    O
cyclic    O
nucleotide    O
phosphodiesterases    O
constitute    O
a    O
group    O
of    O
enzymes    O
that    O
destroy    O
the    O
cyclic    O
nucleotides    O
cyclic    B-Organophosphate114969994
adenosine    I-Organophosphate114969994
monophosphate    I-Organophosphate114969994
(    O
cAMP    O
)    O
and    O
cyclic    B-Organophosphate114969994
guanosine    I-Organophosphate114969994
monophosphate    I-Organophosphate114969994
(    O
cGMP    O
)    O
.    O

These    O
channels    O
are    O
also    O
sensitive    O
to    O
the    O
cyclic    O
nucleotides    O
cAMP    B-Organophosphate114969994
and    O
cGMP    B-Organophosphate114969994
,    O
which    O
alter    O
the    O
voltage    O
sensitivity    O
of    O
the    O
channel    O
â€™s    O
opening    O
.    O

Cyclic    O
nucleotide    O
-    O
gated    O
channels    O
:    O
This    O
family    O
of    O
channels    O
is    O
characterized    O
by    O
activation    O
by    O
either    O
intracellular    O
cAMP    B-Organophosphate114969994
or    O
cGMP    B-Organophosphate114969994
.    O

Transcription    O
of    O
the    O
"    O
lsr    O
"    O
operon    O
is    O
also    O
thought    O
to    O
be    O
inhibited    O
by    O
dihydroxyacetone    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
(    O
DHAP    O
)    O
through    O
its    O
competitive    O
binding    O
to    O
LsrR.    O
Glyceraldehyde    B-Organophosphate114969994
3-phosphate    I-Organophosphate114969994
has    O
also    O
been    O
shown    O
to    O
inhibit    O
the    O
"    O
lsr    O
"    O
operon    O
through    O
cAMP    B-Organophosphate114969994
-    O
CAPK    O
-    O
mediated    O
inhibition    O
.    O

The    O
following    O
table    O
gives    O
these    O
receptors    O
:    O
a    O
)    O
full    O
name    O
;    O
b    O
)    O
shortened    O
names    O
;    O
c    O
)    O
activating    O
prostanoids    O
(    O
presented    O
in    O
order    O
of    O
decreasing    O
potencies    O
)    O
;    O
d    O
)    O
time    O
-    O
honored    O
classification    O
as    O
contractile    O
(    O
i.e.    O
conracting    O
smooth    O
muscle    O
)    O
,    O
relaxant    O
(    O
i.e.    O
relaxing    O
smooth    O
muscle    O
)    O
,    O
or    O
inhibitory    O
(    O
i.e.    O
inhibiting    O
adenyl    O
cyclase    O
(    O
AC    O
)    O
production    O
of    O
cyclic    B-Organophosphate114969994
AMP    I-Organophosphate114969994
[    O
cAMP    O
]    O
)    O
;    O
e    O
)    O
G    O
proteins    O
types    O
to    O
which    O
they    O
link    O
and    O
activate    O
,    O
i.e.    O
those    O
containing    O
the    O
Gs    O
alpha    O
subunit    O
,    O
Gi    O
alpha    O
subunit    O
,    O
Gq    O
alpha    O
subunit    O
and/or    O
G12    O
subunit    O
;    O
and    O
f    O
)    O
signaling    O
pathways    O
which    O
they    O
regulate    O
including    O
Adenyl    O
cyclase    O
which    O
when    O
activated    O
increases    O
cellular    O
cAMP    B-Organophosphate114969994
and    O
when    O
inhibited    O
reduces    O
the    O
cellular    O
levels    O
of    O
this    O
secondary    O
messenger    O
;    O
Phosphoinositide    O
3-kinase    O
which    O
when    O
activated    O
is    O
responsible    O
for    O
forming    O
phosphatidylinositol    O
3-phosphate    O
,    O
phosphatidylinositol    O
(    O
3,4)-bisphosphate    O
,    O
and    O
phosphatidylinositol    O
(    O
3,4,5)-trisphosphate    O
secondary    O
messengers    O
;    O
Phospholipase    O
C    O
(    O
PLC    O
)    O
which    O
when    O
activated    O
is    O
responsible    O
for    O
forming    O
Inositol    B-Organophosphate114969994
trisphosphate    I-Organophosphate114969994
(    O
IP3    O
)    O
and    O
diacylglycerol    O
secondary    O
messengers    O
that    O
are    O
,    O
respectively    O
,    O
responsible    O
for    O
raising    O
the    O
levels    O
of    O
Ca2    O
+    O
in    O
the    O
cellular    O
cytosol    O
to    O
control    O
the    O
activity    O
of    O
Ca2    O
+    O
-cell    O
signaling    O
agents    O
and    O
for    O
activating    O
protein    O
kinase    O
C    O
(    O
PKC    O
)    O
secondary    O
messengers    O
;    O
and    O
Extracellular    O
signal    O
â€“    O
regulated    O
kinases    O
(    O
ERK    O
)    O
,    O
p38    O
mitogen    O
-    O
activated    O
protein    O
kinases    O
(    O
p38    O
Mpk    O
)    O
,    O
and    O
cAMP    O
response    O
element    O
-    O
binding    O
protein    O
(    O
CREB    O
)    O
which    O
when    O
activated    O
phosphorylate    O
and    O
thereby    O
influence    O
the    O
activity    O
of    O
key    O
proteins    O
that    O
govern    O
cell    O
function    O
.    O

First    O
isolated    O
as    O
a    O
nuclear    O
protein    O
that    O
binds    O
to    O
cAMP    B-Organophosphate114969994
-    O
response    O
element    O
-    O
binding    O
protein    O
(    O
CREB    O
)    O
,    O
this    O
gene    O
is    O
now    O
known    O
to    O
play    O
critical    O
roles    O
in    O
embryonic    O
development    O
,    O
growth    O
control    O
,    O
and    O
homeostasis    O
by    O
coupling    O
chromatin    O
remodeling    O
to    O
transcription    O
factor    O
recognition    O
.    O

This    O
leads    O
to    O
inhibition    O
of    O
adenylyl    O
cyclase    O
and    O
lactose    O
permease    O
,    O
therefore    O
cAMP    B-Organophosphate114969994
levels    O
are    O
low    O
and    O
lactose    O
can    O
not    O
be    O
transported    O
inside    O
the    O
bacteria    O
.    O

When    O
glucose    O
levels    O
are    O
low    O
the    O
phosphorylated    O
form    O
of    O
EIIA    O
accumulates    O
and    O
consequently    O
activates    O
the    O
enzyme    O
adenylyl    O
cyclase    O
,    O
which    O
will    O
produce    O
high    O
levels    O
of    O
cAMP    B-Organophosphate114969994
.    O

Gram    O
positive    O
bacteria    O
such    O
as    O
"    O
Bacillus    O
subtilis    O
"    O
have    O
a    O
cAMP    B-Organophosphate114969994
-    O
independent    O
catabolite    O
repression    O
mechanism    O
controlled    O
by    O
catabolite    O
control    O
protein    O
A    O
(    O
CcpA    O
)    O
.    O

In    O
particular    O
,    O
GÎ±s    O
stimulates    O
adenyl    O
cyclase    O
to    O
raise    O
cellular    O
levels    O
of    O
cAMP    B-Organophosphate114969994
thereby    O
activating    O
PKA    O
;    O
PKA    O
activates    O
various    O
types    O
of    O
signaling    O
molecules    O
such    O
as    O
the    O
transcription    O
factor    O
CREB    O
which    O
lead    O
to    O
different    O
types    O
of    O
functional    O
responses    O
depending    O
on    O
cell    O
type    O
.    O

,    O
pathways    O
that    O
activate    O
phospholipase    O
C    O
to    O
convert    O
cellular    O
phospholipids    O
to    O
diacylglycerol    O
which    O
promotes    O
the    O
activation    O
of    O
certain    O
isoforms    O
of    O
protein    O
kinase    O
C    O
,    O
pathways    O
that    O
elevated    O
cellular    O
cytosolic    O
Ca2    O
+    O
which    O
thereby    O
regulate    O
Ca2    O
+    O
-sensitive    O
cell    O
signaling    O
molecules    O
,    O
and    O
pathways    O
that    O
inhibit    O
adenyl    O
cyclase    O
which    O
thereby    O
lowers    O
cellular    O
levels    O
of    O
cyclic    B-Organophosphate114969994
adenosine    I-Organophosphate114969994
monophosphate    I-Organophosphate114969994
(    O
cAMP    O
)    O
to    O
reduce    O
the    O
activity    O
of    O
cAMP    O
-    O
dependent    O
signaling    O
molecules    O
.    O

After    O
binding    O
to    O
calmodulin    O
,    O
cyaA    O
â€“    O
ACD    O
catalyzes    O
the    O
cyclization    O
of    O
AMP    O
into    O
cAMP    B-Organophosphate114969994
.    O

"    O
Genetically    O
engineered    O
mice    O
"    O
:    O
Only    O
few    O
generated    O
mutant    O
lines    O
can    O
be    O
regarded    O
as    O
depression    O
models    O
,    O
for    O
example    O
,    O
Î±2A    O
adrenergic    O
receptor    O
knockout    O
mice    O
,    O
glucocorticoid    O
receptor    O
heterozygous    O
mice    O
,    O
and    O
cAMP    B-Organophosphate114969994
response    O
element    O
-    O
binding    O
protein    O
overexpressing    O
mice    O
.    O

When    O
the    O
Î²2-agonist    O
binds    O
and    O
activates    O
the    O
Î²2-adrenoreceptor    O
intracellular    O
signaling    O
becomes    O
largely    O
affected    O
through    O
cyclic    O
adenosine    O
monophosphate    O
(    O
cAMP    B-Organophosphate114969994
)    O
and    O
protein    O
kinase    O
A    O
(    O
PKA    O
)    O
.    O

1971    O
-    O
Earl    O
W.    O
Sutherland    O
(    O
Chair    O
of    O
Pharmacology    O
)    O
,    O
Nobel    O
Prize    O
in    O
Physiology    O
or    O
Medicine    O
,    O
for    O
establishing    O
identity    O
and    O
importance    O
of    O
cyclic    B-Organophosphate114969994
adenosine    I-Organophosphate114969994
monophosphate    I-Organophosphate114969994
or    O
cyclic    O
AMP    O
in    O
regulation    O
of    O
cell    O
metabolism    O
.    O

Rodent    O
studies    O
have    O
consistently    O
shown    O
upregulation    O
of    O
the    O
3,    B-Organophosphate114969994
5-cyclic    I-Organophosphate114969994
adenosine    I-Organophosphate114969994
monophosphate    I-Organophosphate114969994
(    O
cAMP    O
)    O
system    O
induced    O
by    O
different    O
types    O
of    O
chronic    O
but    O
not    O
acute    O
antidepressant    O
treatment    O
,    O
including    O
serotonin    O
and    O
norepinephrine    O
uptake    O
inhibitors    O
,    O
monoamine    O
oxidase    O
inhibitors    O
,    O
tricyclic    O
antidepressants    O
,    O
lithium    O
and    O
electroconvulsions    O
.    O

Cyclic    B-Organophosphate114969994
adenosine    I-Organophosphate114969994
monophosphate    I-Organophosphate114969994
(    O
cAMP    O
or    O
cyclic    O
AMP    O
)    O
is    O
a    O
second    O
messenger    O
that    O
has    O
been    O
implicated    O
in    O
facilitating    O
mushroom    O
body    O
calcium    O
influx    O
in    O
Drosophila    O
melanogaster    O
MBNs    O
.    O

In    O
a    O
classical    O
conditioning    O
paradigm    O
,    O
pairing    O
neuronal    O
depolarization    O
(    O
via    O
acetylcholine    O
application    O
to    O
represent    O
the    O
odor    O
or    O
CS    O
)    O
with    O
subsequent    O
dopamine    O
application    O
(    O
to    O
represent    O
the    O
shock    O
or    O
US    O
)    O
,    O
results    O
in    O
a    O
synergistic    O
increase    O
in    O
cAMP    B-Organophosphate114969994
in    O
the    O
mushroom    O
body    O
lobes    O
.    O

This    O
AC    O
activation    O
increases    O
the    O
concentration    O
of    O
cAMP    B-Organophosphate114969994
,    O
which    O
activates    O
PKA    O
.    O

For    O
example    O
,    O
the    O
cyclic    B-Organophosphate114969994
adenosine    I-Organophosphate114969994
monophosphate    I-Organophosphate114969994
(cAMP)    I-Organophosphate114969994
and    O
protein    O
kinase    O
A    O
(    O
PKA    O
)    O
pathways    O
appear    O
to    O
participate    O
in    O
neuronal    O
allocation    O
.    O

When    O
activated    O
by    O
the    O
second    O
messengers    O
such    O
as    O
cAMP    B-Organophosphate114969994
and    O
calcium    O
ions    O
,    O
enzymes    O
such    O
as    O
PKA    O
and    O
MAP    O
kinase    O
can    O
translocate    O
to    O
the    O
nucleus    O
and    O
phosphorylate    O
CREB    O
to    O
initiate    O
transcription    O
of    O
target    O
genes    O
.    O

In    O
decidual    O
cells    O
and    O
in    O
lymphocytes    O
the    O
distal    O
promoter    O
and    O
thus    O
prolactin    O
expression    O
is    O
stimulated    O
by    O
cAMP    B-Organophosphate114969994
.    O

Resting    O
platelets    O
maintain    O
active    O
calcium    O
efflux    O
via    O
a    O
cyclic    B-Organophosphate114969994
AMP    I-Organophosphate114969994
activated    O
calcium    O
pump    O
.    O

It    O
is    O
thought    O
that    O
regulation    O
of    O
argininosuccinate    O
synthetase    O
activity    O
in    O
arginine    O
synthesis    O
occurs    O
primarily    O
at    O
the    O
transcriptional    O
level    O
in    O
response    O
to    O
glucocorticoids    O
,    O
cAMP    B-Organophosphate114969994
,    O
glucagon    O
,    O
and    O
insulin    O
.    O

Recently    O
,    O
it    O
has    O
been    O
noted    O
that    O
extrasynaptic    O
NMDA    O
receptor    O
activation    O
,    O
triggered    O
by    O
both    O
glutamate    O
exposure    O
or    O
hypoxic    O
/    O
ischemic    O
conditions    O
,    O
activate    O
a    O
CREB    O
(    O
cAMP    B-Organophosphate114969994
response    O
element    O
binding    O
)    O
protein    O
shut    O
-    O
off    O
,    O
which    O
in    O
turn    O
caused    O
loss    O
of    O
mitochondrial    O
membrane    O
potential    O
and    O
apoptosis    O
.    O

He    O
elucidated    O
the    O
pleiotropic    O
functions    O
of    O
cyclic    B-Organophosphate114969994
AMP    I-Organophosphate114969994
in    O
Escherichia    O
coli    O
and    O
elaborated    O
on    O
the    O
antitermination    O
and    O
antiparallel    O
transcription    O
and    O
transcription    O
termination    O
sites    O
of    O
Lambda    O
phage    O
.    O

A    O
number    O
of    O
other    O
small    O
molecules    O
can    O
compensate    O
for    O
the    O
ATP    O
-    O
induced    O
shift    O
in    O
equilibrium    O
conformation    O
and    O
reactivate    O
PFK    O
,    O
including    O
cyclic    B-Organophosphate114969994
AMP    I-Organophosphate114969994
,    O
ammonium    O
ions    O
,    O
inorganic    O
phosphate    O
,    O
and    O
fructose-1,6-    O
and    O
-2,6-biphosphate    O
.    O

Cyclic    B-Organophosphate114969994
adenosine    I-Organophosphate114969994
monophosphate    I-Organophosphate114969994
(    O
cAMP    O
)    O

While    O
it    O
is    O
known    O
that    O
myosin    O
phosphatase    O
is    O
regulated    O
by    O
rho    O
-    O
associated    O
protein    O
kinases    O
,    O
there    O
is    O
current    O
debate    O
about    O
whether    O
other    O
molecules    O
,    O
such    O
as    O
arachidonic    O
acid    O
and    O
cAMP    B-Organophosphate114969994
,    O
also    O
regulate    O
the    O
enzyme    O
.    O

Group    O
II    O
and    O
III    O
receptors    O
are    O
linked    O
to    O
the    O
inhibition    O
of    O
the    O
cyclic    B-Organophosphate114969994
AMP    I-Organophosphate114969994
cascade    O
but    O
differ    O
in    O
their    O
agonist    O
selectivities    O
.    O

Group    O
I    O
includes    O
GRM1    O
and    O
GRM5    O
and    O
these    O
receptors    O
have    O
been    O
shown    O
to    O
activate    O
phospholipase    O
C.    O
Group    O
II    O
includes    O
GRM2    O
(    O
this    O
receptor    O
)    O
and    O
GRM3    O
while    O
Group    O
III    O
includes    O
GRM4    O
,    O
GRM6    O
,    O
GRM7    O
and    O
GRM8    O
.    O
Group    O
II    O
and    O
III    O
receptors    O
are    O
linked    O
to    O
the    O
inhibition    O
of    O
the    O
cyclic    B-Organophosphate114969994
AMP    I-Organophosphate114969994
cascade    O
but    O
differ    O
in    O
their    O
agonist    O
selectivities    O
.    O

Group    O
II    O
and    O
III    O
receptors    O
are    O
linked    O
to    O
the    O
inhibition    O
of    O
the    O
cyclic    B-Organophosphate114969994
AMP    I-Organophosphate114969994
cascade    O
but    O
differ    O
in    O
their    O
agonist    O
selectivities    O
.    O

Group    O
I    O
includes    O
GRM1    O
and    O
GRM5    O
and    O
these    O
receptors    O
have    O
been    O
shown    O
to    O
activate    O
phospholipase    O
C.    O
Group    O
II    O
includes    O
GRM2    O
and    O
GRM3    O
while    O
Group    O
III    O
includes    O
GRM4    O
,    O
GRM6    O
,    O
GRM7    O
and    O
GRM8    O
.    O
Group    O
II    O
and    O
III    O
receptors    O
are    O
linked    O
to    O
the    O
inhibition    O
of    O
the    O
cyclic    B-Organophosphate114969994
AMP    I-Organophosphate114969994
cascade    O
but    O
differ    O
in    O
their    O
agonist    O
selectivities    O
.    O

cAMP    B-Organophosphate114969994

The    O
5-HT7    O
receptor    O
is    O
a    O
member    O
of    O
the    O
GPCR    O
superfamily    O
of    O
cell    O
surface    O
receptors    O
and    O
is    O
activated    O
by    O
the    O
neurotransmitter    O
serotonin    O
(    O
5-hydroxytryptamine    O
,    O
5-HT    O
)    O
The    O
5-HT7    O
receptor    O
is    O
coupled    O
to    O
Gs    O
(    O
stimulates    O
the    O
production    O
of    O
the    O
intracellular    O
signaling    O
molecule    O
cAMP    B-Organophosphate114969994
)    O
and    O
is    O
expressed    O
in    O
a    O
variety    O
of    O
human    O
tissues    O
,    O
particularly    O
in    O
the    O
brain    O
,    O
the    O
gastrointestinal    O
tract    O
,    O
and    O
in    O
various    O
blood    O
vessels    O
.    O

Gs    O
in    O
turn    O
activates    O
adenylate    O
cyclase    O
which    O
increases    O
intracellular    O
levels    O
of    O
the    O
second    O
messenger    O
cAMP    B-Organophosphate114969994
.    O

Dipyridamole    O
inhibits    O
the    O
phosphodiesterase    O
enzymes    O
that    O
normally    O
break    O
down    O
cAMP    B-Organophosphate114969994
(    O
increasing    O
cellular    O
cAMP    O
levels    O
and    O
blocking    O
the    O
platelet    O
aggregation    O
response    O
to    O
ADP    O
)    O
and/or    O
cGMP    B-Organophosphate114969994
.    O

cAMP    B-Organophosphate114969994
impairs    O
platelet    O
aggregation    O
and    O
also    O
causes    O
arteriolar    O
smooth    O
muscle    O
relaxation    O
.    O

Transcription    O
activation    O
requires    O
the    O
binding    O
of    O
adenosine    O
triphosphate    O
(    O
ATP    O
)    O
and    O
maltotriose    O
to    O
MalT    O
and    O
the    O
binding    O
of    O
cyclic    B-Organophosphate114969994
AMP    I-Organophosphate114969994
to    O
the    O
dimer    O
of    O
CRP    O
.    O

JDP2    O
regulates    O
12-O    O
-    O
tetradecanoylphorbol-13-acetate    O
(    O
TPA    O
)    O
response    O
element    O
(    O
TRE)-    O
and    O
cAMP    B-Organophosphate114969994
-    O
responsive    O
element    O
(    O
CRE)-dependent    O
transcription    O
.    O

The    O
rationale    O
for    O
use    O
of    O
these    O
drugs    O
was    O
their    O
ability    O
to    O
increase    O
intracellular    O
cyclic    B-Organophosphate114969994
AMP    I-Organophosphate114969994
(    O
adenosine    O
monophosphate    O
)    O
levels    O
,    O
which    O
might    O
counteract    O
inflammatory    O
signaling    O
pathways    O
that    O
induce    O
endothelial    O
permeability    O
.    O

With    O
Robert    O
L.    O
Perlman    O
he    O
established    O
the    O
first    O
general    O
mechanism    O
of    O
positive    O
gene    O
regulation    O
in    O
bacteria    O
,    O
showing    O
that    O
cyclic    B-Organophosphate114969994
AMP    I-Organophosphate114969994
and    O
its    O
receptor    O
protein    O
CRP    O
(    O
cyclic    O
AMP    O
receptor    O
protein    O
)    O
positively    O
regulated    O
the    O
activity    O
of    O
many    O
genes    O
.    O

MT1302    O
encodes    O
an    O
adenylyl    O
cyclase    O
that    O
converts    O
ATP    O
to    O
cAMP    B-Organophosphate114969994
,    O
the    O
expression    O
of    O
ncrMT1302    O
is    O
regulated    O
by    O
cAMP    O
and    O
pH.    O

OPN    O
also    O
has    O
a    O
large    O
number    O
of    O
consensus    O
sequence    O
sites    O
for    O
post    O
-    O
translational    O
phosphorylation    O
of    O
Ser    O
residues    O
to    O
form    O
phosphoserine    B-Organophosphate114969994
,    O
providing    O
additional    O
negative    O
charge    O
.    O

The    O
3    O
substrates    O
of    O
this    O
enzyme    O
are    O
O-phospho-L-serine    B-Organophosphate114969994
,    O
O    O
-    O
phospho    O
-    O
D    O
-    O
serine    O
,    O
and    O
H2O    O
,    O
whereas    O
its    O
3    O
products    O
are    O
L    O
-    O
serine    O
,    O
D    O
-    O
serine    O
,    O
and    O
phosphate    O
.    O

Phosphoserine    B-Organophosphate114969994

Phosphamidon    B-Organophosphate114969994
(    O
certain    O
formulations    O
)    O

Thus    O
,    O
in    O
the    O
first    O
case    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
3-phospho-D-glycerate    B-Organophosphate114969994
and    O
NAD+    O
,    O
whereas    O
its    O
3    O
products    O
are    O
3-phosphohydroxypyruvate    B-Organophosphate114969994
,    O
NADH    O
,    O
and    O
H+    O
;    O
in    O
the    O
second    O
case    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
2-hydroxyglutarate    O
and    O
NAD+    O
,    O
whereas    O
its    O
3    O
products    O
are    O
2-oxoglutarate    O
,    O
NADH    O
,    O
and    O
H+    O
.    O

Hence    O
,    O
this    O
enzyme    O
has    O
one    O
substrate    O
,    O
4-diphosphocytidyl-2-C-methyl-D-erythritol    B-Organophosphate114969994
2-phosphate    I-Organophosphate114969994
(    O
CDP    O
-    O
MEP    O
)    O
,    O
and    O
two    O
products    O
,    O
2-C-methyl-D-erythritol    B-Organophosphate114969994
2,4-cyclodiphosphate    I-Organophosphate114969994
(    O
MEcPP    O
)    O
and    O
CMP    O
.    O

Dimethylamidophosphoric    O
dicyanide    O
could    O
be    O
prepared    O
by    O
reacting    O
Dimethylamidophosphoric    B-Organophosphate114969994
dichloride    I-Organophosphate114969994
with    O
sodium    O
cyanide    O
.    O

Amidophosphoribosyltransferase    O
(    O
ATase    O
)    O
,    O
also    O
known    O
as    O
glutamine    O
phosphoribosylpyrophosphate    O
amidotransferase    O
(    O
GPAT    O
)    O
,    O
is    O
an    O
enzyme    O
responsible    O
for    O
catalyzing    O
the    O
conversion    O
of    O
5-phosphoribosyl-1-pyrophosphate    B-Organophosphate114969994
(    O
PRPP    O
)    O
into    O
5-phosphoribosyl-1-amine    B-Organophosphate114969994
(    O
PRA    O
)    O
,    O
using    O
the    O
ammonia    O
group    O
from    O
a    O
glutamine    O
side    O
-    O
chain    O
.    O

Image    O
:    O
Phosphoribosyl    O
PRPP    B-Organophosphate114969994

The    O
inosinate    O
synthesis    O
is    O
complex    O
,    O
beginning    O
with    O
a    O
5-phosphoribosyl-1-pyrophosphate    B-Organophosphate114969994
(    O
PRPP    O
)    O
.    O

Plants    O
and    O
microorganisms    O
commonly    O
synthesize    O
tryptophan    O
from    O
shikimic    O
acid    O
or    O
anthranilate    O
:    O
anthranilate    O
condenses    O
with    O
phosphoribosylpyrophosphate    B-Organophosphate114969994
(    O
PRPP    O
)    O
,    O
generating    O
pyrophosphate    O
as    O
a    O
by    O
-    O
product    O
.    O

The    O
enzyme    O
ribose    O
-    O
phosphate    O
diphosphokinase    O
converts    O
ribose-5-phosphate    O
into    O
phosphoribosyl    B-Organophosphate114969994
pyrophosphate    I-Organophosphate114969994
.    O

This    O
is    O
the    O
same    O
mechanism    O
of    O
action    O
as    O
nerve    O
agents    O
such    O
as    O
VX    B-Organophosphate114969994
,    O
although    O
sulfotep    O
is    O
significantly    O
less    O
potent    O
.    O

The    O
anticonvulsant    O
effects    O
of    O
diazepam    O
can    O
help    O
in    O
the    O
treatment    O
of    O
seizures    O
due    O
to    O
a    O
drug    O
overdose    O
or    O
chemical    O
toxicity    O
as    O
a    O
result    O
of    O
exposure    O
to    O
sarin    O
,    O
VX    B-Organophosphate114969994
,    O
or    O
soman    O
(    O
or    O
other    O
organophosphate    O
poisons    O
)    O
,    O
lindane    O
,    O
chloroquine    O
,    O
physostigmine    O
,    O
or    O
pyrethroids    O
.    O

Purple    B-Organophosphate114969994
Possum    I-Organophosphate114969994
-    O
VX    B-Organophosphate114969994
Nerve    I-Organophosphate114969994
Agent    I-Organophosphate114969994
.    O

On    O
August    O
20    O
,    O
1998    O
the    O
Al    O
-    O
Shifa    O
pharmaceutical    O
factory    O
was    O
destroyed    O
by    O
a    O
cruise    O
missile    O
because    O
the    O
United    O
States    O
accused    O
the    O
factory    O
of    O
making    O
VX    B-Organophosphate114969994
(nerve    I-Organophosphate114969994
agent)    I-Organophosphate114969994
for    O
al    O
-    O
Qaeda    O
.    O

After    O
completion    O
of    O
the    O
GB    O
campaigns    O
,    O
the    O
plant    O
was    O
converted    O
to    O
dispose    O
of    O
similar    O
weapons    O
containing    O
VX    B-Organophosphate114969994
agent    O
:    O

All    O
GB    O
(    O
sarin    O
)    O
was    O
destroyed    O
by    O
March    O
2002    O
and    O
all    O
VX    B-Organophosphate114969994
by    O
June    O
2005    O
.    O

The    O
facility    O
created    O
the    O
two    O
toxic    O
agents    O
that    O
would    O
combine    O
to    O
form    O
VX    B-Organophosphate114969994
as    O
well    O
as    O
built    O
the    O
bombs    O
to    O
deliver    O
the    O
nerve    O
agent    O
.    O

By    O
May    O
2007    O
,    O
the    O
facility    O
had    O
destroyed    O
all    O
of    O
its    O
GB    O
(    O
sarin)-    O
containing    O
rockets    O
and    O
began    O
processing    O
VX    B-Organophosphate114969994
-    O
containing    O
munitions    O
.    O

BGAD    O
stores    O
a    O
small    O
stockpile    O
of    O
chemical    O
agents    O
,    O
comprising    O
of    O
nerve    O
agents    O
GB    O
(    O
sarin    O
)    O
and    O
VX    B-Organophosphate114969994
,    O
and    O
mustard    O
gas    O
,    O
or    O
about    O
two    O
percent    O
of    O
the    O
United    O
States    O
chemical    O
weapons    O
stockpile    O
.    O

By    O
July    O
2010    O
,    O
it    O
had    O
destroyed    O
by    O
incineration    O
75%    O
of    O
the    O
depot    O
's    O
total    O
stockpile    O
including    O
all    O
437    O
tons    O
(    O
397    O
metric    O
tons    O
)    O
of    O
GB    O
(    O
sarin    O
)    O
and    O
all    O
VX    B-Organophosphate114969994
nerve    O
agent    O
on    O
site    O
.    O

Subsequent    O
research    O
took    O
the    O
newly    O
discovered    O
German    O
nerve    O
agents    O
as    O
a    O
starting    O
point    O
,    O
and    O
eventually    O
VX    B-Organophosphate114969994
nerve    O
agent    O
was    O
developed    O
at    O
Porton    O
Down    O
in    O
1952    O
.    O

Aum    O
Shinrikyo    O
,    O
who    O
succeeded    O
in    O
developing    O
Sarin    O
and    O
VX    B-Organophosphate114969994
nerve    I-Organophosphate114969994
gas    I-Organophosphate114969994
is    O
regarded    O
to    O
have    O
lacked    O
the    O
technical    O
expertise    O
to    O
develop    O
,    O
or    O
steal    O
,    O
a    O
nuclear    O
weapon    O
.    O

From    O
1949    O
to    O
1969    O
,    O
the    O
United    O
States    O
Army    O
used    O
Carroll    O
Island    O
(    O
a    O
large    O
island    O
near    O
Chase    O
)    O
,    O
and    O
Graces    O
Quarters    O
(    O
a    O
large    O
peninsula    O
between    O
the    O
Dundee    O
Creek    O
and    O
Gunpowder    O
River    O
)    O
to    O
test    O
and    O
dispose    O
of    O
chemical    O
weapons    O
,    O
including    O
:    O
VX    B-Organophosphate114969994
(nerve    I-Organophosphate114969994
agent)    I-Organophosphate114969994
,    O
sarin    O
,    O
mustard    O
gas    O
,    O
incapacitating    O
agents    O
,    O
and    O
other    O
lethal    O
agents    O
.    O

Like    O
other    O
pesticides    O
in    O
this    O
class    O
,    O
it    O
owes    O
its    O
insecticidal    O
properties    O
(    O
and    O
human    O
toxicity    O
)    O
to    O
the    O
fact    O
that    O
it    O
is    O
an    O
acetylcholinesterase    O
inhibitor    O
(    O
the    O
same    O
mechanism    O
is    O
responsible    O
for    O
the    O
toxic    O
effects    O
of    O
the    O
V-series    B-Organophosphate114969994
nerve    O
agent    O
chemical    O
weapons    O
)    O
.    O

VM    O
(    O
Edemo    O
)    O
is    O
a    O
"    O
V    O
-    O
series    O
"    O
nerve    O
agent    O
closely    O
related    O
to    O
the    O
better    O
-    O
known    O
VX    B-Organophosphate114969994
nerve    I-Organophosphate114969994
agent    I-Organophosphate114969994
.    O

VG    B-Organophosphate114969994
(    O
IUPAC    O
name    O
:    O
O","O    O
"-    O
diethyl    O
"    O
S"-[2-(diethylamino)ethyl    O
]    O
phosphorothioate    O
)    B-Organophosphate114969994
(also    I-Organophosphate114969994
called    I-Organophosphate114969994
"'Amiton    I-Organophosphate114969994
or    O
Tetram    B-Organophosphate114969994
)    O
is    O
a    O
"    O
V    O
-    O
series    O
"    O
nerve    O
agent    O
chemically    O
similar    O
to    O
the    O
better    O
-    O
known    O
VX    B-Organophosphate114969994
nerve    I-Organophosphate114969994
agent    I-Organophosphate114969994
.    O

With    O
a    O
toxicity    O
of    O
about    O
1/10    O
that    O
of    O
VX    B-Organophosphate114969994
,    O
i.e.    O
similar    O
to    O
that    O
of    O
sarin    O
,    O
it    O
is    O
now    O
considered    O
too    O
dangerous    O
for    O
use    O
in    O
agriculture    O
but    O
unlike    O
other    O
nerve    O
agents    O
it    O
is    O
classified    O
under    O
Schedule    O
2    O
of    O
the    O
Chemical    O
Weapons    O
Convention    O
rather    O
than    O
the    O
more    O
restrictive    O
Schedule    O
1    O
.    O

VE    O
(    O
S-(Diethylamino)ethyl    O
O    O
-    O
ethyl    O
ethylphosphonothioate    O
)    O
is    O
a    O
"    O
V    O
-    O
series    O
"    O
nerve    O
agent    O
closely    O
related    O
to    O
the    O
better    O
-    O
known    O
VX    B-Organophosphate114969994
nerve    I-Organophosphate114969994
agent    I-Organophosphate114969994
.    O

Chemical    O
attacks    O
against    O
Kurdish    O
villages    O
from    O
1986    O
to    O
1988    O
,    O
including    O
the    O
Halabja    O
attack    O
,    O
when    O
the    O
Iraqi    O
Air    O
Force    O
dropped    O
sarin    O
,    O
VX    B-Organophosphate114969994
and    O
tabun    O
chemical    O
agents    O
on    O
the    O
civilian    O
population    O
,    O
killing    O
5,000    O
people    O
immediately    O
and    O
causing    O
long    O
-    O
term    O
medical    O
problems    O
,    O
related    O
deaths    O
,    O
and    O
birth    O
defects    O
among    O
the    O
progeny    O
of    O
thousands    O
more    O
.    O

VG    B-Organophosphate114969994
(nerve    I-Organophosphate114969994
agent)    I-Organophosphate114969994
,    O
the    O
NATO    O
designation    O
for    O
a    O
chemical    O
weapon    O
agent    O
,    O
a.k.a    O
.    O

VG    B-Organophosphate114969994
(    O
IUPAC    O
name    O
:    O
O","O    O
"-    O
diethyl    O
"    O
S"-[2-(diethylamino)ethyl    O
]    O
phosphorothioate    O
)    B-Organophosphate114969994
(also    I-Organophosphate114969994
called    I-Organophosphate114969994
"'Amiton    I-Organophosphate114969994
or    O
Tetram    B-Organophosphate114969994
)    O
is    O
a    O
"    O
V    O
-    O
series    O
"    O
nerve    O
agent    O
chemically    O
similar    O
to    O
the    O
better    O
-    O
known    O
VX    B-Organophosphate114969994
nerve    I-Organophosphate114969994
agent    I-Organophosphate114969994
.    O

At    O
this    O
stage    O
,    O
phosphoenolpyruvate    B-Organophosphate114969994
and    O
erythrose-4-phosphate    O
react    O
to    O
form    O
3-deoxy-D-arabinoheptulosonate-7-phosphate    B-Organophosphate114969994
(    O
DAHP    O
)    O
,    O
in    O
a    O
reaction    O
catalyzed    O
by    O
the    O
enzyme    O
DAHP    O
synthase    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
GDP    B-Organophosphate114969994
and    O
alpha-D-mannose    B-Organophosphate114969994
1-phosphate    I-Organophosphate114969994
,    O
whereas    O
its    O
two    O
products    O
are    O
phosphate    O
and    O
GDP    O
-    O
mannose    O
.    O

"    O
Pholiotina    O
cyanopus    O
"    O
is    O
hallucinogenic    O
,    O
containing    O
psilocin    O
,    O
psilocybin    O
,    O
baeocystin    B-Organophosphate114969994
,    O
norbaeocystin    B-Organophosphate114969994
and    O
aeruginascin    B-Organophosphate114969994
.    O

Monocrotophos    B-Organophosphate114969994

Monocrotophos    B-Organophosphate114969994
is    O
an    O
organophosphate    O
insecticide    O
.    O

zinc    B-Organophosphate114969994
dialkyl    I-Organophosphate114969994
dithio    I-Organophosphate114969994
phosphate    I-Organophosphate114969994
(    O
ZDDP    O
)    O
,    O
probably    O
the    O
most    O
widely    O
used    O
in    O
formulated    O
engine    O
oils    O
,    O
also    O
acts    O
as    O
a    O
corrosion    O
inhibitor    O
and    O
antioxidant    O

During    O
the    O
1950s    O
the    O
use    O
of    O
lead    O
soaps    O
was    O
eliminated    O
and    O
replaced    O
by    O
zinc    O
and    O
phosphorus    O
compounds    O
such    O
as    O
zinc    B-Organophosphate114969994
dithiophosphate    I-Organophosphate114969994
.    O

The    O
compound    O
is    O
mainly    O
converted    O
to    O
other    O
derivatives    O
for    O
use    O
as    O
lubrication    O
additives    O
such    O
zinc    B-Organophosphate114969994
dithiophosphate    I-Organophosphate114969994
.    O

Nicotinic    B-Organophosphate114969994
acid    I-Organophosphate114969994
adenine    I-Organophosphate114969994
dinucleotide    I-Organophosphate114969994
phosphate    I-Organophosphate114969994
,    O
(    O
NAADP    B-Organophosphate114969994
)    O
,    O
is    O
a    O
Ca2    O
+    O
-mobilizing    O
second    O
messenger    O
synthesised    O
in    O
response    O
to    O
extracellular    O
stimuli    O
.    O

Cyclic    B-Organophosphate114969994
guanosine    I-Organophosphate114969994
monophosphate    I-Organophosphate114969994
.    O

They    O
serve    O
as    O
sources    O
of    O
chemical    O
energy    O
(    O
adenosine    O
triphosphate    O
and    O
guanosine    B-Organophosphate114969994
triphosphate    I-Organophosphate114969994
)    O
,    O
participate    O
in    O
cellular    O
signaling    O
(    O
cyclic    B-Organophosphate114969994
guanosine    I-Organophosphate114969994
monophosphate    I-Organophosphate114969994
and    O
cyclic    B-Organophosphate114969994
adenosine    I-Organophosphate114969994
monophosphate    I-Organophosphate114969994
)    O
,    O
and    O
are    O
incorporated    O
into    O
important    O
cofactors    O
of    O
enzymatic    O
reactions    O
(    O
coenzyme    B-Organophosphate114969994
A    I-Organophosphate114969994
,    O
flavin    B-Organophosphate114969994
adenine    I-Organophosphate114969994
dinucleotide    I-Organophosphate114969994
,    O
flavin    B-Organophosphate114969994
mononucleotide    I-Organophosphate114969994
,    O
and    O
nicotinamide    O
adenine    O
dinucleotide    O
phosphate    O
)    O
.    O

These    O
drugs    O
,    O
including    O
sildenafil    O
,    O
inhibit    O
the    O
action    O
of    O
the    O
phosphodiesterase    O
,    O
allowing    O
for    O
a    O
higher    O
concentration    O
of    O
cyclic    B-Organophosphate114969994
GMP    I-Organophosphate114969994
in    O
the    O
penis    O
when    O
it    O
is    O
physically    O
stimulated    O
.    O

This    O
response    O
is    O
mediated    O
by    O
the    O
release    O
of    O
nitric    O
oxide    O
(    O
NO    O
)    O
from    O
nerve    O
terminals    O
and    O
endothelial    O
cells    O
,    O
which    O
stimulates    O
the    O
synthesis    O
of    O
cyclic    B-Organophosphate114969994
guanosine    I-Organophosphate114969994
monophosphate    I-Organophosphate114969994
(    O
more    O
commonly    O
known    O
as    O
cyclic    O
GMP    O
or    O
cGMP    O
)    O
in    O
smooth    O
muscle    O
cells    O
.    O

Transducin    O
removes    O
the    O
inhibition    O
from    O
cGMP    B-Organophosphate114969994
Phosphodiesterase    O
,    O
which    O
leads    O
to    O
the    O
breakdown    O
of    O
cGMP    O
.    O

cyclic    B-Organophosphate114969994
guanosine    I-Organophosphate114969994
monophosphate    I-Organophosphate114969994

In    O
addition    O
Dithranol    O
may    O
act    O
by    O
reducing    O
the    O
elevated    O
levels    O
of    O
cGMP    B-Organophosphate114969994
that    O
occurs    O
in    O
psoriasis    O
.    O

It    O
is    O
believed    O
that    O
the    O
core    O
contains    O
common    O
structural    O
elements    O
that    O
are    O
important    O
for    O
the    O
hydrolysis    O
of    O
cAMP    B-Organophosphate114969994
and    O
cGMP    B-Organophosphate114969994
phosphodiester    O
bonds    O
.    O

At    O
first    O
,    O
the    O
PDE3s    O
were    O
purified    O
and    O
described    O
as    O
enzymes    O
that    O
hydrolyse    O
both    O
cGMP    B-Organophosphate114969994
and    O
cAMP    B-Organophosphate114969994
with    O
Km    O
values    O
between    O
0.1    O
â€“    O
0.8    O
ÂµM.    O
However    O
the    O
Vmax    O
for    O
cAMP    B-Organophosphate114969994
hydrolysis    O
is    O
4    O
â€“    O
10    O
times    O
higher    O
than    O
Vmax    O
for    O
cGMP    B-Organophosphate114969994
hydrolysis    O
.    O

Hydrolysis    O
of    O
cAMP    B-Organophosphate114969994
by    O
PDE3    O
isoforms    O
is    O
also    O
directly    O
inhibited    O
by    O
cGMP    B-Organophosphate114969994
,    O
although    O
PDE3B    O
is    O
only    O
â‰ˆ10%    O
as    O
sensitive    O
to    O
cGMP    B-Organophosphate114969994
inhibition    O
as    O
PDE3A.    O

The    O
cyclic    O
nucleotide    O
phosphodiesterases    O
constitute    O
a    O
group    O
of    O
enzymes    O
that    O
destroy    O
the    O
cyclic    O
nucleotides    O
cyclic    B-Organophosphate114969994
adenosine    I-Organophosphate114969994
monophosphate    I-Organophosphate114969994
(    O
cAMP    O
)    O
and    O
cyclic    B-Organophosphate114969994
guanosine    I-Organophosphate114969994
monophosphate    I-Organophosphate114969994
(    O
cGMP    O
)    O
.    O

These    O
channels    O
are    O
also    O
sensitive    O
to    O
the    O
cyclic    O
nucleotides    O
cAMP    B-Organophosphate114969994
and    O
cGMP    B-Organophosphate114969994
,    O
which    O
alter    O
the    O
voltage    O
sensitivity    O
of    O
the    O
channel    O
â€™s    O
opening    O
.    O

Cyclic    O
nucleotide    O
-    O
gated    O
channels    O
:    O
This    O
family    O
of    O
channels    O
is    O
characterized    O
by    O
activation    O
by    O
either    O
intracellular    O
cAMP    B-Organophosphate114969994
or    O
cGMP    B-Organophosphate114969994
.    O

Sodium    O
nitroprusside    O
and    O
nitroglycerin    O
function    O
by    O
causing    O
vasodilation    O
through    O
nitric    O
oxide    O
,    O
which    O
manipulates    O
cGMP    B-Organophosphate114969994
levels    O
through    O
guanylate    O
cyclase    O
.    O

Dipyridamole    O
inhibits    O
the    O
phosphodiesterase    O
enzymes    O
that    O
normally    O
break    O
down    O
cAMP    B-Organophosphate114969994
(    O
increasing    O
cellular    O
cAMP    O
levels    O
and    O
blocking    O
the    O
platelet    O
aggregation    O
response    O
to    O
ADP    O
)    O
and/or    O
cGMP    B-Organophosphate114969994
.    O

In    O
2012    O
the    O
government    O
of    O
the    O
State    O
of    O
Washington    O
was    O
discussing    O
a    O
bill    O
to    O
ban    O
certain    O
agents    O
such    O
as    O
chlorinated    B-Organophosphate114969994
tris    I-Organophosphate114969994
(    O
an    O
agent    O
banned    O
from    O
children    O
â€™s    O
pajamas    O
more    O
than    O
30    O
years    O
ago    O
because    O
of    O
its    O
toxicity    O
)    O
from    O
children    O
â€™s    O
products    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
CTP    B-Organophosphate114969994
and    O
2-C-methyl-D-erythritol    B-Organophosphate114969994
4-phosphate    I-Organophosphate114969994
,    O
whereas    O
its    O
two    O
products    O
are    O
diphosphate    O
and    O
4-diphosphocytidyl-2-C-methylerythritol    B-Organophosphate114969994
.    O

Dicrotophos    B-Organophosphate114969994

The    O
residue    O
of    O
lysine-142    O
in    O
the    O
active    O
site    O
of    O
transaldolase    O
forms    O
a    O
Schiff    O
base    O
with    O
the    O
keto    O
group    O
in    O
sedoheptulose-7-phosphate    B-Organophosphate114969994
after    O
deprotonation    O
by    O
another    O
active    O
site    O
residue    O
,    O
glutamate-106    O
.    O

Sedoheptulose    B-Organophosphate114969994
7-phosphate    I-Organophosphate114969994
is    O
an    O
intermediate    O
in    O
the    O
pentose    O
phosphate    O
pathway    O
.    O

RelA    O
converts    O
GTP    B-Organophosphate114969994
and    O
ATP    O
into    O
pppGpp    B-Organophosphate114969994
by    O
adding    O
the    O
pyrophosphate    O
from    O
ATP    O
onto    O
the    O
3    O
'    O
carbon    O
of    O
the    O
ribose    O
in    O
GTP    O
,    O
releasing    O
AMP    O
.    O

pppGpp    O
is    O
converted    O
to    O
ppGpp    B-Organophosphate114969994
by    O
the    O
"    O
gpp    O
"    O
gene    O
product    O
,    O
releasing    O
Pi    O
.    O

3-Methylglutaconyl    B-Organophosphate114969994
CoA    I-Organophosphate114969994
is    O
an    O
intermediate    O
in    O
the    O
metabolism    O
of    O
leucine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
dCTP    B-Organophosphate114969994
and    O
H2O    O
,    O
whereas    O
its    O
two    O
products    O
are    O
dCMP    O
and    O
diphosphate    O
.    O

Illustrative    O
organophosphates    O
and    O
related    O
compounds    O
:    O
phosphatidylcholine    O
,    O
triphenylphosphate    B-Organophosphate114969994
,    O
cyclophosphamide    O
,    O
parathion    O
,    O
and    O
zinc    B-Organophosphate114969994
dithiophosphate    I-Organophosphate114969994
.    O

In    O
2005    O
the    O
Partnership    O
published    O
evaluations    O
of    O
alternatives    O
to    O
pentaBDE    O
,    O
including    O
triphenyl    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
,    O
tribromoneopentyl    O
alcohol    O
,    O
tris(1,3-dicholoro-2-propyl)phosphate    O
,    O
and    O
12    O
proprietary    O
chemicals    O
.    O

Topical    O
treatment    O
of    O
livestock    O
,    O
dogs    O
and    O
cats    O
with    O
organophosphates    O
(    O
such    O
as    O
ecothiopate    B-Organophosphate114969994
iodide    I-Organophosphate114969994
or    O
isofluorophate    O
)    O
and    O
systemic    O
treatment    O
with    O
anthelmintics    O
(    O
such    O
as    O
ivermectin    O
,    O
levamisole    O
,    O
and    O
doramectin    O
)    O
are    O
recommended    O
by    O
the    O
Merck    O
Veterinary    O
Manual    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
ATP    O
and    O
lombricine    B-Organophosphate114969994
,    O
whereas    O
its    O
two    O
products    O
are    O
ADP    O
and    O
N    O
-    O
phospholombricine    O
.    O

It    O
is    O
a    O
structural    O
analogue    O
of    O
2-C-methyl-D-erythrose    B-Organophosphate114969994
4-phosphate    I-Organophosphate114969994
.    O

"    O
Pholiotina    O
cyanopus    O
"    O
is    O
hallucinogenic    O
,    O
containing    O
psilocin    O
,    O
psilocybin    O
,    O
baeocystin    B-Organophosphate114969994
,    O
norbaeocystin    B-Organophosphate114969994
and    O
aeruginascin    B-Organophosphate114969994
.    O

Bis(dicyclohexylphosphino)ethane    O
,    O
abbreviated    O
dcpe    O
,    O
is    O
an    O
organophosphorus    B-Organophosphate114969994
compound    I-Organophosphate114969994
with    O
the    O
formula    O
(    O
C6H11)2PCH2CH2P(C6H11)2    O
.    O

Triethylphosphite    O
is    O
an    O
organophosphorus    B-Organophosphate114969994
compound    I-Organophosphate114969994
with    O
the    O
formula    O
P(OCH2CH3)3    O
,    O
often    O
abbreviated    O
P(OEt)3    O
.    O

Trimethylphosphite    O
is    O
an    O
organophosphorus    B-Organophosphate114969994
compound    I-Organophosphate114969994
with    O
the    O
formula    O
P(OCH3)3    O
,    O
often    O
abbreviated    O
P(OMe)3    O
.    O

DIOP    O
(    O
2,3-"O    O
"-    O
isopropylidene-2,3-dihydroxy-1,4-bis(diphenylphosphino)butane    O
)    O
is    O
an    O
organophosphorus    B-Organophosphate114969994
compound    I-Organophosphate114969994
that    O
is    O
used    O
as    O
a    O
chiral    O
ligand    O
in    O
asymmetric    O
catalysis    O
.    O

Sheldon    O
was    O
educated    O
at    O
the    O
University    O
of    O
Leicester    O
where    O
he    O
was    O
awarded    O
a    O
PhD    O
in    O
1967    O
for    O
research    O
on    O
the    O
chemical    O
reactions    O
of    O
the    O
organophosphorus    B-Organophosphate114969994
compound    I-Organophosphate114969994
tetraphenyldiphosphine    O
.    O

In    O
chemistry    O
,    O
a    O
diphosphene    O
is    O
an    O
organophosphorus    B-Organophosphate114969994
compound    I-Organophosphate114969994
that    O
has    O
a    O
phosphorus    O
-    O
phosphorus    O
double    O
bond    O
,    O
denoted    O
by    O
R    O
-    O
P    O
=    O
P    O
-    O
R    O
'    O
.    O

Dimethylphosphine    O
is    O
the    O
organophosphorus    B-Organophosphate114969994
compound    I-Organophosphate114969994
with    O
the    O
formula    O
(    O
CH3)2PH    O
,    O
often    O
written    O
Me2PH    O
.    O

Methylphosphine    O
is    O
the    O
simplest    O
organophosphorus    B-Organophosphate114969994
compound    I-Organophosphate114969994
with    O
the    O
formula    O
CH3PH2    O
,    O
often    O
written    O
MePH2    O
.    O

In    O
Japan    O
,    O
the    O
insecticide    O
to    O
the    O
sawyers    O
use    O
organophosphorus    B-Organophosphate114969994
compound    I-Organophosphate114969994
or    O
neonicotinoid    O
.    O

Methylphosphonic    O
acid    O
is    O
an    O
organophosphorus    B-Organophosphate114969994
compound    I-Organophosphate114969994
with    O
the    O
chemical    O
formula    O
.    O

Phanephos    O
is    O
an    O
organophosphorus    B-Organophosphate114969994
compound    I-Organophosphate114969994
with    O
the    O
chemical    O
formula    O
(    O
C2H4)2(C6H3PPh2)2    O
(    O
Ph    O
=    O
C6H5    O
)    O
.    O

Oximes    O
are    O
drugs    O
known    O
for    O
their    O
ability    O
to    O
reverse    O
the    O
binding    O
of    O
organophosphorus    B-Organophosphate114969994
compounds    O
to    O
the    O
enzyme    O
acetylcholinesterase    O
(    O
AChE    O
)    O
.    O

These    O
compounds    O
are    O
of    O
theoretical    O
interest    O
but    O
also    O
serve    O
as    O
ligands    O
for    O
transition    O
metals    O
and    O
as    O
precursors    O
to    O
more    O
complex    O
organophosphorus    B-Organophosphate114969994
compound    I-Organophosphate114969994
.    O

Organophosphorus    B-Organophosphate114969994
chemistry    I-Organophosphate114969994

Azinphos    O
-    O
methyl    O
(    O
Guthion    O
)    O
(    O
also    O
spelled    O
azinophos    O
-    O
methyl    O
)    O
is    O
a    O
broad    O
spectrum    O
organophosphate    B-Organophosphate114969994
insecticide    O
manufactured    O
by    O
Bayer    O
CropScience    O
,    O
Gowan    O
Co.    O
,    O
and    O
Makhteshim    O
Agan    O
.    O

Organocopper    O
compounds    O
form    O
complexes    O
with    O
a    O
variety    O
of    O
soft    O
ligands    O
such    O
as    O
alkylphosphine    B-Organophosphate114969994
(    O
R3P    O
)    O
,    O
thioethers    O
(    O
R2S    O
)    O
,    O
and    O
cyanide    O
(    O
CNâˆ’    O
)    O
.    O

Phosphaalkenes    O
(    O
IUPAC    O
name    O
:    O
alkylidenephosphanes    O
)    O
are    O
organophosphorus    B-Organophosphate114969994
compound    I-Organophosphate114969994
with    O
double    O
bonds    O
between    O
carbon    O
and    O
phosphorus(III    O
)    O
with    O
the    O
formula    O
R2C    O
=    O
PR    O
.    O

Physiological    O
agonist    O
:    O
Cyclic    B-Organophosphate114969994
ADP-ribose    I-Organophosphate114969994
can    O
act    O
as    O
a    O
physiological    O
gating    O
agent    O
.    O

NAD+    O
is    O
converted    O
into    O
cyclic    B-Organophosphate114969994
ADP    I-Organophosphate114969994
ribose    I-Organophosphate114969994
(    O
cADPR    O
)    O
,    O
a    O
second    O
messenger    O
which    O
interacts    O
with    O
ryanodine    O
receptors    O
(    O
RyR    O
)    O
on    O
the    O
surface    O
of    O
the    O
rough    O
endoplasmic    O
reticulum    O
.    O

Though    O
this    O
method    O
has    O
never    O
been    O
explored    O
with    O
5-MeO    O
-    O
DMT    O
,    O
it    O
has    O
been    O
used    O
successfully    O
for    O
changing    O
DET    O
into    O
4-HO    O
-    O
DET    O
and    O
4-PO-DET    B-Organophosphate114969994
,    O
both    O
of    O
which    O
had    O
never    O
before    O
been    O
found    O
in    O
nature    O
.    O

The    O
proposed    O
mechanism    O
of    O
the    O
characteristic    O
haemolytic    O
anaemia    O
in    O
Zieve    O
's    O
syndrome    O
is    O
due    O
to    O
alteration    O
of    O
the    O
red    O
cell    O
metabolism    O
,    O
namely    O
pyruvate    O
kinase    O
instability    O
leaving    O
them    O
susceptible    O
to    O
circulating    O
hemolysin    O
such    O
as    O
lysolecithin    B-Organophosphate114969994
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
2-lysophosphatidylcholine    B-Organophosphate114969994
and    O
H2O    O
,    O
whereas    O
its    O
two    O
products    O
are    O
glycerophosphocholine    B-Organophosphate114969994
and    O
carboxylate    O
.    O

A    O
different    O
study    O
showed    O
that    O
the    O
length    O
of    O
the    O
hydrophobic    O
tail    O
affects    O
its    O
functioning    O
as    O
well    O
as    O
supporting    O
the    O
different    O
states    O
,    O
Phosphatidylcholine    O
(    O
PC    O
)    O
18    O
stabilizes    O
better    O
the    O
open    O
state    O
of    O
the    O
MscL    O
channel    O
,    O
PC    O
14    O
stabilizes    O
the    O
intermediate    O
state    O
,    O
and    O
a    O
mixture    O
of    O
PC    O
18    O
and    O
lysophosphatidylcholine    B-Organophosphate114969994
(    O
LPC    O
)    O
stabilizes    O
the    O
closed    O
state    O
,    O
suggesting    O
that    O
the    O
bilayer    O
thickness    O
(    O
for    O
carbon    O
tail    O
lengths    O
of    O
16    O
,    O
18    O
and    O
20    O
)    O
affects    O
channel    O
function    O
.    O

Its    O
genome    O
contains    O
no    O
mitochondrial    O
DNA    O
(    O
mtDNA    O
)    O
,    O
and    O
no    O
genes    O
for    O
cardiolipin    B-Organophosphate114969994
,    O
a    O
lipid    O
for    O
energy    O
-    O
transducing    O
membranes    O
.    O

Sphingomyelin    O
(    O
4.42%    O
of    O
the    O
total    O
phospholipids    O
)    O
,    O
phosphatidyl    B-Organophosphate114969994
ethanolamine    I-Organophosphate114969994
(    O
12.8%    O
)    O
,    O
phosphatidyl    O
choline    O
(    O
21.9%    O
)    O
,    O
phosphatidyl    B-Organophosphate114969994
serine    I-Organophosphate114969994
(    O
2.9%    O
)    O
,    O
phosphatidyl    O
inositol    O
(    O
2.7%    O
)    O
,    O
lysophosphatidyl    B-Organophosphate114969994
choline    I-Organophosphate114969994
(    O
5.3%    O
)    O
,    O
phosphatidyl    O
glycerol    O
(    O
8.9%    O
)    O
,    O
phosphatidic    O
acid    O
(    O
4.9%    O
)    O
,    O
and    O
cardiolipin    B-Organophosphate114969994
(    O
3.6%    O
)    O
were    O
identified    O
in    O
the    O
nine    O
genotypes    O
.    O

Recent    O
findings    O
suggest    O
that    O
PLSCR3    O
is    O
involved    O
in    O
regulation    O
of    O
biosynthesis    O
of    O
cardiolipin    B-Organophosphate114969994
in    O
mitochondria    O
,    O
and    O
its    O
overexpression    O
in    O
cultured    O
cells    O
resulted    O
in    O
increased    O
cardiolipin    O
synthase    O
,    O
activity    O
.    O

Phosphatidate    O
can    O
then    O
be    O
converted    O
into    O
an    O
activated    O
form    O
,    O
CDP    O
-    O
DAG    O
,    O
through    O
the    O
liberation    O
of    O
a    O
pyrophosphate    O
from    O
a    O
CTP    O
molecule    O
,    O
or    O
into    O
cardiolipin    B-Organophosphate114969994
.    O

PAP    O
is    O
upregulated    O
by    O
CDP    O
-    O
diacylglycerol    O
,    O
phosphatidylinositol    O
(    O
formed    O
from    O
reaction    O
of    O
CDP    O
-    O
DAG    O
with    O
inositol    O
)    O
,    O
and    O
cardiolipin    B-Organophosphate114969994
.    O

This    O
is    O
a    O
family    O
of    O
proteins    O
that    O
acts    O
as    O
a    O
mitochondrial    O
phosphatase    O
in    O
cardiolipin    B-Organophosphate114969994
biosynthesis    O
.    O

The    O
B.    O
stolpii    O
homologue    O
also    O
features    O
substrate    O
inhibition    O
by    O
palmitoyl-CoA    B-Organophosphate114969994
,    O
a    O
feature    O
shared    O
by    O
the    O
yeast    O
and    O
mammalian    O
homologues    O
.    O

In    O
2008    O
,    O
it    O
was    O
determined    O
that    O
MenH    O
has    O
poor    O
catalytic    O
activity    O
toward    O
palmitoyl-CoA    B-Organophosphate114969994
,    O
casting    O
doubt    O
on    O
its    O
role    O
as    O
a    O
thioesterase    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
palmitoyl-CoA    B-Organophosphate114969994
and    O
H2O    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    B-Organophosphate114969994
and    O
palmitate    O
.    O

Expressed    O
specifically    O
in    O
the    O
hippocampus    O
and    O
Purkinje    O
cells    O
of    O
the    O
brain    O
,    O
the    O
encoded    O
protein    O
is    O
a    O
glycolytic    O
enzyme    O
that    O
catalyzes    O
the    O
reversible    O
aldol    O
cleavage    O
of    O
fructose    B-Organophosphate114969994
1,6-bisphosphate    I-Organophosphate114969994
and    O
fructose-1-phosphate    B-Organophosphate114969994
to    O
dihydroxyacetone    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
and    O
either    O
glyceraldehyde    B-Organophosphate114969994
3-phosphate    I-Organophosphate114969994
or    O
glyceraldehyde    O
,    O
respectively.[provided    O
by    O
RefSeq    O
,    O
Jul    O
2008    O
]    O

It    O
can    O
form    O
by    O
action    O
of    O
ketolase    O
on    O
fructose    B-Organophosphate114969994
1,6-bisphosphate    I-Organophosphate114969994
in    O
an    O
alternate    O
glycolysis    O
pathway    O
.    O

Fructose-1,6-bisphosphatase    O
1    O
,    O
a    O
gluconeogenesis    O
regulatory    O
enzyme    O
,    O
catalyzes    O
the    O
hydrolysis    O
of    O
fructose    B-Organophosphate114969994
1,6-bisphosphate    I-Organophosphate114969994
to    O
fructose    B-Organophosphate114969994
6-phosphate    I-Organophosphate114969994
and    O
inorganic    O
phosphate    O
.    O

Fructose    B-Organophosphate114969994
1,6-bisphosphate    I-Organophosphate114969994

Fructose    O
-    O
bisphosphate    O
aldolase    O
,    O
often    O
just    O
aldolase    O
,    O
is    O
an    O
enzyme    O
catalyzing    O
a    O
reversible    O
reaction    O
that    O
splits    O
the    O
aldol    O
,    O
fructose    B-Organophosphate114969994
1,6-bisphosphate    I-Organophosphate114969994
,    O
into    O
the    O
triose    O
phosphates    O
dihydroxyacetone    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
(    O
DHAP    O
)    O
and    O
glyceraldehyde    B-Organophosphate114969994
3-phosphate    I-Organophosphate114969994
(    O
G3P    O
)    O
.    O

Franz    O
Anton    O
Voegeli    O
(    O
1825â€“1874    O
)    O
was    O
a    O
Swiss    O
chemist    O
who    O
was    O
the    O
first    O
to    O
synthesize    O
the    O
triethyl    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
(    O
TEP    O
)    O
while    O
he    O
was    O
working    O
in    O
Gustav    O
Magnus    O
's    O
laboratory    O
in    O
Berlin    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
ATP    O
and    O
D-ribose    B-Organophosphate114969994
5-phosphate    I-Organophosphate114969994
,    O
whereas    O
its    O
two    O
products    O
are    O
ADP    O
and    O
D    O
-    O
ribose    O
1,5-bisphosphate    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
ATP    O
and    O
D    O
-    O
ribose    O
,    O
whereas    O
its    O
two    O
products    O
are    O
ADP    O
and    O
D-ribose    B-Organophosphate114969994
5-phosphate    I-Organophosphate114969994
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
ADP    O
and    O
D-ribose    B-Organophosphate114969994
5-phosphate    I-Organophosphate114969994
,    O
whereas    O
its    O
two    O
products    O
are    O
phosphate    O
and    O
ADP-ribose    B-Organophosphate114969994
.    O

Ribose    B-Organophosphate114969994
5-phosphate    I-Organophosphate114969994
is    O
both    O
a    O
product    O
and    O
an    O
intermediate    O
of    O
the    O
pentose    O
phosphate    O
pathway    O
.    O

Carbamoyl    B-Organophosphate114969994
phosphate    I-Organophosphate114969994

Without    O
NAG    O
stimulation    O
,    O
CPS1    O
can    O
not    O
convert    O
ammonia    O
to    O
carbamoyl    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
,    O
resulting    O
in    O
toxic    O
ammonia    O
accumulation    O
.    O

Carbamoyl    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
is    O
an    O
anion    O
of    O
biochemical    O
significance    O
.    O

While    O
the    O
use    O
of    O
urea    O
as    O
a    O
source    O
of    O
yeast    O
assimilable    O
nitrogen    O
(    O
no    O
longer    O
legal    O
in    O
most    O
countries    O
)    O
was    O
the    O
most    O
common    O
cause    O
of    O
ethyl    O
carbamate    O
in    O
wine    O
,    O
both    O
"    O
O.    O
oeni    O
"    O
and    O
"    O
L.    O
buchneri    O
"    O
have    O
been    O
known    O
to    O
produce    O
carbamyl    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
and    O
citrulline    O
which    O
can    O
be    O
precursors    O
to    O
ethyl    O
carbamate    O
formation    O
.    O
"    O

Ammonia    O
is    O
converted    O
to    O
carbamoyl    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
by    O
the    O
enzyme    O
carbamoyl    O
phosphate    O
synthetase    O
,    O
and    O
then    O
enters    O
the    O
urea    O
cycle    O
to    O
be    O
either    O
incorporated    O
into    O
amino    O
acids    O
or    O
excreted    O
in    O
the    O
urine    O
.    O

Thiamine    B-Organophosphate114969994
monophosphate    I-Organophosphate114969994
is    O
a    O
thiamine    O
derivative    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
2-lysophosphatidylcholine    B-Organophosphate114969994
and    O
H2O    O
,    O
whereas    O
its    O
two    O
products    O
are    O
glycerophosphocholine    B-Organophosphate114969994
and    O
carboxylate    O
.    O

GMP    O
is    O
formed    O
by    O
the    O
inosinate    O
oxidation    O
to    O
xanthylate    B-Organophosphate114969994
(    O
XMP    O
)    O
,    O
and    O
afterwards    O
adds    O
an    O
amino    O
group    O
on    O
carbon    O
2    O
.    O

Xanthosine    B-Organophosphate114969994
monophosphate    I-Organophosphate114969994

Xanthosine    B-Organophosphate114969994
monophosphate    I-Organophosphate114969994

In    O
the    O
process    O
,    O
phosphatidylinositol    O
4,5-bisphosphate    O
(    O
PIP2    O
)    O
is    O
cleaved    O
into    O
diacyl    O
glycerol    O
(    O
DAG    O
)    O
and    O
inositol    B-Organophosphate114969994
1,4,5-trisphosphate    I-Organophosphate114969994
(    O
IP3    O
)    O
.    O

Upon    O
activation    O
,    O
a    O
heterotrimeric    O
G    O
protein    O
,    O
Gq    O
,    O
activates    O
phospholipase    O
C    O
(    O
PLC    O
)    O
,    O
which    O
causes    O
an    O
increase    O
in    O
IP3    B-Organophosphate114969994
and    O
calcium    O
.    O

This    O
is    O
thought    O
to    O
result    O
from    O
Ca2    O
+    O
release    O
from    O
intracellular    O
stores    O
,    O
due    O
to    O
inositol    B-Organophosphate114969994
triphosphate    I-Organophosphate114969994
and    O
ryanodine    O
-    O
sensitive    O
channel    O
activation    O
.    O

Born    O
and    O
raised    O
in    O
Southern    O
Rhodesia    O
(    O
today    O
Zimbabwe    O
)    O
,    O
he    O
is    O
best    O
known    O
for    O
his    O
work    O
on    O
cellular    O
transmembrane    O
signalling    O
,    O
in    O
particular    O
the    O
discovery    O
that    O
inositol    B-Organophosphate114969994
trisphosphate    I-Organophosphate114969994
acts    O
as    O
a    O
second    O
messenger    O
,    O
linking    O
events    O
at    O
the    O
plasma    O
membrane    O
with    O
the    O
release    O
of    O
Ca2    O
+    O
within    O
the    O
cell    O
.    O
,    O
he    O
is    O
the    O
Emeritus    O
Babraham    O
Fellow    O
in    O
the    O
Signalling    O
Programme    O
Department    O
of    O
the    O
Babraham    O
Institute    O
,    O
Cambridge    O
,    O
and    O
honorary    O
professor    O
of    O
cell    O
signalling    O
at    O
the    O
University    O
of    O
Cambridge    O
.    O

G    O
protein    O
dependent    O
activation    O
of    O
phospholipase    O
C    O
(    O
PLC    O
)    O
which    O
results    O
in    O
the    O
breakdown    O
of    O
the    O
membrane    O
constituent    O
phospholipid    O
,    O
phosphatidylinositol    O
(    O
4,5)-bisphosphate    O
(    O
PIP2    O
)    O
into    O
inositol    B-Organophosphate114969994
(1,4,5)-trisphosphate    I-Organophosphate114969994
(    O
IP3    O
)    O
and    O
diacyl    O
glycerol    O
(    O
DAG    O
)    O
.    O

Inositol    B-Organophosphate114969994
triphosphate    I-Organophosphate114969994

#    O
IP3    B-Organophosphate114969994
induces    O
calcium    O
ion    O
release    O

Phospholipase    O
C    O
cleaves    O
the    O
membrane    O
phospholipid    O
,    O
phosphatidyl    O
inositol    O
4,5-bisphosphate    O
,    O
into    O
inositol    B-Organophosphate114969994
1,4,5-trisphosphate    I-Organophosphate114969994
and    O
diacylglycerol    O
.    O

The    O
following    O
table    O
gives    O
these    O
receptors    O
:    O
a    O
)    O
full    O
name    O
;    O
b    O
)    O
shortened    O
names    O
;    O
c    O
)    O
activating    O
prostanoids    O
(    O
presented    O
in    O
order    O
of    O
decreasing    O
potencies    O
)    O
;    O
d    O
)    O
time    O
-    O
honored    O
classification    O
as    O
contractile    O
(    O
i.e.    O
conracting    O
smooth    O
muscle    O
)    O
,    O
relaxant    O
(    O
i.e.    O
relaxing    O
smooth    O
muscle    O
)    O
,    O
or    O
inhibitory    O
(    O
i.e.    O
inhibiting    O
adenyl    O
cyclase    O
(    O
AC    O
)    O
production    O
of    O
cyclic    B-Organophosphate114969994
AMP    I-Organophosphate114969994
[    O
cAMP    O
]    O
)    O
;    O
e    O
)    O
G    O
proteins    O
types    O
to    O
which    O
they    O
link    O
and    O
activate    O
,    O
i.e.    O
those    O
containing    O
the    O
Gs    O
alpha    O
subunit    O
,    O
Gi    O
alpha    O
subunit    O
,    O
Gq    O
alpha    O
subunit    O
and/or    O
G12    O
subunit    O
;    O
and    O
f    O
)    O
signaling    O
pathways    O
which    O
they    O
regulate    O
including    O
Adenyl    O
cyclase    O
which    O
when    O
activated    O
increases    O
cellular    O
cAMP    B-Organophosphate114969994
and    O
when    O
inhibited    O
reduces    O
the    O
cellular    O
levels    O
of    O
this    O
secondary    O
messenger    O
;    O
Phosphoinositide    O
3-kinase    O
which    O
when    O
activated    O
is    O
responsible    O
for    O
forming    O
phosphatidylinositol    O
3-phosphate    O
,    O
phosphatidylinositol    O
(    O
3,4)-bisphosphate    O
,    O
and    O
phosphatidylinositol    O
(    O
3,4,5)-trisphosphate    O
secondary    O
messengers    O
;    O
Phospholipase    O
C    O
(    O
PLC    O
)    O
which    O
when    O
activated    O
is    O
responsible    O
for    O
forming    O
Inositol    B-Organophosphate114969994
trisphosphate    I-Organophosphate114969994
(    O
IP3    O
)    O
and    O
diacylglycerol    O
secondary    O
messengers    O
that    O
are    O
,    O
respectively    O
,    O
responsible    O
for    O
raising    O
the    O
levels    O
of    O
Ca2    O
+    O
in    O
the    O
cellular    O
cytosol    O
to    O
control    O
the    O
activity    O
of    O
Ca2    O
+    O
-cell    O
signaling    O
agents    O
and    O
for    O
activating    O
protein    O
kinase    O
C    O
(    O
PKC    O
)    O
secondary    O
messengers    O
;    O
and    O
Extracellular    O
signal    O
â€“    O
regulated    O
kinases    O
(    O
ERK    O
)    O
,    O
p38    O
mitogen    O
-    O
activated    O
protein    O
kinases    O
(    O
p38    O
Mpk    O
)    O
,    O
and    O
cAMP    O
response    O
element    O
-    O
binding    O
protein    O
(    O
CREB    O
)    O
which    O
when    O
activated    O
phosphorylate    O
and    O
thereby    O
influence    O
the    O
activity    O
of    O
key    O
proteins    O
that    O
govern    O
cell    O
function    O
.    O

In    O
particular    O
,    O
Gq    O
stimulates    O
cell    O
signal    O
pathways    O
involving    O
a    O
)    O
phospholipase    O
C    O
/    O
IP3    B-Organophosphate114969994
Ca2    O
+    O
mobilization    O
/    O
diacylglycerol    O
/    O
protein    O
kinase    O
Cs    O
;    O
calmodulin    O
-    O
modulated    O
myosin    O
light    O
chain    O
kinase    O
;    O
RAF    O
/    O
MEK    O
/    O
Mitogen    O
-    O
activated    O
protein    O
kinases    O
;    O
PKC    O
/    O
Ca2+/Calcineurin    O
/    O
Nuclear    O
factor    O
of    O
activated    O
T    O
-    O
cells    O
;    O
and    O
the    O
EGF    O
cellular    O
receptor    O
.    O

When    O
bound    O
to    O
PGI2    O
or    O
other    O
of    O
its    O
agonists    O
,    O
IP    O
stimulates    O
one    O
or    O
more    O
of    O
three    O
types    O
of    O
G    O
protein    O
complexes    O
,    O
depending    O
on    O
cell    O
type    O
:    O
a    O
)    O
Gs    O
alpha    O
subunit    O
-    O
GÎ²Î³    O
complexes    O
which    O
release    O
Gs    O
that    O
then    O
stimulates    O
adenyl    O
cyclase    O
to    O
raise    O
intracellular    O
levels    O
of    O
cAMP    O
and    O
thereby    O
activate    O
cAMP    O
-    O
regulated    O
protein    O
kinases    O
A    O
-    O
dependent    O
cell    O
signaling    O
pathways    O
(    O
see    O
PKA    O
)    O
;    O
b    O
)    O
Gq    O
alpha    O
subunit    O
-    O
GÎ²Î³    O
complexes    O
which    O
release    O
Gq    O
that    O
then    O
stimulates    O
other    O
cell    O
signaling    O
pathways    O
(    O
e.g.    O
phospholipase    O
C    O
/    O
IP3    B-Organophosphate114969994
Ca2    O
+    O
mobilization    O
/    O
diacylglycerol    O
/    O
protein    O
kinase    O
Cs    O
,    O
calmodulin    O
-    O
modulated    O
myosin    O
light    O
chain    O
kinase    O
,    O
RAF    O
/    O
MEK    O
/    O
Mitogen    O
-    O
activated    O
protein    O
kinases    O
,    O
PKC    O
/    O
Ca2+/Calcineurin    O
/    O
Nuclear    O
factor    O
of    O
activated    O
T    O
-    O
cells    O
;    O
and    O
EGF    O
cellular    O
receptors    O
;    O
and    O
c    O
)    O
Gi    O
alpha    O
subunit    O
-    O
GiÎ²Î³    O
)    O
complexes    O
which    O
releases    O
Gi    O
that    O
then    O
simulates    O
phospholipase    O
C    O
to    O
cleave    O
phosphatidylinositol    O
triphosphate    O
into    O
inositol    B-Organophosphate114969994
triphosphate    I-Organophosphate114969994
that    O
raises    O
intracellular    O
CaCa2    O
levels    O
thereby    O
regulating    O
Calcium    O
signaling    O
pathways    O
and    O
diacylglycerol    O
that    O
activates    O
certain    O
protein    O
kinase    O
C    O
enzymes    O
)    O
that    O
phosphorylate    O
and    O
thereby    O
regulate    O
target    O
proteins    O
involved    O
in    O
cell    O
signaling    O
(    O
see    O
Protein    O
kinase    O
C#Function    O
)    O
.    O

The    O
Ca2    O
+    O
,    O
IP3    B-Organophosphate114969994
,    O
and    O
DAG    O
work    O
together    O
in    O
a    O
signal    O
transduction    O
pathway    O
to    O
internalize    O
AMPA    O
receptors    O
and    O
decrease    O
the    O
sensitivity    O
of    O
the    O
postsynaptic    O
cell    O
to    O
glutamate    O
.    O

Inositol    O
1,4,5-trisphosphate    O
3-kinase    O
(    O
ITP3    O
K    O
)    O
catalyzes    O
the    O
transfer    O
of    O
the    O
gamma    O
-    O
phosphate    O
from    O
ATP    O
to    O
the    O
3-position    O
of    O
inositol    B-Organophosphate114969994
1,4,5-trisphosphate    I-Organophosphate114969994
to    O
form    O
inositol    O
1,3,4,5-tetrakisphosphate    O
.    O

These    O
intracellular    O
events    O
eventually    O
lead    O
to    O
activation    O
of    O
phospholipase    O
C    O
(    O
PLC    O
)    O
,    O
which    O
cleaves    O
the    O
phospholipid    O
PIP2    O
into    O
diacylglycerol    O
(    O
DAG    O
)    O
and    O
inositol    B-Organophosphate114969994
1,4,5-trisphosphate    I-Organophosphate114969994
(IP3)    I-Organophosphate114969994
.    O

The    O
other    O
ADP    O
-    O
receptor    O
P2Y1    O
couples    O
to    O
Gq    O
that    O
activates    O
phospholipase    O
C    O
-    O
beta    O
2    O
PLCB2    O
,    O
resulting    O
in    O
inositol    B-Organophosphate114969994
1,4,5-trisphosphate    I-Organophosphate114969994
(    O
IP3)generation    O
and    O
intracellular    O
release    O
of    O
more    O
calcium    O
.    O

PLC    O
hydrolyses    O
the    O
membrane    O
phospholipid    O
PIP2    O
to    O
form    O
IP3    B-Organophosphate114969994
and    O
diacylglycerol    O
(    O
DAG    O
)    O
,    O
two    O
classical    O
second    O
messengers    O
.    O

Aldolase    O
has    O
also    O
been    O
implicated    O
in    O
many    O
"    O
moonlighting    O
"    O
or    O
non    O
-    O
catalytic    O
functions    O
,    O
based    O
upon    O
its    O
binding    O
affinity    O
for    O
multiple    O
other    O
proteins    O
including    O
F    O
-    O
actin    O
,    O
Î±-tubulin    O
,    O
light    O
chain    O
dynein    O
,    O
WASP    O
,    O
Band    O
3    O
anion    O
exchanger    O
,    O
phospholipase    O
D    O
(    O
PLD2    O
)    O
,    O
glucose    O
transporter    O
GLUT4    O
,    O
inositol    B-Organophosphate114969994
trisphosphate    I-Organophosphate114969994
,    O
V    O
-    O
ATPase    O
and    O
ARNO    O
(    O
a    O
guanine    O
nucleotide    O
exchange    O
factor    O
of    O
ARF6    O
)    O
.    O

Finally    O
,    O
certain    O
alkylated    O
amines    O
have    O
been    O
described    O
to    O
activate    O
VÎ³9/VÎ´2    O
T    O
cells    O
"    O
in    O
vitro    O
"    O
,    O
however    O
only    O
at    O
millimolar    O
concentrations    O
,    O
i.e.    O
with    O
potencies    O
106    O
-    O
108fold    O
lower    O
than    O
those    O
of    O
HMB-PP    B-Organophosphate114969994
,    O
thereby    O
questioning    O
their    O
physiological    O
relevance    O
.    O

Thus    O
,    O
the    O
presence    O
of    O
a    O
functional    O
VÎ³9/VÎ´2    O
TCR    O
appears    O
mandatory    O
for    O
a    O
response    O
to    O
non    O
-    O
peptidic    O
antigens    O
although    O
the    O
basis    O
for    O
the    O
huge    O
differences    O
in    O
bioactivity    O
between    O
closely    O
related    O
molecules    O
like    O
HMB-PP    B-Organophosphate114969994
and    O
IPP    B-Organophosphate114969994
can    O
not    O
be    O
explained    O
by    O
conventional    O
epitope    O
presentation    O
/    O
recognition    O
models    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
dolichyl    O
beta    O
-    O
D    O
-    O
mannosyl    O
phosphate    O
and    O
H2O    O
,    O
whereas    O
its    O
two    O
products    O
are    O
dolichyl    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
and    O
D    O
-    O
mannose    O
.    O

First    O
,    O
two    O
"    O
N    O
"-    O
acetyl    O
glucosamine    O
residues    O
are    O
attached    O
to    O
dolichol    B-Organophosphate114969994
monophosphate    I-Organophosphate114969994
,    O
a    O
lipid    O
,    O
on    O
the    O
external    O
side    O
of    O
the    O
endoplasmic    O
reticulum    O
membrane    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
UDP    O
-    O
N    O
-    O
acetyl    O
-    O
D    O
-    O
glucosamine    O
and    O
dolichyl    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
,    O
whereas    O
its    O
two    O
products    O
are    O
UMP    O
and    O
N    O
-    O
acetyl    O
-    O
D    O
-    O
glucosaminyl    O
-    O
diphosphodolichol    O
.    O

Creatinolfosfate    B-Organophosphate114969994
(    O
creatinol-"O    O
"-    O
phosphate    O
,    O
creatinol    O
phosphate    O
,    O
COP    O
)    O
is    O
a    O
cardiac    O
preparation    O
,    O
not    O
to    O
be    O
confused    O
with    O
phosphocreatine    O
.    O

Glyceraldehyde-3-phosphate    B-Organophosphate114969994
is    O
converted    O
to    O
glucose    O
which    O
is    O
later    O
converted    O
by    O
the    O
plant    O
to    O
storage    O
forms    O
(    O
e.g.    O
,    O
starch    O
or    O
cellulose    O
)    O
or    O
used    O
for    O
energy    O
.    O

Transcription    O
of    O
the    O
"    O
lsr    O
"    O
operon    O
is    O
also    O
thought    O
to    O
be    O
inhibited    O
by    O
dihydroxyacetone    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
(    O
DHAP    O
)    O
through    O
its    O
competitive    O
binding    O
to    O
LsrR.    O
Glyceraldehyde    B-Organophosphate114969994
3-phosphate    I-Organophosphate114969994
has    O
also    O
been    O
shown    O
to    O
inhibit    O
the    O
"    O
lsr    O
"    O
operon    O
through    O
cAMP    B-Organophosphate114969994
-    O
CAPK    O
-    O
mediated    O
inhibition    O
.    O

The    O
heterotrophic    O
processing    O
of    O
carbohydrates    O
involves    O
isomerization    O
of    O
triose    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
and    O
interconversion    O
between    O
fructose-6-phosphate    B-Organophosphate114969994
and    O
glucose-6-phosphate    B-Organophosphate114969994
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
pyruvate    O
and    O
D-glyceraldehyde    B-Organophosphate114969994
3-phosphate    I-Organophosphate114969994
,    O
whereas    O
its    O
two    O
products    O
are    O
1-deoxy-D-xylulose    B-Organophosphate114969994
5-phosphate    I-Organophosphate114969994
and    O
CO2    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
D    O
-    O
xylulose    O
5-phosphate    O
and    O
formaldehyde    O
,    O
whereas    O
its    O
two    O
products    O
are    O
glyceraldehyde    B-Organophosphate114969994
3-phosphate    I-Organophosphate114969994
and    O
glycerone    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
D-glyceraldehyde    B-Organophosphate114969994
3-phosphate    I-Organophosphate114969994
and    O
L    O
-    O
arginine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
N2-(2-carboxyethyl)-L    O
-    O
arginine    O
and    O
phosphate    O
.    O

Pyruvate    O
and    O
glyceraldehyde    B-Organophosphate114969994
3-phosphate    I-Organophosphate114969994
are    O
converted    O
by    O
DOXP    O
synthase    O
(    O
Dxs    O
)    O
to    O
1-deoxy    O
-    O
D    O
-    O
xylulose    O
5-phosphate    O
,    O
and    O
by    O
DOXP    O
reductase    O
(    O
Dxr    O
,    O
IspC    O
)    O
to    O
2-"C    O
"-    O
methyl    O
-    O
D    O
-    O
erythritol    O
4-phosphate    O
(    O
MEP    O
)    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
ATP    O
and    O
D    O
-    O
glyceraldehyde    O
,    O
whereas    O
its    O
two    O
products    O
are    O
ADP    O
and    O
D-glyceraldehyde    B-Organophosphate114969994
3-phosphate    I-Organophosphate114969994
.    O

sedoheptulose    B-Organophosphate114969994
7-phosphate    I-Organophosphate114969994
+    O
glyceraldehyde    B-Organophosphate114969994
3-phosphate    I-Organophosphate114969994
erythrose    B-Organophosphate114969994
4-phosphate    I-Organophosphate114969994
+    O
fructose    B-Organophosphate114969994
6-phosphate    I-Organophosphate114969994

Then    O
transaldolase    O
catalyzes    O
the    O
condensation    O
of    O
glyceraldehyde-3-phosphate    B-Organophosphate114969994
with    O
the    O
Schiff    O
base    O
of    O
dihydroxyacetone    O
,    O
yielding    O
enzyme    O
-    O
bound    O
fructose    B-Organophosphate114969994
6-phosphate    I-Organophosphate114969994
.    O

Ribulose    O
5-phosphate    O
can    O
alternatively    O
undergo    O
a    O
series    O
of    O
isomerizations    O
as    O
well    O
as    O
transaldolations    O
and    O
transketolations    O
that    O
result    O
in    O
the    O
production    O
of    O
other    O
pentose    O
phosphates    O
as    O
well    O
as    O
fructose    B-Organophosphate114969994
6-phosphate    I-Organophosphate114969994
and    O
glyceraldehyde    B-Organophosphate114969994
3-phosphate    I-Organophosphate114969994
(    O
both    O
intermediates    O
in    O
glycolysis    O
)    O
.    O

Fructose    O
-    O
bisphosphate    O
aldolase    O
,    O
often    O
just    O
aldolase    O
,    O
is    O
an    O
enzyme    O
catalyzing    O
a    O
reversible    O
reaction    O
that    O
splits    O
the    O
aldol    O
,    O
fructose    B-Organophosphate114969994
1,6-bisphosphate    I-Organophosphate114969994
,    O
into    O
the    O
triose    O
phosphates    O
dihydroxyacetone    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
(    O
DHAP    O
)    O
and    O
glyceraldehyde    B-Organophosphate114969994
3-phosphate    I-Organophosphate114969994
(    O
G3P    O
)    O
.    O

Glyceraldehyde    B-Organophosphate114969994
3-phosphate    I-Organophosphate114969994

6-Phosphogluconolactone    B-Organophosphate114969994
is    O
an    O
intermediate    O
in    O
the    O
pentose    O
phosphate    O
pathway    O
.    O

:    O
"    O
Phosphorylcholine    O
refers    O
to    O
the    O
functional    O
group    O
derived    O
from    O
phosphocholine    B-Organophosphate114969994
.    O

:    O
(    O
1    O
)    O
CDP-choline    B-Organophosphate114969994
+    O
H2O    O
CMP    O
+    O
phosphocholine    B-Organophosphate114969994

Phosphocholine    B-Organophosphate114969994

para-Nitrophenylphosphate    B-Organophosphate114969994
is    O
converted    O
into    O
a    O
yellow    O
product    O
by    O
alkaline    O
phosphatase    O
enzyme    O
.    O

NOSs    O
can    O
be    O
dimeric    O
,    O
calmodulin    O
-    O
dependent    O
or    O
calmodulin    O
-    O
containing    O
cytochrome    O
p450-like    O
hemoprotein    O
that    O
combines    O
reductase    O
and    O
oxygenase    O
catalytic    O
domains    O
in    O
one    O
dimer    O
,    O
bear    O
both    O
flavin    B-Organophosphate114969994
adenine    I-Organophosphate114969994
dinucleotide    I-Organophosphate114969994
(    O
FAD    O
)    O
and    O
flavin    B-Organophosphate114969994
mononucleotide    I-Organophosphate114969994
(    O
FMN    O
)    O
,    O
and    O
carry    O
out    O
a    O
5`-electron    O
oxidation    O
of    O
non    O
-    O
aromatic    O
amino    O
acid    O
arginine    O
with    O
the    O
aid    O
of    O
tetrahydrobiopterin    O
.    O

Phototropins    O
are    O
composed    O
of    O
two    O
LOV    O
domains    O
,    O
each    O
containing    O
a    O
non    O
-    O
covalently    O
bound    O
flavin    B-Organophosphate114969994
mononucleotide    I-Organophosphate114969994
(    O
FMN    O
)    O
chromophore    O
in    O
its    O
dark    O
-    O
state    O
form    O
,    O
and    O
a    O
C    O
-    O
terminal    O
Ser    O
-    O
Thr    O
kinase    O
.    O

An    O
example    O
of    O
the    O
Rossmann    O
fold    O
,    O
a    O
structural    O
domain    O
of    O
a    O
decarboxylase    O
protein    O
from    O
the    O
bacterium    O
Staphylococcus    O
epidermidis    O
(    O
PDB    O
ID    O
1G5Q    O
)    O
with    O
the    O
bound    O
flavin    B-Organophosphate114969994
mononucleotide    I-Organophosphate114969994
cofactor    O
shown    O
.    O

Luciferase    O
produces    O
blue    O
/    O
green    O
light    O
through    O
the    O
oxidation    O
of    O
reduced    O
flavin    B-Organophosphate114969994
mononucleotide    I-Organophosphate114969994
and    O
a    O
long    O
-    O
chain    O
aldehyde    O
by    O
diatomic    O
oxygen    O
.    O

This    O
saturation    O
reaction    O
is    O
assisted    O
by    O
a    O
FMN    B-Organophosphate114969994
cofactor    I-Organophosphate114969994
and    O
the    O
enzyme    O
is    O
a    O
member    O
of    O
the    O
a    O
/    O
ÃŸ    O
-    O
barrel    O
flavoprotein    O
family    O
.    O

The    O
B    O
protein    O
is    O
a    O
flavin    B-Organophosphate114969994
mononucleotide    I-Organophosphate114969994
(    O
FMN)-dependent    O
dehydrogenase    O
which    O
oxidizes    O
certain    O
azoline    O
rings    O
into    O
azoles    O
.    O

In    O
addition    O
to    O
NADPH    O
,    O
E.    O
Coli    O
DECR    O
requires    O
a    O
set    O
of    O
FAD    B-Organophosphate114969994
,    O
FMN    B-Organophosphate114969994
and    O
iron    O
-    O
sulfur    O
cluster    O
molecules    O
to    O
complete    O
the    O
electron    O
transfer    O
.    O

Flavodoxin    O
is    O
a    O
bacterial    O
protein    O
that    O
includes    O
flavin    B-Organophosphate114969994
mononucleotide    I-Organophosphate114969994
.    O

It    O
can    O
emit    O
bluish    O
-    O
green    O
light    O
(    O
490    O
nm    O
)    O
due    O
to    O
a    O
chemical    O
reaction    O
between    O
FMN    B-Organophosphate114969994
,    O
luciferin    O
and    O
molecular    O
oxygen    O
catalysed    O
by    O
an    O
enzyme    O
called    O
luciferase    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
ATP    O
and    O
riboflavin    O
,    O
whereas    O
its    O
two    O
products    O
are    O
ADP    O
and    O
FMN    B-Organophosphate114969994
.    O

The    O
enzyme    O
contains    O
a    O
magnesium    O
binding    O
site    O
at    O
amino    O
acids    O
131    O
and    O
133    O
,    O
and    O
a    O
Flavin    B-Organophosphate114969994
mononucleotide    I-Organophosphate114969994
binding    O
site    O
at    O
amino    O
acids    O
188    O
and    O
195    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
alpha    O
-    O
D    O
-    O
glucose    O
1-phosphate    O
and    O
riboflavin    O
,    O
whereas    O
its    O
two    O
products    O
are    O
D    O
-    O
glucose    O
and    O
FMN    B-Organophosphate114969994
.    O

An    O
example    O
of    O
the    O
Rossmann    O
fold    O
,    O
a    O
structural    O
domain    O
of    O
a    O
decarboxylase    O
enzyme    O
from    O
the    O
bacterium    O
"    O
Staphylococcus    O
epidermidis    O
"    O
with    O
a    O
bound    O
flavin    B-Organophosphate114969994
mononucleotide    I-Organophosphate114969994
cofactor    O
.    O

A    O
particularly    O
rich    O
natural    O
source    O
of    O
F420    O
is    O
"    O
Mycobacterium    O
smegmatis    O
"    O
,    O
in    O
which    O
several    O
dozen    O
enzymes    O
use    O
F420    O
instead    O
of    O
the    O
related    O
cofactor    O
FMN    B-Organophosphate114969994
used    O
by    O
homologous    O
enzymes    O
in    O
most    O
other    O
species    O
.    O

Then    O
m1G37    O
acts    O
as    O
a    O
substrate    O
for    O
the    O
enzyme    O
TYW1    O
and    O
forms    O
the    O
tricyclic    O
core    O
of    O
wybutosine    O
with    O
flavin    B-Organophosphate114969994
mononucleotide    I-Organophosphate114969994
(    O
FMN    O
)    O
as    O
a    O
cofactor    O
.    O

:    O
ATP    O
+    O
tetrahydromethanopterin    B-Organophosphate114969994
+    O
L    O
-    O
glutamate    O
ADP    O
+    O
phosphate    O
+    O
5,6,7,8-tetrahydrosarcinapterin    O

Tetrahydromethanopterin    B-Organophosphate114969994

They    O
made    O
several    O
discoveries    O
critical    O
to    O
understanding    O
carbohydrate    O
metabolism    O
,    O
including    O
the    O
isolation    O
and    O
discovery    O
of    O
the    O
Cori    B-Organophosphate114969994
ester    I-Organophosphate114969994
,    O
glucose-1    O
phosphate    O
,    O
and    O
the    O
understanding    O
of    O
the    O
Cori    O
cycle    O
.    O

Hence    O
,    O
this    O
enzyme    O
has    O
one    O
substrate    O
,    O
beta-D-glucose    B-Organophosphate114969994
1-phosphate    I-Organophosphate114969994
,    O
and    O
one    O
product    O
,    O
beta    O
-    O
D    O
-    O
glucose    O
6-phosphate    O
.    O

Galactose    O
is    O
therefore    O
preferentially    O
converted    O
into    O
glucose-1-phosphate    B-Organophosphate114969994
,    O
which    O
may    O
be    O
shunted    O
into    O
glycolysis    O
or    O
the    O
inositol    O
synthesis    O
pathway    O
.    O

The    O
enzyme    O
removes    O
1,4    O
glycosyl    O
residues    O
from    O
outer    O
branches    O
of    O
glycogen    O
and    O
adds    O
inorganic    O
phosphate    O
to    O
form    O
glucose-1-phosphate    B-Organophosphate114969994
.    O

They    O
include    O
allosteric    O
enzymes    O
that    O
catalyze    O
the    O
production    O
of    O
glucose-1-phosphate    B-Organophosphate114969994
from    O
a    O
glucan    O
such    O
as    O
glycogen    O
,    O
starch    O
or    O
maltodextrin    O
.    O

Hence    O
,    O
this    O
enzyme    O
has    O
one    O
substrate    O
,    O
dimethylallyl    B-Organophosphate114969994
diphosphate    I-Organophosphate114969994
,    O
and    O
two    O
products    O
,    O
diphosphate    O
and    O
lavandulyl    O
diphosphate    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
dimethylallyl    B-Organophosphate114969994
diphosphate    I-Organophosphate114969994
and    O
(    O
-)-(2S)-naringenin    O
,    O
whereas    O
its    O
two    O
products    O
are    O
diphosphate    O
and    O
sophoraflavanone    O
B.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
dimethylallyl    B-Organophosphate114969994
diphosphate    I-Organophosphate114969994
and    O
L    O
-    O
tryptophan    O
,    O
whereas    O
its    O
two    O
products    O
are    O
diphosphate    O
and    O
4-(3-methylbut-2-enyl)-L    O
-    O
tryptophan    O
.    O

The    O
biosynthesis    O
of    O
Î±-terpinene    O
and    O
other    O
terpenoids    O
occurs    O
via    O
the    O
mevalonate    O
pathway    O
because    O
its    O
starting    O
reactant    O
,    O
dimethylallyl    B-Organophosphate114969994
pyrophosphate    I-Organophosphate114969994
(    O
DMAPP    O
)    O
,    O
is    O
derived    O
from    O
mevalonic    O
acid    O
.    O

Dimethylallyl    B-Organophosphate114969994
pyrophosphate    I-Organophosphate114969994
is    O
then    O
obtained    O
from    O
the    O
deoxyxylulose    O
pathway    O
,    O
where    O
prenylation    O
of    O
the    O
benzenoid    O
occurs    O
,    O
yielding    O
humulone    O
.    O

IPP    O
is    O
isomerized    O
to    O
the    O
allylic    O
ester    O
dimethylallyl    B-Organophosphate114969994
pyrophosphate    I-Organophosphate114969994
(    O
DMAPP    O
)    O
by    O
IPP    O
isomerase    O
.    O

Finally    O
,    O
MEcPP    O
is    O
converted    O
to    O
(    O
"    O
E")-4-hydroxy-3-methyl    O
-    O
but-2-enyl    O
pyrophosphate    O
(    O
HMB-PP    B-Organophosphate114969994
)    O
by    O
HMB    O
-    O
PP    O
synthase    O
(    O
GcpE    O
,    O
IspG    O
)    O
,    O
and    O
HMB    O
-    O
PP    O
is    O
converted    O
to    O
isopentenyl    B-Organophosphate114969994
pyrophosphate    I-Organophosphate114969994
(    O
IPP    O
)    O
and    O
dimethylallyl    B-Organophosphate114969994
pyrophosphate    I-Organophosphate114969994
(    O
DMAPP    O
)    O
by    O
HMB    O
-    O
PP    O
reductase    O
(    O
LytB    O
,    O
IspH    O
)    O
.    O

Simplified    O
version    O
of    O
the    O
steroid    O
synthesis    O
pathway    O
with    O
the    O
terpenoid    O
intermediates    O
isopentenyl    B-Organophosphate114969994
pyrophosphate    I-Organophosphate114969994
(    O
IPP    O
)    O
,    O
dimethylallyl    B-Organophosphate114969994
pyrophosphate    I-Organophosphate114969994
(    O
DMAPP    O
)    O
,    O
geranyl    B-Organophosphate114969994
pyrophosphate    I-Organophosphate114969994
(    O
GPP    O
)    O
,    O
and    O
squalene    O
shown    O
.    O

Isoprene    O
itself    O
does    O
not    O
undergo    O
the    O
building    O
process    O
,    O
but    O
rather    O
activated    O
forms    O
,    O
isopentenyl    B-Organophosphate114969994
pyrophosphate    I-Organophosphate114969994
(    O
IPP    O
or    O
also    O
isopentenyl    O
diphosphate    O
)    O
and    O
dimethylallyl    B-Organophosphate114969994
pyrophosphate    I-Organophosphate114969994
(    O
DMAPP    O
or    O
also    O
dimethylallyl    O
diphosphate    O
)    O
,    O
are    O
the    O
components    O
in    O
the    O
biosynthetic    O
pathway    O
.    O

Isopentenyl    O
pyrophosphate    O
isomerase    O
(    O
IPP    O
isomerase    O
)    O
,    O
also    O
known    O
as    O
Isopentenyl    O
-    O
diphosphate    O
delta    O
isomerase    O
,    O
is    O
an    O
isomerase    O
that    O
catalyzes    O
the    O
conversion    O
of    O
the    O
relatively    O
un    O
-    O
reactive    O
isopentenyl    B-Organophosphate114969994
pyrophosphate    I-Organophosphate114969994
(    O
IPP    O
)    O
to    O
the    O
more    O
-    O
reactive    O
electrophile    O
dimethylallyl    B-Organophosphate114969994
pyrophosphate    I-Organophosphate114969994
(    O
DMAPP    O
)    O
.    O

The    O
metabolism    O
of    O
propionyl    O
-    O
CoA    O
occurs    O
in    O
the    O
mitochondria    O
and    O
requires    O
Vitamin    O
(    O
as    O
adenosylcobalamin    O
)    O
to    O
make    O
succinyl-CoA    B-Organophosphate114969994
When    O
the    O
conversion    O
of    O
propionyl    O
-    O
CoA    O
to    O
succinyl    O
-    O
CoA    O
in    O
the    O
mitochondria    O
fails    O
due    O
to    O
Vitamin    O
deficiency    O
,    O
elevated    O
blood    O
levels    O
of    O
methylmalonic    O
acid    O
(    O
MMA    O
)    O
occur    O
.    O

Processing    O
of    O
cholesterol    O
and    O
protein    O
gives    O
propionyl    O
-    O
CoA    O
that    O
is    O
converted    O
to    O
methylmalonyl-CoA    B-Organophosphate114969994
,    O
which    O
is    O
used    O
by    O
MUT    O
enzyme    O
to    O
make    O
succinyl-CoA    B-Organophosphate114969994
Vitamin    O
is    O
needed    O
to    O
prevent    O
anemia    O
,    O
since    O
making    O
porphyrin    O
and    O
heme    O
in    O
mitochondria    O
for    O
producing    O
hemoglobin    O
in    O
red    O
blood    O
cells    O
depends    O
on    O
succinyl-CoA    B-Organophosphate114969994
made    O
by    O
vitamin    O
.    O

The    O
3    O
substrates    O
of    O
this    O
enzyme    O
are    O
succinyl-CoA    B-Organophosphate114969994
,    O
(    O
S)-2,3,4,5-tetrahydropyridine-2,6-dicarboxylate    O
,    O
and    O
H2O    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    B-Organophosphate114969994
and    O
N    O
-    O
succinyl    O
-    O
L-2-amino-6-oxoheptanedioate    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
succinyl-CoA    B-Organophosphate114969994
and    O
acetyl-CoA    B-Organophosphate114969994
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    B-Organophosphate114969994
and    O
3-oxoadipyl    O
-    O
CoA.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
succinyl-CoA    B-Organophosphate114969994
and    O
L    O
-    O
arginine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    B-Organophosphate114969994
and    O
N2-succinyl    O
-    O
L    O
-    O
arginine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
succinyl-CoA    B-Organophosphate114969994
and    O
enzyme    O
N6-(dihydrolipoyl)lysine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    B-Organophosphate114969994
and    O
enzyme    O
N6-(S    O
-    O
succinyldihydrolipoyl)lysine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
succinyl-CoA    B-Organophosphate114969994
and    O
L    O
-    O
homoserine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    B-Organophosphate114969994
and    O
O    O
-    O
succinyl    O
-    O
L    O
-    O
homoserine    O
.    O

During    O
a    O
metabolic    O
network    O
reconstruction    O
of    O
"    O
Lactobacillus    O
plantarum    O
"    O
,    O
the    O
model    O
showed    O
that    O
succinyl-CoA    B-Organophosphate114969994
was    O
one    O
of    O
the    O
reactants    O
for    O
a    O
reaction    O
that    O
was    O
a    O
part    O
of    O
the    O
biosynthesis    O
of    O
methionine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
succinyl-CoA    B-Organophosphate114969994
and    O
H2O    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    B-Organophosphate114969994
and    O
succinate    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
geranyl    B-Organophosphate114969994
diphosphate    I-Organophosphate114969994
(    O
a    O
10    O
carbon    O
precursor    O
)    O
and    O
isopentenyl    B-Organophosphate114969994
diphosphate    I-Organophosphate114969994
(    O
a    O
5    O
carbon    O
precursor    O
)    O
whereas    O
its    O
two    O
products    O
are    O
diphosphate    O
and    O
trans,trans-farnesyl    B-Organophosphate114969994
diphosphate    I-Organophosphate114969994
(    O
a    O
15    O
carbon    O
product    O
)    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
geranyl    B-Organophosphate114969994
diphosphate    I-Organophosphate114969994
and    O
isopentenyl    B-Organophosphate114969994
diphosphate    I-Organophosphate114969994
,    O
whereas    O
its    O
two    O
products    O
are    O
diphosphate    O
and    O
(    O
2Z,6E)-farnesyl    O
diphosphate    O
.    O

Geranyl    B-Organophosphate114969994
pyrophosphate    I-Organophosphate114969994
(    O
GPP    O
)    O
is    O
produced    O
from    O
the    O
reaction    O
of    O
a    O
resonance    O
-    O
stable    O
allylic    O
cation    O
,    O
formed    O
from    O
the    O
loss    O
of    O
the    O
pyrophosphate    O
group    O
from    O
DMAPP    O
,    O
and    O
isopentenyl    B-Organophosphate114969994
pyrophosphate    I-Organophosphate114969994
(    O
IPP    O
)    O
,    O
and    O
the    O
subsequent    O
loss    O
of    O
a    O
proton    O
.    O

Geranyl    B-Organophosphate114969994
pyrophosphate    I-Organophosphate114969994
(    O
GPP    O
)    O
is    O
the    O
precursor    O
for    O
iridoids    O
.    O

Through    O
a    O
multi    O
-    O
step    O
process    O
,    O
including    O
the    O
dephosphorylation    O
DMAPP    O
,    O
IPP    O
and    O
DMAPP    O
are    O
combined    O
to    O
form    O
the    O
C10    O
compound    O
geranyl    B-Organophosphate114969994
pyrophosphate    I-Organophosphate114969994
(    O
GPP    O
)    O
.    O

Synthesis    O
of    O
all    O
higher    O
terpenoids    O
proceeds    O
via    O
formation    O
of    O
geranyl    B-Organophosphate114969994
pyrophosphate    I-Organophosphate114969994
(    O
GPP    O
)    O
,    O
farnesyl    B-Organophosphate114969994
pyrophosphate    I-Organophosphate114969994
(    O
FPP    O
)    O
,    O
and    O
geranylgeranyl    B-Organophosphate114969994
pyrophosphate    I-Organophosphate114969994
(    O
GGPP    O
)    O
.    O

Simplified    O
version    O
of    O
the    O
steroid    O
synthesis    O
pathway    O
with    O
the    O
terpenoid    O
intermediates    O
isopentenyl    B-Organophosphate114969994
pyrophosphate    I-Organophosphate114969994
(    O
IPP    O
)    O
,    O
dimethylallyl    B-Organophosphate114969994
pyrophosphate    I-Organophosphate114969994
(    O
DMAPP    O
)    O
,    O
geranyl    B-Organophosphate114969994
pyrophosphate    I-Organophosphate114969994
(    O
GPP    O
)    O
,    O
and    O
squalene    O
shown    O
.    O

In    O
higher    O
plants    O
,    O
linalool    O
,    O
as    O
other    O
monoterpenoids    O
,    O
is    O
produced    O
from    O
isopentenyl    O
pyrophosphate    O
via    O
the    O
universal    O
isoprenoid    O
intermediate    O
geranyl    B-Organophosphate114969994
pyrophosphate    I-Organophosphate114969994
,    O
through    O
a    O
class    O
of    O
membrane    O
-    O
bound    O
enzymes    O
named    O
monoterpene    O
synthases    O
.    O

The    O
biosynthesis    O
of    O
CBG    O
begins    O
by    O
loading    O
hexanoyl    O
-    O
CoA    O
onto    O
a    O
polyketide    O
synthase    O
assembly    O
protein    O
and    O
subsequent    O
condensation    O
with    O
three    O
molecules    O
of    O
malonyl    O
-    O
CoA.    O
This    O
polyketide    O
is    O
cyclized    O
to    O
olivetolic    O
acid    O
via    O
olivetolic    O
acid    O
cyclase    O
,    O
and    O
then    O
prenylated    O
with    O
a    O
ten    O
carbon    O
isoprenoid    O
precursor    O
,    O
geranyl    B-Organophosphate114969994
pyrophosphate    I-Organophosphate114969994
(    O
GPP    O
)    O
,    O
using    O
an    O
aromatic    O
prenyltransferase    O
enzyme    O
,    O
geranyl    O
-    O
pyrophosphateâ€”    O

An    O
organic    O
solvent    O
composed    O
of    O
30%    O
tributyl    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
(    O
TBP    O
)    O
in    O
a    O
hydrocarbon    O
solvent    O
,    O
such    O
as    O
kerosene    O
,    O
is    O
used    O
to    O
extract    O
the    O
uranium    O
as    O
UO2(NO3)2Â·2TBP    O
complexes    O
,    O
and    O
plutonium    O
as    O
similar    O
complexes    O
,    O
from    O
other    O
fission    O
products    O
,    O
which    O
remain    O
in    O
the    O
aqueous    O
phase    O
.    O

The    O
other    O
is    O
from    O
the    O
medium    O
-    O
active    O
cycle    O
in    O
which    O
the    O
uranium    O
and    O
plutonium    O
are    O
refined    O
by    O
a    O
second    O
extraction    O
with    O
tributyl    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
.    O

The    O
plant    O
uses    O
the    O
"    O
plutonium    O
uranium    O
extraction    O
"    O
Purex    O
method    O
for    O
reprocessing    O
spent    O
fuel    O
,    O
with    O
tributyl    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
as    O
an    O
extraction    O
agent    O
.    O

The    O
concentration    O
of    O
gold(III    O
)    O
in    O
the    O
extracts    O
may    O
exceed    O
1    O
mol    O
/    O
L.    O
The    O
most    O
frequently    O
used    O
extractants    O
for    O
this    O
purpose    O
are    O
dibutyl    O
glycol    O
,    O
methyl    O
isobutyl    O
ketone    O
,    O
tributyl    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
,    O
dichlorodiethyl    O
ether    O
(    O
chlorex    O
)    O
.    O

Thorium    O
is    O
extracted    O
mostly    O
from    O
monazite    O
:    O
thorium    O
pyrophosphate    O
(    O
ThP2O7    O
)    O
is    O
reacted    O
with    O
nitric    O
acid    O
,    O
and    O
the    O
produced    O
thorium    O
nitrate    O
treated    O
with    O
tributyl    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
.    O

Geranyl    B-Organophosphate114969994
pyrophosphate    I-Organophosphate114969994
(    O
GPP    O
)    O
is    O
produced    O
from    O
the    O
reaction    O
of    O
a    O
resonance    O
-    O
stable    O
allylic    O
cation    O
,    O
formed    O
from    O
the    O
loss    O
of    O
the    O
pyrophosphate    O
group    O
from    O
DMAPP    O
,    O
and    O
isopentenyl    B-Organophosphate114969994
pyrophosphate    I-Organophosphate114969994
(    O
IPP    O
)    O
,    O
and    O
the    O
subsequent    O
loss    O
of    O
a    O
proton    O
.    O

Phosphosphomevalonate    O
decarboxylase    O
through    O
a    O
concerted    O
decarboxylation    O
reaction    O
affords    O
isopentenyl    B-Organophosphate114969994
pyrophosphate    I-Organophosphate114969994
(    O
IPP    O
)    O
.    O

Finally    O
,    O
MEcPP    O
is    O
converted    O
to    O
(    O
"    O
E")-4-hydroxy-3-methyl    O
-    O
but-2-enyl    O
pyrophosphate    O
(    O
HMB-PP    B-Organophosphate114969994
)    O
by    O
HMB    O
-    O
PP    O
synthase    O
(    O
GcpE    O
,    O
IspG    O
)    O
,    O
and    O
HMB    O
-    O
PP    O
is    O
converted    O
to    O
isopentenyl    B-Organophosphate114969994
pyrophosphate    I-Organophosphate114969994
(    O
IPP    O
)    O
and    O
dimethylallyl    B-Organophosphate114969994
pyrophosphate    I-Organophosphate114969994
(    O
DMAPP    O
)    O
by    O
HMB    O
-    O
PP    O
reductase    O
(    O
LytB    O
,    O
IspH    O
)    O
.    O

Chemical    O
structure    O
of    O
the    O
terpenoid    O
isopentenyl    B-Organophosphate114969994
pyrophosphate    I-Organophosphate114969994
,    O
an    O
intermediate    O
in    O
the    O
HMG    O
-    O
CoA    O
reductase    O
pathway    O
.    O

Simplified    O
version    O
of    O
the    O
steroid    O
synthesis    O
pathway    O
with    O
the    O
terpenoid    O
intermediates    O
isopentenyl    B-Organophosphate114969994
pyrophosphate    I-Organophosphate114969994
(    O
IPP    O
)    O
,    O
dimethylallyl    B-Organophosphate114969994
pyrophosphate    I-Organophosphate114969994
(    O
DMAPP    O
)    O
,    O
geranyl    B-Organophosphate114969994
pyrophosphate    I-Organophosphate114969994
(    O
GPP    O
)    O
,    O
and    O
squalene    O
shown    O
.    O

Isoprene    O
itself    O
does    O
not    O
undergo    O
the    O
building    O
process    O
,    O
but    O
rather    O
activated    O
forms    O
,    O
isopentenyl    B-Organophosphate114969994
pyrophosphate    I-Organophosphate114969994
(    O
IPP    O
or    O
also    O
isopentenyl    O
diphosphate    O
)    O
and    O
dimethylallyl    B-Organophosphate114969994
pyrophosphate    I-Organophosphate114969994
(    O
DMAPP    O
or    O
also    O
dimethylallyl    O
diphosphate    O
)    O
,    O
are    O
the    O
components    O
in    O
the    O
biosynthetic    O
pathway    O
.    O

Of    O
note    O
,    O
all    O
VÎ³9/VÎ´2    O
T    O
cells    O
recognize    O
the    O
same    O
small    O
microbial    O
compound    O
(    O
"    O
E")-4-hydroxy-3-methyl    O
-    O
but-2-enyl    O
pyrophosphate    O
(    O
HMB-PP    B-Organophosphate114969994
)    O
,    O
a    O
natural    O
intermediate    O
of    O
the    O
non-mevalonate    B-Organophosphate114969994
pathway    I-Organophosphate114969994
of    O
isopentenyl    B-Organophosphate114969994
pyrophosphate    I-Organophosphate114969994
(    O
IPP    O
)    O
biosynthesis    O
.    O

IPP    B-Organophosphate114969994
itself    O
is    O
structurally    O
closely    O
related    O
to    O
HMB-PP    B-Organophosphate114969994
and    O
ubiquitously    O
present    O
in    O
all    O
living    O
cells    O
(    O
i.e.    O
also    O
in    O
human    O
cells    O
)    O
,    O
yet    O
its    O
potency    O
"    O
in    O
vitro    O
"    O
is    O
reduced    O
10,000    O
fold    O
;    O
whether    O
IPP    O
represents    O
a    O
physiological    O
'    O
danger    O
'    O
signal    O
of    O
stressed    O
or    O
transformed    O
cells    O
is    O
still    O
unclear    O
.    O

Thus    O
,    O
the    O
presence    O
of    O
a    O
functional    O
VÎ³9/VÎ´2    O
TCR    O
appears    O
mandatory    O
for    O
a    O
response    O
to    O
non    O
-    O
peptidic    O
antigens    O
although    O
the    O
basis    O
for    O
the    O
huge    O
differences    O
in    O
bioactivity    O
between    O
closely    O
related    O
molecules    O
like    O
HMB-PP    B-Organophosphate114969994
and    O
IPP    B-Organophosphate114969994
can    O
not    O
be    O
explained    O
by    O
conventional    O
epitope    O
presentation    O
/    O
recognition    O
models    O
.    O

Isopentenyl    O
pyrophosphate    O
isomerase    O
(    O
IPP    O
isomerase    O
)    O
,    O
also    O
known    O
as    O
Isopentenyl    O
-    O
diphosphate    O
delta    O
isomerase    O
,    O
is    O
an    O
isomerase    O
that    O
catalyzes    O
the    O
conversion    O
of    O
the    O
relatively    O
un    O
-    O
reactive    O
isopentenyl    B-Organophosphate114969994
pyrophosphate    I-Organophosphate114969994
(    O
IPP    O
)    O
to    O
the    O
more    O
-    O
reactive    O
electrophile    O
dimethylallyl    B-Organophosphate114969994
pyrophosphate    I-Organophosphate114969994
(    O
DMAPP    O
)    O
.    O

Cyclic    B-Organophosphate114969994
pyranopterin    I-Organophosphate114969994
monophosphate    I-Organophosphate114969994

The    O
3    O
substrates    O
of    O
this    O
enzyme    O
are    O
phosphoenolpyruvate    B-Organophosphate114969994
,    O
N    O
-    O
acyl    O
-    O
D    O
-    O
mannosamine    O
6-phosphate    O
,    O
and    O
H2O    O
,    O
whereas    O
its    O
two    O
products    O
are    O
N    O
-    O
acylneuraminate    O
9-phosphate    O
and    O
phosphate    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
phosphoenolpyruvate    B-Organophosphate114969994
and    O
UDP    O
-    O
N    O
-    O
acetyl    O
-    O
D    O
-    O
glucosamine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
phosphate    O
and    O
UDP    O
-    O
N    O
-    O
acetyl-3-O-(1-carboxyvinyl)-D    O
-    O
glucosamine    O
.    O

During    O
gluconeogenesis    O
,    O
pyruvate    O
carboxylase    O
is    O
involved    O
in    O
the    O
synthesis    O
of    O
phosphoenolpyruvate    B-Organophosphate114969994
(    O
PEP    O
)    O
from    O
pyruvate    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
phosphoenolpyruvate    B-Organophosphate114969994
and    O
glycerone    O
,    O
whereas    O
its    O
two    O
products    O
are    O
pyruvate    O
and    O
glycerone    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
phosphoenolpyruvate    B-Organophosphate114969994
and    O
protein    O
histidine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
pyruvate    O
and    O
protein    O
Npi    O
-    O
phospho    O
-    O
L    O
-    O
histidine    O
.    O

PPDK    O
catalyses    O
the    O
conversion    O
of    O
pyruvate    O
to    O
phosphoenolpyruvate    B-Organophosphate114969994
(    O
PEP    O
)    O
,    O
consuming    O
1    O
molecule    O
of    O
ATP    O
,    O
and    O
producing    O
one    O
molecule    O
of    O
AMP    O
in    O
the    O
process    O
.    O

The    O
3    O
substrates    O
of    O
this    O
enzyme    O
are    O
ATP    O
,    O
pyruvate    O
,    O
and    O
H2O    O
,    O
whereas    O
its    O
3    O
products    O
are    O
AMP    O
,    O
phosphoenolpyruvate    B-Organophosphate114969994
,    O
and    O
phosphate    O
.    O

The    O
shikimate    O
pathway    O
consists    O
of    O
seven    O
enzymatic    O
reactions    O
by    O
which    O
phosphoenolpyruvate    B-Organophosphate114969994
and    O
erythrose    B-Organophosphate114969994
4-phosphate    I-Organophosphate114969994
are    O
converted    O
to    O
chorismate    O
,    O
the    O
common    O
precursor    O
of    O
the    O
aromatic    O
amino    O
acids    O
phenylalanine    O
,    O
tyrosine    O
,    O
and    O
tryptophan    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
phosphoenolpyruvate    B-Organophosphate114969994
and    O
H2O    O
,    O
whereas    O
its    O
two    O
products    O
are    O
pyruvate    O
and    O
phosphate    O
.    O

At    O
this    O
stage    O
,    O
phosphoenolpyruvate    B-Organophosphate114969994
and    O
erythrose-4-phosphate    O
react    O
to    O
form    O
3-deoxy-D-arabinoheptulosonate-7-phosphate    B-Organophosphate114969994
(    O
DAHP    O
)    O
,    O
in    O
a    O
reaction    O
catalyzed    O
by    O
the    O
enzyme    O
DAHP    O
synthase    O
.    O

:    O
PEP    B-Organophosphate114969994
+    O
NADH    O
+    O
H+    O
+    O
ATP    O
+    O
H2O    O
)    O
fructose    O
1,6-bisphosphate    O
+    O
2(NAD+    O
+    O
ADP    O
+    O
Pi    O
)    O

G6PD    O
converts    O
glucose-6-phosphate    B-Organophosphate114969994
into    O
6-phosphoglucono-Î´-lactone    B-Organophosphate114969994
and    O
is    O
the    O
rate    O
-    O
limiting    O
enzyme    O
of    O
this    O
metabolic    O
pathway    O
that    O
supplies    O
reducing    O
energy    O
to    O
cells    O
by    O
maintaining    O
the    O
level    O
of    O
the    O
reduced    O
form    O
of    O
the    O
co    O
-    O
enzyme    O
nicotinamide    O
adenine    O
dinucleotide    O
phosphate    O
(    O
NADPH    O
)    O
.    O

More    O
precisely    O
,    O
it    O
facilitates    O
the    O
interconversion    O
of    O
glucose    B-Organophosphate114969994
1-phosphate    I-Organophosphate114969994
and    O
glucose    B-Organophosphate114969994
6-phosphate    I-Organophosphate114969994
.    O

Hence    O
,    O
this    O
enzyme    O
has    O
one    O
substrate    O
,    O
D-glucose    B-Organophosphate114969994
6-phosphate    I-Organophosphate114969994
,    O
and    O
one    O
product    O
,    O
1D-myo-inositol    B-Organophosphate114969994
3-phosphate    I-Organophosphate114969994
.    O

The    O
glucose-1-phosphate    O
generated    O
in    O
step    O
3    O
of    O
the    O
Leloir    O
pathway    O
may    O
be    O
isomerized    O
to    O
glucose-6-phosphate    B-Organophosphate114969994
by    O
phosphoglucomutase    O
.    O

G6PD    B-Organophosphate114969994
reduces    O
NADP+    O
to    O
NADPH    O
while    O
oxidizing    O
glucose-6-phosphate    O
.    O

Reaction    O
1    O
is    O
a    O
pretreatment    O
of    O
the    O
sample    O
performed    O
by    O
adding    O
glucokinase    O
to    O
convert    O
glucose    O
to    O
glucose    B-Organophosphate114969994
6-phosphate    I-Organophosphate114969994
in    O
the    O
presence    O
of    O
adenosine    O
triphosphate    O
,    O
pyruvate    O
kinase    O
,    O
and    O
phosphoenol    B-Organophosphate114969994
pyruvate    I-Organophosphate114969994
.    O

G6Pase    O
is    O
located    O
in    O
the    O
endoplasmic    O
reticulum    O
(    O
ER    O
)    O
and    O
catalyzes    O
the    O
hydrolysis    O
of    O
glucose    B-Organophosphate114969994
6-phosphate    I-Organophosphate114969994
to    O
glucose    O
and    O
phosphate    O
in    O
the    O
last    O
step    O
of    O
the    O
gluconeogenic    O
and    O
glycogenolytic    O
pathways    O
.    O

The    O
glucose    O
that    O
enters    O
the    O
Î²-cell    O
is    O
phosphorylated    O
to    O
glucose-6-phosphate    B-Organophosphate114969994
(    O
G-6-P    O
)    O
by    O
glucokinase    O
(    O
hexokinase    O
IV    O
)    O
which    O
is    O
not    O
inhibited    O
by    O
G-6-P    O
in    O
the    O
way    O
that    O
the    O
hexokinases    O
in    O
other    O
tissues    O
(    O
hexokinase    O
I    O
â€“    O

The    O
heterotrophic    O
processing    O
of    O
carbohydrates    O
involves    O
isomerization    O
of    O
triose    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
and    O
interconversion    O
between    O
fructose-6-phosphate    B-Organophosphate114969994
and    O
glucose-6-phosphate    B-Organophosphate114969994
.    O

It    O
is    O
produced    O
from    O
glucose-6-phosphate    B-Organophosphate114969994
by    O
glucose-6-phosphate    O
dehydrogenase    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
GDP    O
-    O
mannose    O
and    O
dolichyl    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
,    O
whereas    O
its    O
two    O
products    O
are    O
GDP    B-Organophosphate114969994
and    O
dolichyl    B-Organophosphate114969994
D-mannosyl    I-Organophosphate114969994
phosphate    I-Organophosphate114969994
.    O

Kappadione    B-Organophosphate114969994
is    O
a    O
Vitamin    O
K    O
derivative    O
.    O

Cytosolic    O
Glycerol-3-phosphate    O
dehydrogenase    O
(    O
GPD1    O
)    O
,    O
is    O
an    O
NAD+-dependent    O
enzyme    O
that    O
reduces    O
dihydroxyacetone    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
to    O
glycerol-3-phosphate    B-Organophosphate114969994
.    O

Mitochondrial    O
glycerol-3-phosphate    O
dehydrogenase    O
(    O
GPD2    O
)    O
,    O
catalyzes    O
the    O
irreversible    O
oxidation    O
of    O
glycerol-3-phosphate    B-Organophosphate114969994
to    O
dihydroxyacetone    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
and    O
concomitantly    O
transfers    O
two    O
electrons    O
from    O
FAD    B-Organophosphate114969994
to    O
the    O
electron    O
transport    O
chain    O
.    O

Oxidation    O
of    O
cytoplasmic    O
NADH    O
by    O
the    O
cytosolic    O
form    O
of    O
the    O
enzyme    O
creates    O
glycerol-3-phosphate    B-Organophosphate114969994
from    O
dihydroxyacetone    O
phosphate    O
.    O

substrate    O
pages    O
:    O
glycerol    B-Organophosphate114969994
3-phosphate    I-Organophosphate114969994
,    O
dihydroxyacetone    B-Organophosphate114969994
phosphate    I-Organophosphate114969994

(    O
D    O
)    O
glycerol    O
pathway    O
reducing    O
DHAP    O
to    O
glycerol-3-phosphate    B-Organophosphate114969994
(    O
G3P    O
)    O
by    O
G3P    O
dehydrogenase    O
,    O
followed    O
by    O
dephosphorylation    O
to    O
glycerol    O
by    O
G3Pase    O
.    O
(    O
E    O
)    O
The    O
lower    O
part    O
of    O
glycolysis    O
converts    O
GAP    O
to    O
pyruvate    O
while    O
generating    O
1    O
NADH    O
and    O
2    O
ATP    O
via    O
a    O
series    O
of    O
5    O
enzymes    O
.    O

2-Phosphoglyceric    B-Organophosphate114969994
acid    I-Organophosphate114969994

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
ATP    O
and    O
(    O
R)-glycerate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
ADP    O
and    O
either    O
3-phospho-(R)-glycerate    B-Organophosphate114969994
or    O
2-phospho-(R)-glycerate    B-Organophosphate114969994
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
D-glycerate    B-Organophosphate114969994
2-phosphate    I-Organophosphate114969994
and    O
H2O    O
,    O
whereas    O
its    O
two    O
products    O
are    O
D    O
-    O
glycerate    O
and    O
phosphate    O
.    O

mangafodipir    B-Organophosphate114969994
(    O
INN    O
)    O

It    O
is    O
an    O
organophosphate    O
oxon    B-Organophosphate114969994
,    O
and    O
the    O
active    O
metabolite    O
of    O
the    O
insecticide    O
parathion    O
.    O

3-Phosphoglycerate    B-Organophosphate114969994

3-Phosphoglyceric    B-Organophosphate114969994
acid    I-Organophosphate114969994

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
ATP    O
and    O
(    O
R)-glycerate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
ADP    O
and    O
either    O
3-phospho-(R)-glycerate    B-Organophosphate114969994
or    O
2-phospho-(R)-glycerate    B-Organophosphate114969994
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
GTP    B-Organophosphate114969994
and    O
3-phospho-D-glycerate    B-Organophosphate114969994
,    O
whereas    O
its    O
two    O
products    O
are    O
GDP    B-Organophosphate114969994
and    O
3-phospho-D-glyceroyl    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
.    O

Glycerate    B-Organophosphate114969994
3-phosphate    I-Organophosphate114969994
,    O
a    O
3-carbon    O
molecule    O

The    O
occurrence    O
of    O
photorespiration    O
in    O
plants    O
,    O
due    O
to    O
the    O
lack    O
of    O
substrate    O
specificity    O
of    O
rubisco    O
,    O
leads    O
to    O
the    O
formation    O
of    O
2-phosphoglycolate    O
and    O
3-phosphogylcerate    B-Organophosphate114969994
)    O
.    O

In    O
both    O
pathways    O
3-phosphoglycerate    B-Organophosphate114969994
(    O
3-PGA    O
or    O
3-PG    O
)    O
is    O
reduced    O
to    O
fructose    O
1,6-bisphosphate    O
with    O
aldolase    O
catalyzing    O
the    O
last    O
reaction    O
.    O

:    O
3-PG    B-Organophosphate114969994
+    O
NADPH    O
+    O
H+    O
+    O
ATP    O
+    O
H2O    O
)    O
fructose    O
1,6-bisphosphate    O
+    O
2(NADP+    O
+    O
ADP    O
+    O
Pi    O
)    O

Defined    O
by    O
their    O
mechanisms    O
,    O
two    O
main    O
classes    O
of    O
histone    O
demethylases    O
exist    O
:    O
a    O
flavin    B-Organophosphate114969994
adenine    I-Organophosphate114969994
dinucleotide    I-Organophosphate114969994
(FAD)    I-Organophosphate114969994
amine    O
oxidase    O
,    O
and    O
an    O
Fe(II    O
)    O
and    O
Î±-ketoglutarate    O
-    O
dependent    O
dioxygenase    O
,    O
with    O
the    O
general    O
proposed    O
mechanisms    O
shown    O
in    O
the    O
figure    O
below    O
.    O

The    O
cry2    O
mutation    O
identified    O
in    O
position    O
260    O
(    O
A260    O
T    O
)    O
affects    O
the    O
cofactor    O
(    O
FAD    B-Organophosphate114969994
)    O
binding    O
domain    O
of    O
CRY2    O
.    O

In    O
functional    O
"    O
Neurospora    O
''    O
,    O
the    O
WC-1    O
LOV    O
domain    O
binds    O
to    O
the    O
flavin    B-Organophosphate114969994
adenine    I-Organophosphate114969994
dinucleotide    I-Organophosphate114969994
(FAD)    I-Organophosphate114969994
chromophore    O
,    O
which    O
is    O
responsible    O
for    O
the    O
conversion    O
of    O
light    O
to    O
mechanical    O
energy    O
.    O

It    O
also    O
allows    O
high    O
energy    O
molecules    O
to    O
form    O
;    O
3x    O
NADH    O
,    O
FADH2    B-Organophosphate114969994
,    O
and    O
GTP    B-Organophosphate114969994
/    O
ATP    O
are    O
all    O
produced    O
by    O
one    O
iteration    O
of    O
the    O
cycle    O
.    O

In    O
molecular    O
biology    O
,    O
the    O
FAD    O
dependent    O
oxidoreductase    O
family    O
of    O
proteins    O
is    O
a    O
family    O
of    O
FAD    B-Organophosphate114969994
dependent    O
oxidoreductases    O
.    O

In    O
addition    O
to    O
NADPH    O
,    O
E.    O
Coli    O
DECR    O
requires    O
a    O
set    O
of    O
FAD    B-Organophosphate114969994
,    O
FMN    B-Organophosphate114969994
and    O
iron    O
-    O
sulfur    O
cluster    O
molecules    O
to    O
complete    O
the    O
electron    O
transfer    O
.    O

Squalene    O
monooxygenase    O
contains    O
a    O
loosely    O
bound    O
FAD    B-Organophosphate114969994
flavin    O
and    O
obtains    O
electrons    O
from    O
NADPH    O
-    O
cytochrome    O
P450    O
reductase    O
,    O
rather    O
than    O
binding    O
the    O
nicotinamide    O
cofactor    O
NADPH    O
directly    O
.    O

It    O
was    O
discovered    O
by    O
J.G.    O
Hauge    O
as    O
the    O
third    O
redox    O
cofactor    O
after    O
nicotinamide    O
and    O
flavin    B-Organophosphate114969994
in    O
bacteria    O
(    O
although    O
he    O
hypothesised    O
that    O
it    O
was    O
naphthoquinone    O
)    O
.    O

Cellular    O
respiration    O
(    O
both    O
aerobic    O
and    O
anaerobic    O
)    O
utilizes    O
highly    O
reduced    O
chemical    O
compounds    O
such    O
as    O
NADH    O
and    O
FADH2    B-Organophosphate114969994
(    O
for    O
example    O
produced    O
during    O
glycolysis    O
and    O
the    O
citric    O
acid    O
cycle    O
)    O
to    O
establish    O
an    O
electrochemical    O
gradient    O
(    O
often    O
a    O
proton    O
gradient    O
)    O
across    O
a    O
membrane    O
,    O
resulting    O
in    O
an    O
electrical    O
potential    O
or    O
ion    O
concentration    O
difference    O
across    O
the    O
membrane    O
.    O

Path    O
A    O
involved    O
a    O
nucleophilic    O
attack    O
on    O
the    O
coenzyme    O
FAD    B-Organophosphate114969994
,    O
while    O
path    O
B    O
involves    O
a    O
free    O
-    O
radical    O
intermediate    O
.    O

Initially    O
,    O
SDHA    O
oxidizes    O
succinate    O
via    O
deprotonation    O
at    O
the    O
FAD    B-Organophosphate114969994
binding    O
site    O
,    O
leaving    O
fumarate    O
,    O
loosely    O
bound    O
to    O
the    O
active    O
site    O
,    O
free    O
to    O
exit    O
the    O
protein    O
.    O

Initially    O
,    O
SDHA    O
oxidizes    O
succinate    O
via    O
deprotonation    O
at    O
the    O
FAD    B-Organophosphate114969994
binding    O
site    O
,    O
forming    O
FADH2    B-Organophosphate114969994
and    O
leaving    O
fumarate    O
,    O
loosely    O
bound    O
to    O
the    O
active    O
site    O
,    O
free    O
to    O
exit    O
the    O
protein    O
.    O

Hence    O
,    O
this    O
enzyme    O
has    O
one    O
substrate    O
,    O
FAD    B-Organophosphate114969994
,    O
and    O
two    O
products    O
,    O
AMP    O
and    O
riboflavin    O
cyclic-4',5'-phosphate    O
.    O

The    O
citric    O
acid    O
cycle    O
oxidizes    O
the    O
acetyl    O
-    O
CoA    O
to    O
carbon    O
dioxide    O
,    O
and    O
,    O
in    O
the    O
process    O
,    O
produces    O
reduced    O
cofactors    O
(    O
three    O
molecules    O
of    O
NADH    O
and    O
one    O
molecule    O
of    O
FADH2    B-Organophosphate114969994
)    O
that    O
are    O
a    O
source    O
of    O
electrons    O
for    O
the    O
"    O
electron    O
transport    O
chain    O
"    O
,    O
and    O
a    O
molecule    O
of    O
GTP    B-Organophosphate114969994
(    O
that    O
is    O
readily    O
converted    O
to    O
an    O
ATP    O
)    O
.    O

The    O
3    O
substrates    O
of    O
this    O
enzyme    O
are    O
5,10-methylenetetrahydrofolate    O
,    O
tRNA    O
containing    O
uridine    O
at    O
position    O
54    O
,    O
and    O
FADH2    B-Organophosphate114969994
,    O
whereas    O
its    O
3    O
products    O
are    O
tetrahydrofolate    O
,    O
tRNA    O
containing    O
ribothymidine    O
at    O
position    O
54    O
,    O
and    O
FAD    B-Organophosphate114969994
.    O

The    O
3    O
substrates    O
of    O
this    O
enzyme    O
are    O
5,10-methylenetetrahydrofolate    O
,    O
dUMP    O
,    O
and    O
FADH2    B-Organophosphate114969994
,    O
whereas    O
its    O
3    O
products    O
are    O
dTMP    O
,    O
tetrahydrofolate    O
,    O
and    O
FAD    B-Organophosphate114969994
.    O

The    O
flavin    B-Organophosphate114969994
adenine    I-Organophosphate114969994
dinucleotide    I-Organophosphate114969994
(    O
FAD    O
)    O
is    O
located    O
at    O
the    O
junction    O
between    O
the    O
middle    O
beta    O
-    O
strand    O
and    O
the    O
carboxyl    O
terminal    O
alpha    O
-    O
helix    O
domain    O
of    O
one    O
subunit    O
and    O
the    O
carboxyl    O
-    O
terminal    O
domain    O
of    O
the    O
neighboring    O
subunit    O
.    O

Flavoprotein    O
pyridine    O
nucleotide    O
cytochrome    O
reductases    O
catalyse    O
the    O
interchange    O
of    O
reducing    O
equivalents    O
between    O
one    O
-    O
electron    O
carriers    O
and    O
the    O
two    O
-    O
electron    O
-    O
carrying    O
nicotinamide    B-Organophosphate114969994
dinucleotide    I-Organophosphate114969994
.    O

The    O
products    O
of    O
this    O
process    O
are    O
carbon    O
dioxide    O
and    O
water    O
,    O
but    O
the    O
energy    O
transferred    O
is    O
used    O
to    O
break    O
bonds    O
in    O
ADP    O
as    O
the    O
third    O
phosphate    O
group    O
is    O
added    O
to    O
form    O
ATP    O
(    O
adenosine    O
triphosphate    O
)    O
,    O
by    O
substrate    O
-    O
level    O
phosphorylation    O
,    O
NADH    O
and    O
FADH2    B-Organophosphate114969994

In    O
oxidation    O
,    O
the    O
electrons    O
are    O
stripped    O
from    O
a    O
glucose    O
molecule    O
to    O
reduce    O
NAD+    O
and    O
FAD    B-Organophosphate114969994
.    O

Each    O
monomer    O
contains    O
a    O
FAD    B-Organophosphate114969994
prosthetic    O
group    O
,    O
a    O
NADPH    O
binding    O
domain    O
,    O
and    O
an    O
active    O
site    O
containing    O
a    O
redox    O
-    O
active    O
disulfide    O
bond    O
.    O

E.    O
coli    O
:    O
In    O
"    O
E.    O
coli    O
"    O
ThxR    O
there    O
are    O
two    O
binding    O
domains    O
,    O
one    O
for    O
FAD    B-Organophosphate114969994
and    O
another    O
for    O
NADPH    O
.    O

It    O
contains    O
a    O
FAD    B-Organophosphate114969994
and    O
NADPH    O
binding    O
domain    O
,    O
and    O
an    O
interface    O
between    O
two    O
monomer    O
subunits    O
.    O

In    O
mammalian    O
ThxR    O
there    O
is    O
an    O
insertion    O
in    O
the    O
FAD    B-Organophosphate114969994
binding    O
domain    O
between    O
two    O
alpha    O
helices    O
which    O
forms    O
a    O
small    O
pair    O
of    O
beta    O
strands    O
.    O

The    O
active    O
disulfide    O
in    O
the    O
enzyme    O
is    O
located    O
on    O
one    O
of    O
these    O
helices    O
and    O
thus    O
the    O
active    O
disulfide    O
bond    O
is    O
located    O
in    O
the    O
FAD    B-Organophosphate114969994
domain    O
and    O
not    O
the    O
NADPH    O
domain    O
as    O
in    O
"    O
E.    O
coli    O
"    O
and    O
other    O
prokaryotes    O
.    O

NADH    O
and    O
FADH2    O
are    O
recycled    O
to    O
(    O
NAD+    O
and    O
FAD    B-Organophosphate114969994
,    O
respectively    O
)    O
,    O
generating    O
additional    O
ATP    O
by    O
oxidative    O
phosphorylation    O
.    O

Electron    O
transport    O
chain    O
â€“    O
a    O
biochemical    O
process    O
which    O
associates    O
electron    O
carriers    O
(    O
such    O
as    O
NADH    O
and    O
FADH2    B-Organophosphate114969994
)    O
and    O
mediating    O
biochemical    O
reactions    O
that    O
produce    O
adenosine    O
triphosphate    O
(    O
ATP    O
)    O
,    O
which    O
is    O
a    O
major    O
energy    O
intermediate    O
in    O
living    O
organisms    O
.    O

Electron    O
transport    O
chain    O
â€“    O
A    O
biochemical    O
process    O
which    O
associates    O
electron    O
carriers    O
(    O
such    O
as    O
NADH    O
and    O
FADH2    B-Organophosphate114969994
)    O
and    O
mediating    O
biochemical    O
reactions    O
that    O
produce    O
adenosine    O
triphosphate    O
(    O
ATP    O
)    O
,    O
which    O
is    O
a    O
major    O
energy    O
intermediate    O
in    O
living    O
organisms    O
.    O

AO    O
is    O
a    O
homodimer    O
,    O
and    O
requires    O
FAD    B-Organophosphate114969994
,    O
molybdenum    O
(    O
MoCo    O
)    O
and    O
two    O
2FE-2S    O
clusters    O
as    O
cofactors    O
.    O

Mitochondrial    O
glycerol-3-phosphate    O
dehydrogenase    O
(    O
GPD2    O
)    O
,    O
catalyzes    O
the    O
irreversible    O
oxidation    O
of    O
glycerol-3-phosphate    B-Organophosphate114969994
to    O
dihydroxyacetone    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
and    O
concomitantly    O
transfers    O
two    O
electrons    O
from    O
FAD    B-Organophosphate114969994
to    O
the    O
electron    O
transport    O
chain    O
.    O

Once    O
the    O
glycerol-3-phosphate    O
has    O
moved    O
through    O
the    O
inner    O
mitochondrial    O
membrane    O
it    O
can    O
then    O
be    O
oxidised    O
by    O
a    O
separate    O
isoform    O
of    O
glycerol-3-phosphate    O
dehydrogenase    O
that    O
uses    O
quinone    O
as    O
an    O
oxidant    O
and    O
FAD    B-Organophosphate114969994
as    O
a    O
co    O
-    O
factor    O
.    O

GPDH    O
-    O
M    O
in    O
addition    O
uses    O
FAD    B-Organophosphate114969994
as    O
a    O
co    O
-    O
factor    O
.    O

:    O
geranylgeranyl    B-Organophosphate114969994
diphosphate    I-Organophosphate114969994
+    O
isopentenyl    B-Organophosphate114969994
diphosphate    I-Organophosphate114969994
(    O
geranylfarnesyl    B-Organophosphate114969994
diphosphate    I-Organophosphate114969994
+    O
diphosphate    O

Pyrazophos    B-Organophosphate114969994
is    O
an    O
organic    O
compound    O
used    O
as    O
a    O
fungicide    O
and    O
an    O
insecticide    O
.    O

In    O
the    O
first    O
transesterification    O
,    O
5    O
'    O
end    O
of    O
the    O
intron    O
is    O
cleaved    O
from    O
the    O
upstream    O
exon    O
and    O
joined    O
to    O
the    O
branch    O
site    O
A    O
by    O
a    O
phosphodiester    B-Organophosphate114969994
linkage    O
.    O

However    O
,    O
some    O
of    O
these    O
modified    O
2â€™-sugar    O
AMOs    O
led    O
to    O
negative    O
effects    O
on    O
cell    O
growth    O
.    O
Modifying    O
the    O
5'-3    O
'    O
phosphodiester    B-Organophosphate114969994
backbone    I-Organophosphate114969994
linkage    O
to    O
a    O
phosphorothiorate    O
(    O
P    O
-    O
S    O
)    O
backbone    O
linkage    O

#    O
The    O
first    O
phosphodiester    B-Organophosphate114969994
bond    I-Organophosphate114969994
is    O
formed    O
.    O

RTA    O
specifically    O
and    O
irreversibly    O
hydrolyses    O
the    O
N    O
-    O
glycosidic    O
bond    O
of    O
the    O
adenine    O
residue    O
at    O
position    O
4324    O
(    O
A4324    O
)    O
within    O
the    O
28S    O
rRNA    O
,    O
but    O
leaves    O
the    O
phosphodiester    B-Organophosphate114969994
backbone    O
of    O
the    O
RNA    O
intact    O
.    O

As    O
a    O
result    O
,    O
following    O
incorporation    O
of    O
an    O
NRTI    O
or    O
an    O
NtRTI    O
,    O
the    O
next    O
incoming    O
deoxynucleotide    O
can    O
not    O
form    O
the    O
next    O
5â€²â€“3â€²    O
phosphodiester    B-Organophosphate114969994
bond    O
needed    O
to    O
extend    O
the    O
DNA    O
chain    O
.    O

Nucleic    O
acids    O
can    O
only    O
be    O
synthesized    O
in    O
vivo    O
in    O
the    O
5â€²-to-3â€²    O
direction    O
,    O
as    O
the    O
polymerases    O
that    O
assemble    O
various    O
types    O
of    O
new    O
strands    O
generally    O
rely    O
on    O
the    O
energy    O
produced    O
by    O
breaking    O
nucleoside    O
triphosphate    O
bonds    O
to    O
attach    O
new    O
nucleoside    O
monophosphates    O
to    O
the    O
3â€²-hydroxyl    O
(    O
-OH    O
)    O
group    O
,    O
via    O
a    O
phosphodiester    B-Organophosphate114969994
bond    I-Organophosphate114969994
.    O

A    O
phosphate    O
group    O
attached    O
to    O
the    O
5â€²-end    O
permits    O
ligation    O
of    O
two    O
nucleotides    O
,    O
i.e.    O
,    O
the    O
covalent    O
binding    O
of    O
a    O
5â€²-phosphate    O
to    O
the    O
3â€²-hydroxyl    O
group    O
of    O
another    O
nucleotide    O
,    O
to    O
form    O
a    O
phosphodiester    B-Organophosphate114969994
bond    I-Organophosphate114969994
.    O

Phosphodiester    B-Organophosphate114969994
bond    I-Organophosphate114969994
(    O
circled    O
)    O
between    O
nucleotides    O
.    O

The    O
possible    O
letters    O
are    O
"    O
A    O
"    O
,    O
"    O
C    O
"    O
,    O
"    O
G    O
"    O
,    O
and    O
"    O
T    O
"    O
,    O
representing    O
the    O
four    O
nucleotide    O
bases    O
of    O
a    O
DNA    O
strand    O
â€”    O
adenine    O
,    O
cytosine    O
,    O
guanine    O
,    O
thymine    O
â€”    O
covalently    O
linked    O
to    O
a    O
phosphodiester    B-Organophosphate114969994
backbone    O
.    O

LigIV    O
then    O
joins    O
the    O
DNA    O
ends    O
by    O
catalyzing    O
a    O
covalent    O
phosphodiester    B-Organophosphate114969994
bond    I-Organophosphate114969994
.    O

RNA    O
hydrolysis    O
is    O
a    O
reaction    O
in    O
which    O
a    O
phosphodiester    B-Organophosphate114969994
bond    I-Organophosphate114969994
in    O
th    O
sugar    O
-    O
phosphate    O
backbone    O
of    O
RNA    O
is    O
broken    O
,    O
cleaving    O
the    O
RNA    O
molecule    O
.    O

p53    O
-    O
package    O
-    O
palindromic    O
sequence    O
-    O
Parkinson    O
's    O
disease    O
-    O
pBR322    O
-    O
PCR    O
-    O
pedigree    O
-    O
peptide    O
-    O
peptide    O
bond    O
-    O
phage    O
-    O
phagemid    O
-    O
phenotype    O
-    O
phosphatase    O
,    O
alkaline    O
-    O
phosphodiester    B-Organophosphate114969994
bond    I-Organophosphate114969994
-    O
phosphorylation    O
-    O
physical    O
map    O
-    O
plasmid    O
-    O
point    O
mutation    O
-    O
poly    O
-    O
A    O
track    O
-    O
polyA    O
tail    O
-    O
polyacrylamide    O
gel    O
-    O
polyclonal    O
antibodies    O
-    O
polydactyly    O
-    O
polymerase    O
-    O
polymerase    O
chain    O
reaction    O
-    O
polymorphism    O
-    O
polynucleotide    O
kinase    O
-    O
polypeptide    O
-    O
positional    O
cloning    O
-    O
post    O
-    O
transcriptional    O
regulation    O
-    O
post    O
-    O
translational    O
modification    O
-    O
post    O
-    O
translational    O
processing    O
-    O
post    O
-    O
translational    O
regulation    O
-    O
PRE    O
-    O
Precursor    O
mRNA    O
-    O
primary    O
immunodeficiency    O
-    O
primary    O
transcript    O
-    O
primer    O
-    O
primer    O
extension    O
-    O
probe    O
-    O
processivity    O
-    O
promoter    O
-    O
pronucleus    O
-    O
prostate    O
cancer    O
-    O
protease    O
-    O
protein    O
-    O
Protein    O
translocation    O
-    O
proto    O
-    O
oncogene    O
-    O
pseudogene    O
-    O
pseudoknot    O
-    O
pseudorevertant    O
-    O
pulse    O
sequence    O
database    O
-    O
pulsed    O
field    O
gel    O
electrophoresis    O
-    O
purine    O
-    O
pyrimidine    O

Because    O
nucleases    O
that    O
cleave    O
the    O
phosphodiester    B-Organophosphate114969994
linkage    I-Organophosphate114969994
in    O
DNA    O
are    O
expressed    O
in    O
almost    O
every    O
cell    O
,    O
unmodified    O
DNA    O
molecules    O
are    O
generally    O
degraded    O
before    O
they    O
reach    O
their    O
targets    O
.    O

DNA    O
ligation    O
is    O
the    O
process    O
by    O
which    O
linear    O
DNA    O
pieces    O
are    O
connected    O
to    O
each    O
other    O
via    O
covalent    O
bonds    O
;    O
more    O
specifically    O
,    O
these    O
bonds    O
are    O
phosphodiester    B-Organophosphate114969994
bond    I-Organophosphate114969994
.    O

It    O
is    O
used    O
in    O
immunology    O
for    O
sensitive    O
detection    O
of    O
alkaline    O
phosphatase    O
(    O
with    O
BCIP    B-Organophosphate114969994
)    O
.    O

The    O
acid    O
undergoes    O
a    O
version    O
of    O
the    O
Curtius    O
rearrangement    O
when    O
treated    O
with    O
diphenylphosphoryl    B-Organophosphate114969994
azide    I-Organophosphate114969994
(    O
DPPA    O
)    O
to    O
afford    O
the    O
transient    O
isocyanate    O
(    O
6    O
)    O
.    O

This    O
enzyme    O
participates    O
in    O
inositol    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
metabolism    I-Organophosphate114969994
.    O

This    O
enzyme    O
class    O
participates    O
in    O
10    O
metabolic    O
pathways    O
:    O
inositol    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
metabolism    I-Organophosphate114969994
,    O
phosphatidylinositol    O
signaling    O
system    O
,    O
p53    O
signaling    O
pathway    O
,    O
focal    O
adhesion    O
,    O
tight    O
junction    O
,    O
endometrial    O
cancer    O
,    O
glioma    O
,    O
prostate    O
cancer    O
,    O
melanoma    O
,    O
and    O
small    O
cell    O
lung    O
cancer    O
.    O

This    O
enzyme    O
participates    O
in    O
inositol    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
metabolism    I-Organophosphate114969994
and    O
phosphatidylinositol    O
signaling    O
system    O
.    O

This    O
enzyme    O
participates    O
in    O
inositol    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
metabolism    I-Organophosphate114969994
and    O
phosphatidylinositol    O
signaling    O
system    O
.    O

This    O
enzyme    O
participates    O
in    O
inositol    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
metabolism    I-Organophosphate114969994
and    O
phosphatidylinositol    O
signaling    O
system    O
.    O

Mevinphos    B-Organophosphate114969994

Ethanolamine    O
is    O
the    O
second    O
-    O
most    O
-    O
abundant    O
head    O
group    O
for    O
phospholipids    O
,    O
substances    O
found    O
in    O
biological    O
membranes    O
(    O
particularly    O
those    O
of    O
prokaryotes    O
)    O
,    O
e.g.    O
,    O
phosphatidylethanolamine    B-Organophosphate114969994
.    O

Phosphatidylethanolamines    B-Organophosphate114969994
are    O
a    O
class    O
of    O
phospholipids    O
found    O
in    O
biological    O
membranes    O
.    O

B    O
)    O
Is    O
acylated    O
into    O
membrane    O
phospholipids    O
,    O
particularly    O
Phosphatidylinositols    O
and    O
phosphatidylethanolamine    B-Organophosphate114969994
.    O

B    O
)    O
Is    O
acylated    O
into    O
membrane    O
phospholipids    O
,    O
particularly    O
phosphatidylinositol    O
and    O
phosphatidylethanolamine    B-Organophosphate114969994
.    O

Sphingomyelin    O
(    O
4.42%    O
of    O
the    O
total    O
phospholipids    O
)    O
,    O
phosphatidyl    B-Organophosphate114969994
ethanolamine    I-Organophosphate114969994
(    O
12.8%    O
)    O
,    O
phosphatidyl    O
choline    O
(    O
21.9%    O
)    O
,    O
phosphatidyl    B-Organophosphate114969994
serine    I-Organophosphate114969994
(    O
2.9%    O
)    O
,    O
phosphatidyl    O
inositol    O
(    O
2.7%    O
)    O
,    O
lysophosphatidyl    B-Organophosphate114969994
choline    I-Organophosphate114969994
(    O
5.3%    O
)    O
,    O
phosphatidyl    O
glycerol    O
(    O
8.9%    O
)    O
,    O
phosphatidic    O
acid    O
(    O
4.9%    O
)    O
,    O
and    O
cardiolipin    B-Organophosphate114969994
(    O
3.6%    O
)    O
were    O
identified    O
in    O
the    O
nine    O
genotypes    O
.    O

The    O
inner    O
-    O
leaflet    O
,    O
facing    O
the    O
inside    O
of    O
the    O
cell    O
,    O
contains    O
negatively    O
charged    O
amino    O
-    O
phospholipids    O
and    O
phosphatidylethanolamine    B-Organophosphate114969994
.    O

When    O
PAP    O
is    O
active    O
,    O
diacylglycerols    O
formed    O
by    O
PAP    O
can    O
go    O
on    O
to    O
form    O
any    O
of    O
several    O
products    O
,    O
including    O
phosphatidylethanolamine    B-Organophosphate114969994
,    O
phosphatidylcholine    O
,    O
phosphatidylserine    B-Organophosphate114969994
,    O
and    O
triacylglycerol    O
.    O

PgpB    O
is    O
competitively    O
inhibited    O
by    O
phophatidylethanolamine    B-Organophosphate114969994
(    O
PE    O
)    O
,    O
a    O
phospholipid    O
formed    O
from    O
DAG    O
.    O

The    O
major    O
membrane    O
lipidsPtdCho    O
-    O
Phosphatidylcholine    O
;    O
PtdEtn    O
-    O
Phosphatidylethanolamine    B-Organophosphate114969994
;    O
PtdIns    O
-    O
Phosphatidylinositol    O
;    O
PtdSer    O
-    O
Phosphatidylserine    B-Organophosphate114969994
.    O

ATP    O
+    O
"    O
(    O
R)"-mevalonate    O
ADP    O
+    O
"    O
(    O
phosphomevalonate    B-Organophosphate114969994
.    O

In    O
patients    O
with    O
deficiency    O
of    O
transaldolase    O
,    O
there    O
's    O
an    O
accumulation    O
of    O
erythritol    O
(    O
from    O
erythrose    B-Organophosphate114969994
4-phosphate    I-Organophosphate114969994
)    O
,    O
D    O
-    O
arabitol    O
,    O
and    O
ribitol    O
.    O

This    O
cleavage    O
reaction    O
generates    O
the    O
unusual    O
aldose    O
sugar    O
erythrose-4-phosphate    B-Organophosphate114969994
.    O

Erythrose    B-Organophosphate114969994
4-phosphate    I-Organophosphate114969994
is    O
a    O
phosphate    O
of    O
the    O
simple    O
sugar    O
erythrose    O
.    O

In    O
the    O
Calvin    O
cycle    O
aldolase    O
also    O
catalyzes    O
the    O
production    O
of    O
sedoheptulose    O
1,7-bisphosphate    O
from    O
DHAP    O
and    O
erythrose    B-Organophosphate114969994
4-phosphate    I-Organophosphate114969994
.    O

It    O
is    O
susceptible    O
to    O
oxidation    O
to    O
trimethyl    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
.    O

:    O
(    O
1    O
)    O
CDP-choline    B-Organophosphate114969994
+    O
H2O    O
CMP    O
+    O
phosphocholine    B-Organophosphate114969994

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
CDP-choline    B-Organophosphate114969994
and    O
sphingosine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CMP    O
and    O
sphingosyl    O
-    O
phosphocholine    O
.    O

Perifosine    B-Organophosphate114969994
has    O
been    O
shown    O
to    O
interfere    O
with    O
mTOR    O
activity    O
by    O
degrading    O
its    O
components    O
,    O
such    O
as    O
RICTOR    O
.    O

PI3    O
K    O
inhibitors    O
(    O
e.g.    O
perifosine    B-Organophosphate114969994
in    O
a    O
phase    O
III    O
trial    O
)    O

Disodium    O
guanylate    O
,    O
also    O
known    O
as    O
sodium    O
5'-guanylate    O
and    O
disodium    O
5'-guanylate    O
,    O
is    O
a    O
natural    O
sodium    O
salt    O
of    O
the    O
flavor    O
enhancing    O
nucleotide    O
guanosine    B-Organophosphate114969994
monophosphate    I-Organophosphate114969994
(    O
GMP    O
)    O
.    O

It    O
is    O
produced    O
by    O
combining    O
the    O
sodium    O
salts    O
of    O
the    O
natural    O
compounds    O
guanylic    B-Organophosphate114969994
acid    I-Organophosphate114969994
(    O
E626    O
)    O
and    O
inosinic    B-Organophosphate114969994
acid    I-Organophosphate114969994
(    O
E630    O
)    O
.    O

It    O
reversibly    O
inhibits    O
inosine    O
monophosphate    O
dehydrogenase    O
,    O
the    O
enzyme    O
that    O
controls    O
the    O
rate    O
of    O
synthesis    O
of    O
guanine    B-Organophosphate114969994
monophosphate    I-Organophosphate114969994
in    O
the    O
"    O
de    O
novo    O
"    O
pathway    O
of    O
purine    O
synthesis    O
used    O
in    O
the    O
proliferation    O
of    O
B    O
and    O
T    O
lymphocytes    O
.    O

Guanosine    B-Organophosphate114969994
monophosphate    I-Organophosphate114969994

:    O
ATP    O
+    O
GMP    B-Organophosphate114969994
ADP    O
+    O
GDP    B-Organophosphate114969994

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
ATP    O
and    O
GMP    B-Organophosphate114969994
,    O
whereas    O
its    O
two    O
products    O
are    O
ADP    O
and    O
GDP    B-Organophosphate114969994
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
GDP    O
-    O
mannose    O
and    O
(    O
phosphomannan)n    O
,    O
whereas    O
its    O
two    O
products    O
are    O
GMP    B-Organophosphate114969994
and    O
(    O
phosphomannan)n+1    O
.    O

A    O
congenital    O
molybdenum    O
cofactor    O
deficiency    O
disease    O
,    O
seen    O
in    O
infants    O
,    O
is    O
an    O
inability    O
to    O
synthesize    O
molybdenum    B-Organophosphate114969994
cofactor    I-Organophosphate114969994
,    O
a    O
heterocyclic    O
molecule    O
that    O
binds    O
molybdenum    O
at    O
the    O
active    O
site    O
in    O
all    O
known    O
human    O
enzymes    O
that    O
use    O
molybdenum    O
.    O

The    O
molybdenum    B-Organophosphate114969994
cofactor    I-Organophosphate114969994
(    O
pictured    O
)    O
is    O
composed    O
of    O
a    O
molybdenum    O
-    O
free    O
organic    O
complex    O
called    O
molybdopterin    O
,    O
which    O
has    O
bound    O
an    O
oxidized    O
molybdenum(VI    O
)    O
atom    O
through    O
adjacent    O
sulfur    O
(    O
or    O
occasionally    O
selenium    O
)    O
atoms    O
.    O

The    O
gephyrin    O
protein    O
is    O
also    O
required    O
during    O
molybdenum    B-Organophosphate114969994
cofactor    I-Organophosphate114969994
assembly    O
for    O
insertion    O
of    O
molybdenum    O
.    O

They    O
are    O
also    O
found    O
in    O
several    O
metalloenzymes    O
,    O
e.g.    O
in    O
the    O
molybdenum    B-Organophosphate114969994
cofactor    I-Organophosphate114969994
and    O
in    O
many    O
iron    O
-    O
containing    O
enzymes    O
.    O

The    O
bifunctional    O
6-phosphofructo-2-kinase    O
/    O
fructose-2,6-bisphosphatase    O
(    O
PFKFB    O
)    O
regulates    O
the    O
steady    O
-    O
state    O
concentration    O
of    O
fructose    B-Organophosphate114969994
2,6-bisphosphate    I-Organophosphate114969994
,    O
an    O
activator    O
of    O
a    O
key    O
regulatory    O
enzyme    O
of    O
glycolysis    O
,    O
phosphofructokinase    O
.    O

Phosphofructokinase    O
is    O
an    O
important    O
control    O
point    O
in    O
the    O
glycolytic    O
pathway    O
,    O
since    O
it    O
is    O
one    O
of    O
the    O
irreversible    O
steps    O
and    O
has    O
key    O
allosteric    O
effectors    O
,    O
AMP    O
and    O
fructose    B-Organophosphate114969994
2,6-bisphosphate    I-Organophosphate114969994
(    O
F2,6BP    O
)    O
.    O

Fructose    B-Organophosphate114969994
2,6-bisphosphate    I-Organophosphate114969994
(    O
F2,6BP    O
)    O
is    O
a    O
very    O
potent    O
activator    O
of    O
phosphofructokinase    O
(    O
PFK-1    O
)    O
that    O
is    O
synthesized    O
when    O
F6P    O
is    O
phosphorylated    O
by    O
a    O
second    O
phosphofructokinase    O
(    O
PFK2    O
)    O
.    O

The    O
enzyme    O
adenylosuccinate    O
synthase    O
carries    O
out    O
the    O
reaction    O
by    O
the    O
addition    O
of    O
aspartate    O
to    O
IMP    O
and    O
requires    O
the    O
input    O
of    O
energy    O
from    O
a    O
phosphoanhydride    O
bond    O
in    O
the    O
form    O
of    O
guanosine    B-Organophosphate114969994
triphosphate    I-Organophosphate114969994
(    O
GTP    O
)    O
.    O

In    O
molecular    O
biology    O
,    O
Adenylosuccinate    O
synthase    O
(    O
or    O
adenylosuccinate    O
synthetase    O
)    O
is    O
an    O
enzyme    O
that    O
plays    O
an    O
important    O
role    O
in    O
purine    O
biosynthesis    O
,    O
by    O
catalysing    O
the    O
guanosine    B-Organophosphate114969994
triphosphate    I-Organophosphate114969994
(    O
GTP)-dependent    O
conversion    O
of    O
inosine    B-Organophosphate114969994
monophosphate    I-Organophosphate114969994
(    O
IMP    O
)    O
and    O
aspartic    O
acid    O
to    O
guanosine    B-Organophosphate114969994
diphosphate    I-Organophosphate114969994
(    O
GDP    O
)    O
,    O
phosphate    O
and    O
N(6)-(1,2-dicarboxyethyl)-AMP    O
.    O

The    O
Gs    O
alpha    O
subunit    O
of    O
the    O
stimulated    O
G    O
protein    O
complex    O
exchanges    O
GDP    B-Organophosphate114969994
for    O
GTP    B-Organophosphate114969994
and    O
is    O
released    O
from    O
the    O
complex    O
.    O

It    O
also    O
allows    O
high    O
energy    O
molecules    O
to    O
form    O
;    O
3x    O
NADH    O
,    O
FADH2    B-Organophosphate114969994
,    O
and    O
GTP    B-Organophosphate114969994
/    O
ATP    O
are    O
all    O
produced    O
by    O
one    O
iteration    O
of    O
the    O
cycle    O
.    O

This    O
gene    O
encodes    O
a    O
mitochondrial    O
enzyme    O
that    O
catalyzes    O
the    O
conversion    O
of    O
oxaloacetate    O
(    O
OAA    O
)    O
to    O
phosphoenolpyruvate    B-Organophosphate114969994
(    O
PEP    O
)    O
in    O
the    O
presence    O
of    O
guanosine    B-Organophosphate114969994
triphosphate    I-Organophosphate114969994
(    O
GTP    O
)    O
.    O

When    O
the    O
50S    O
subunit    O
joins    O
,    O
it    O
hydrolyzes    O
GTP    B-Organophosphate114969994
to    O
GDP    B-Organophosphate114969994
and    O
Pi    O
,    O
causing    O
a    O
conformational    O
change    O
in    O
the    O
IF2    O
that    O
causes    O
IF2    O
to    O
release    O
and    O
allow    O
the    O
70S    O
subunit    O
to    O
form    O
.    O

The    O
biosynthesis    O
of    O
molybdopterin    O
begins    O
with    O
guanosine    B-Organophosphate114969994
triphosphate    I-Organophosphate114969994
.    O

Substrate    O
-    O
level    O
phosphorylation    O
is    O
a    O
metabolic    O
reaction    O
that    O
results    O
in    O
the    O
formation    O
of    O
ATP    O
or    O
GTP    B-Organophosphate114969994
by    O
the    O
direct    O
transfer    O
of    O
a    O
phosphoryl    O
(    O
PO3    O
)    O
group    O
to    O
ADP    O
or    O
GDP    B-Organophosphate114969994
from    O
another    O
phosphorylated    O
compound    O
.    O

Their    O
work    O
revealed    O
that    O
the    O
addition    O
of    O
guanine    O
,    O
such    O
as    O
in    O
the    O
molecule    O
guanosine    B-Organophosphate114969994
triphosphate    I-Organophosphate114969994
,    O
to    O
dopamine    O
binding    O
sites    O
could    O
increase    O
the    O
binding    O
affinity    O
of    O
the    O
D4    O
dopamine    O
receptor    O
while    O
decreasing    O
the    O
binding    O
affinity    O
of    O
the    O
D2    O
dopamine    O
receptor    O
.    O

Kinesins    O
are    O
structurally    O
related    O
to    O
G    O
proteins    O
,    O
which    O
hydrolyze    O
GTP    B-Organophosphate114969994
instead    O
of    O
ATP    O
.    O

This    O
enables    O
EF    O
-    O
Tu    O
to    O
bind    O
to    O
a    O
new    O
guanosine    B-Organophosphate114969994
triphosphate    I-Organophosphate114969994
molecule    O
,    O
release    O
EF    O
-    O
Ts    O
,    O
and    O
go    O
on    O
to    O
catalyze    O
another    O
aminoacyl    O
tRNA    O
addition    O
.    O

Aluminum    O
fluoride    O
complexes    O
are    O
used    O
to    O
study    O
the    O
mechanistic    O
aspects    O
of    O
phosphoryl    O
transfer    O
reactions    O
in    O
biology    O
,    O
which    O
are    O
of    O
fundamental    O
importance    O
to    O
cells    O
,    O
as    O
phosphoric    O
acid    O
anhydrides    O
such    O
as    O
ATP    O
and    O
GTP    B-Organophosphate114969994
control    O
most    O
of    O
the    O
reactions    O
involved    O
in    O
metabolism    O
,    O
growth    O
and    O
differentiation    O
.    O

Guanosine    B-Organophosphate114969994
triphosphate    I-Organophosphate114969994
,    O
an    O
organic    O
chemical    O
and    O
energy    O
carrier    O

This    O
protein    O
recruits    O
a    O
small    O
GTPase    O
called    O
Sar1    O
(    O
think    O
of    O
Sar1    O
as    O
a    O
switch    O
,    O
it    O
is    O
active    O
when    O
bound    O
to    O
GTP    B-Organophosphate114969994
and    O
inactive    O
when    O
it    O
hydrolyses    O
the    O
GTP    O
to    O
GDP    B-Organophosphate114969994
)    O
.    O

Oxaloacetate    O
is    O
later    O
decarboxylated    O
and    O
phosphorylated    O
by    O
phosphoenolpyruvate    O
carboxykinase    O
and    O
becomes    O
2-phosphoenolpyruvate    B-Organophosphate114969994
using    O
guanosine    B-Organophosphate114969994
triphosphate    I-Organophosphate114969994
(    O
GTP    O
)    O
as    O
phosphate    O
source    O
.    O

The    O
citric    O
acid    O
cycle    O
oxidizes    O
the    O
acetyl    O
-    O
CoA    O
to    O
carbon    O
dioxide    O
,    O
and    O
,    O
in    O
the    O
process    O
,    O
produces    O
reduced    O
cofactors    O
(    O
three    O
molecules    O
of    O
NADH    O
and    O
one    O
molecule    O
of    O
FADH2    B-Organophosphate114969994
)    O
that    O
are    O
a    O
source    O
of    O
electrons    O
for    O
the    O
"    O
electron    O
transport    O
chain    O
"    O
,    O
and    O
a    O
molecule    O
of    O
GTP    B-Organophosphate114969994
(    O
that    O
is    O
readily    O
converted    O
to    O
an    O
ATP    O
)    O
.    O

Dock11    O
binds    O
and    O
activates    O
nucleotide    O
-    O
free    O
Cdc42    O
via    O
its    O
DHR2    O
domain    O
and    O
has    O
also    O
been    O
reported    O
to    O
mediate    O
positive    O
feedback    O
on    O
active    O
,    O
GTP    B-Organophosphate114969994
-    O
bound    O
Cdc42    O
,    O
although    O
this    O
interaction    O
required    O
a    O
small    O
N    O
-    O
terminal    O
region    O
of    O
Dock11    O
in    O
addition    O
to    O
the    O
DHR2    O
domain    O
.    O

Furthermore    O
,    O
if    O
the    O
bound    O
AdoCbl    O
accrues    O
oxidative    O
damage    O
during    O
normal    O
functioning    O
,    O
"    O
MMAA    O
"    O
protein    O
fosters    O
exchange    O
of    O
the    O
damaged    O
cofactor    O
for    O
a    O
new    O
AdoCbl    O
via    O
a    O
GTP    B-Organophosphate114969994
-    O
reliant    O
pathway    O
.    O

In    O
the    O
activated    O
NMBR    O
/    O
G    O
-    O
protein    O
complex    O
,    O
there    O
occurs    O
an    O
exchange    O
of    O
GTP    B-Organophosphate114969994
for    O
GDP    B-Organophosphate114969994
bound    O
to    O
G-Î±    O
subunit    O
.    O

The    O
main    O
function    O
of    O
the    O
SEC23A    O
protein    O
is    O
to    O
hydrolyze    O
or    O
break    O
down    O
a    O
guanosine    B-Organophosphate114969994
triphosphate    I-Organophosphate114969994
(    O
GTP    O
)    O
molecule    O
bound    O
to    O
the    O
SAR1A    O
protein    O
at    O
the    O
start    O
of    O
the    O
COPII    O
pathway    O
.    O

GTP    B-Organophosphate114969994
,    O
CTP    B-Organophosphate114969994
,    O
and    O
UTP    O
are    O
also    O
nucleotides    O
important    O
in    O
the    O
protein    O
synthesis    O
,    O
lipid    O
synthesis    O
,    O
and    O
carbohydrate    O
metabolism    O
,    O
respectively    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
GTP    B-Organophosphate114969994
and    O
beta    O
-    O
L    O
-    O
fucose    O
1-phosphate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
diphosphate    O
and    O
GDP    O
-    O
L    O
-    O
fucose    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
GTP    B-Organophosphate114969994
and    O
alpha    O
-    O
D    O
-    O
glucose    O
1-phosphate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
diphosphate    O
and    O
GDP    O
-    O
glucose    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
ATP    O
and    O
GTP    B-Organophosphate114969994
,    O
whereas    O
its    O
two    O
products    O
are    O
AMP    O
and    O
guanosine    O
3'-diphosphate    O
5'-triphosphate    O
.    O

Hence    O
,    O
this    O
enzyme    O
has    O
one    O
substrate    O
,    O
GTP    B-Organophosphate114969994
,    O
and    O
two    O
products    O
,    O
diphosphate    O
and    O
P1,P4-bis(5'-guanosyl    O
)    O
tetraphosphate    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
GTP    B-Organophosphate114969994
and    O
5-hydroxy    O
-    O
L    O
-    O
lysine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
GDP    B-Organophosphate114969994
and    O
5-phosphonooxy    O
-    O
L    O
-    O
lysine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
GTP    B-Organophosphate114969994
and    O
alpha-D-mannose    B-Organophosphate114969994
1-phosphate    I-Organophosphate114969994
,    O
whereas    O
its    O
two    O
products    O
are    O
diphosphate    O
and    O
GDP    O
-    O
mannose    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
GTP    B-Organophosphate114969994
and    O
(    O
5')ppPur    O
-    O
mRNA    O
,    O
whereas    O
its    O
two    O
products    O
are    O
diphosphate    O
and    O
G(5')pppPur    O
-    O
mRNA    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
GTP    B-Organophosphate114969994
and    O
3-phospho-D-glycerate    B-Organophosphate114969994
,    O
whereas    O
its    O
two    O
products    O
are    O
GDP    B-Organophosphate114969994
and    O
3-phospho-D-glyceroyl    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
.    O

Every    O
"    O
turn    O
"    O
of    O
the    O
citric    O
acid    O
cycle    O
produces    O
two    O
molecules    O
of    O
carbon    O
dioxide    O
,    O
one    O
equivalent    O
of    O
ATP    O
guanosine    B-Organophosphate114969994
triphosphate    I-Organophosphate114969994
(    O
GTP    O
)    O
through    O
substrate    O
-    O
level    O
phosphorylation    O
catalyzed    O
by    O
succinyl    O
-    O
CoA    O
synthetase    O
,    O
three    O
molecules    O
of    O
NADH    O
,    O
and    O
one    O
equivalent    O
of    O
FADH2    O
.    O

GTP    B-Organophosphate114969994
.    O

fGAR    O
+    O
L    O
-    O
Glutamine    O
+    O
ATP    O
â†’    O
fGAM    B-Organophosphate114969994
+    O
L    O
-    O
Glutamate    O
+    O
ADP    O
+    O
Pi    O

After    O
ingestion    O
,    O
fructose    O
is    O
converted    O
to    O
fructose-1-phosphate    B-Organophosphate114969994
in    O
the    O
liver    O
by    O
fructokinase    O
.    O
Deficiencies    O
of    O
fructokinase    O
cause    O
essential    O
fructosuria    O
,    O
a    O
clinically    O
benign    O
condition    O
characterized    O
by    O
the    O
excretion    O
of    O
unmetabolized    O
fructose    O
in    O
the    O
urine    O
.    O

Aldolase    O
can    O
also    O
produce    O
DHAP    O
from    O
other    O
(    O
3S,4R)-ketose    O
1-phosphates    O
such    O
as    O
fructose    B-Organophosphate114969994
1-phosphate    I-Organophosphate114969994
and    O
sedoheptulose    O
1,7-bisphosphate    O
.    O

Sensitivity    O
to    O
trigger    O
foods    O
may    O
be    O
reduced    O
if    O
calcium    B-Organophosphate114969994
glycerophosphate    I-Organophosphate114969994
and/or    O
sodium    O
bicarbonate    O
is    O
consumed    O
.    O

In    O
the    O
kidney    O
,    O
MIOX    O
converts    O
"    O
myo-"inositol    O
to    O
glucuronic    O
acid    O
which    O
is    O
then    O
able    O
to    O
enter    O
the    O
glucuronate    O
-    O
xylulose    O
pathway    O
for    O
conversion    O
to    O
xylulose-5-phosphate    B-Organophosphate114969994
.    O

D-Xylulose    B-Organophosphate114969994
5-phosphate    I-Organophosphate114969994
(    O
D    O
-    O
xylulose-5-P    O
)    O
is    O
an    O
intermediate    O
in    O
the    O
pentose    O
phosphate    O
pathway    O
.    O

Drugs    O
used    O
in    O
treatment    O
of    O
"    O
A.    O
caninum    O
"    O
infections    O
of    O
dogs    O
include    O
:    O
dichlorvos    B-Organophosphate114969994
,    O
fenbendazole    O
,    O
flubendazole    O
,    O
mebendazole    O
,    O
nitroscanate    O
,    O
piperazine    O
,    O
pyrantel    O
,    O
milbemycin    O
,    O
moxidectin    O
,    O
diethylcarbamazine    O
,    O
oxibendazole    O
,    O
and    O
ivermectin    O
.    O

In    O
2014    O
,    O
Khon    O
Kaen    O
University    O
concluded    O
after    O
a    O
study    O
,    O
that    O
Thailand    O
should    O
ban    O
155    O
types    O
of    O
pesticides    O
,    O
with    O
14    O
listed    O
as    O
urgent    O
:    O
Carbofuran    O
,    O
Methyl    O
Bromide    O
,    O
Dichlorvos    B-Organophosphate114969994
,    O
Lambda    O
-    O
cyhalothrin    O
,    O
Methidathion    O
-    O
methyl    O
,    O
Omethoate    O
,    O
Zeta    O
Cypermethrin    O
,    O
Endosulfan    O
sulfate    O
,    O
Aldicarb    O
,    O
Azinphos    O
-    O
methyl    O
,    O
Chlorpyrifos    O
-    O
ethyl    O
,    O
Methoxychlor    O
and    O
Paraquat    O
.    O

In    O
managing    O
"    O
M.    O
rotundata    O
"    O
for    O
pollination    O
,    O
such    O
methods    O
as    O
dichlorvos    B-Organophosphate114969994
pest    O
strips    O
and    O
ultraviolet    O
lamps    O
placed    O
above    O
liquid    O
traps    O
are    O
effective    O
in    O
killing    O
parasitoids    O
but    O
not    O
harming    O
"    O
M.    O
rotundata    O
.    O

Prior    O
to    O
development    O
of    O
these    O
drugs    O
,    O
during    O
the    O
1950s    O
and    O
1960s    O
,    O
treatment    O
with    O
piperazine    O
,    O
dichlorvos    B-Organophosphate114969994
and    O
trichlorfon    O
was    O
used    O
.    O

Amidophosphoribosyltransferase    O
(    O
ATase    O
)    O
,    O
also    O
known    O
as    O
glutamine    O
phosphoribosylpyrophosphate    O
amidotransferase    O
(    O
GPAT    O
)    O
,    O
is    O
an    O
enzyme    O
responsible    O
for    O
catalyzing    O
the    O
conversion    O
of    O
5-phosphoribosyl-1-pyrophosphate    B-Organophosphate114969994
(    O
PRPP    O
)    O
into    O
5-phosphoribosyl-1-amine    B-Organophosphate114969994
(    O
PRA    O
)    O
,    O
using    O
the    O
ammonia    O
group    O
from    O
a    O
glutamine    O
side    O
-    O
chain    O
.    O

Image    O
:    O
5-phosphoribosylamine    B-Organophosphate114969994

FN3    O
K    O
is    O
responsible    O
for    O
the    O
formation    O
of    O
fructose    B-Organophosphate114969994
3-phosphate    I-Organophosphate114969994
(    O
F3P    O
)    O
,    O
a    O
compound    O
identified    O
in    O
the    O
lenses    O
of    O
diabetic    O
rats    O
.    O

Tagetitoxin    B-Organophosphate114969994
(    O
TGT    O
)    O
is    O
a    O
bacterial    O
phytotoxin    O
produced    O
by    O
"    O
Pseudomonas    O
syringae    O
pv    O
.    O

If    O
the    O
correct    O
anticodon    O
binds    O
to    O
the    O
mRNA    O
codon    O
,    O
the    O
ribosome    O
changes    O
configuration    O
and    O
alters    O
the    O
geometry    O
of    O
the    O
GTPase    O
domain    O
of    O
EF    O
-    O
Tu    O
,    O
resulting    O
in    O
the    O
hydrolysis    O
of    O
the    O
GTP    O
associated    O
with    O
the    O
EF    O
-    O
Tu    O
to    O
GDP    B-Organophosphate114969994
and    O
Pi    O
.    O

In    O
molecular    O
biology    O
,    O
Adenylosuccinate    O
synthase    O
(    O
or    O
adenylosuccinate    O
synthetase    O
)    O
is    O
an    O
enzyme    O
that    O
plays    O
an    O
important    O
role    O
in    O
purine    O
biosynthesis    O
,    O
by    O
catalysing    O
the    O
guanosine    B-Organophosphate114969994
triphosphate    I-Organophosphate114969994
(    O
GTP)-dependent    O
conversion    O
of    O
inosine    B-Organophosphate114969994
monophosphate    I-Organophosphate114969994
(    O
IMP    O
)    O
and    O
aspartic    O
acid    O
to    O
guanosine    B-Organophosphate114969994
diphosphate    I-Organophosphate114969994
(    O
GDP    O
)    O
,    O
phosphate    O
and    O
N(6)-(1,2-dicarboxyethyl)-AMP    O
.    O

In    O
an    O
example    O
of    O
feedback    O
inhibition    O
,    O
ATase    O
is    O
inhibited    O
mainly    O
by    O
the    O
end    O
-    O
products    O
of    O
the    O
purine    O
synthesis    O
pathway    O
,    O
AMP    O
,    O
GMP    B-Organophosphate114969994
,    O
ADP    O
,    O
and    O
GDP    B-Organophosphate114969994
.    O

The    O
Gs    O
alpha    O
subunit    O
of    O
the    O
stimulated    O
G    O
protein    O
complex    O
exchanges    O
GDP    B-Organophosphate114969994
for    O
GTP    B-Organophosphate114969994
and    O
is    O
released    O
from    O
the    O
complex    O
.    O

When    O
the    O
50S    O
subunit    O
joins    O
,    O
it    O
hydrolyzes    O
GTP    B-Organophosphate114969994
to    O
GDP    B-Organophosphate114969994
and    O
Pi    O
,    O
causing    O
a    O
conformational    O
change    O
in    O
the    O
IF2    O
that    O
causes    O
IF2    O
to    O
release    O
and    O
allow    O
the    O
70S    O
subunit    O
to    O
form    O
.    O

Substrate    O
-    O
level    O
phosphorylation    O
is    O
a    O
metabolic    O
reaction    O
that    O
results    O
in    O
the    O
formation    O
of    O
ATP    O
or    O
GTP    B-Organophosphate114969994
by    O
the    O
direct    O
transfer    O
of    O
a    O
phosphoryl    O
(    O
PO3    O
)    O
group    O
to    O
ADP    O
or    O
GDP    B-Organophosphate114969994
from    O
another    O
phosphorylated    O
compound    O
.    O

EF    O
-    O
Ts    O
serves    O
as    O
the    O
guanine    O
nucleotide    O
exchange    O
factor    O
for    O
EF    O
-    O
Tu    O
(    O
elongation    O
factor    O
thermo    O
unstable    O
)    O
,    O
catalyzing    O
the    O
release    O
of    O
guanosine    B-Organophosphate114969994
diphosphate    I-Organophosphate114969994
from    O
EF    O
-    O
Tu    O
.    O

This    O
protein    O
recruits    O
a    O
small    O
GTPase    O
called    O
Sar1    O
(    O
think    O
of    O
Sar1    O
as    O
a    O
switch    O
,    O
it    O
is    O
active    O
when    O
bound    O
to    O
GTP    B-Organophosphate114969994
and    O
inactive    O
when    O
it    O
hydrolyses    O
the    O
GTP    O
to    O
GDP    B-Organophosphate114969994
)    O
.    O

In    O
the    O
activated    O
NMBR    O
/    O
G    O
-    O
protein    O
complex    O
,    O
there    O
occurs    O
an    O
exchange    O
of    O
GTP    B-Organophosphate114969994
for    O
GDP    B-Organophosphate114969994
bound    O
to    O
G-Î±    O
subunit    O
.    O

:    O
ATP    O
+    O
GMP    B-Organophosphate114969994
ADP    O
+    O
GDP    B-Organophosphate114969994

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
ATP    O
and    O
GMP    B-Organophosphate114969994
,    O
whereas    O
its    O
two    O
products    O
are    O
ADP    O
and    O
GDP    B-Organophosphate114969994
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
GTP    B-Organophosphate114969994
and    O
5-hydroxy    O
-    O
L    O
-    O
lysine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
GDP    B-Organophosphate114969994
and    O
5-phosphonooxy    O
-    O
L    O
-    O
lysine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
GDP    B-Organophosphate114969994
and    O
alpha-D-mannose    B-Organophosphate114969994
1-phosphate    I-Organophosphate114969994
,    O
whereas    O
its    O
two    O
products    O
are    O
phosphate    O
and    O
GDP    O
-    O
mannose    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
GTP    B-Organophosphate114969994
and    O
3-phospho-D-glycerate    B-Organophosphate114969994
,    O
whereas    O
its    O
two    O
products    O
are    O
GDP    B-Organophosphate114969994
and    O
3-phospho-D-glyceroyl    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
.    O

Sulfotep    B-Organophosphate114969994
(O,O,O',O'-Tetraethyldithiopyrophosphate)    I-Organophosphate114969994
is    O
a    O
pesticide    O
commonly    O
used    O
in    O
greenhouses    O
as    O
a    O
fumigative    O
agent    O
.    O

Phospholipid    O
group    O
alkylphosphocholine    B-Organophosphate114969994
were    O
known    O
since    O
the    O
early    O
1980s    O
,    O
particularly    O
in    O
terms    O
of    O
their    O
binding    O
affinity    O
with    O
cobra    O
venom    O
.    O

Hence    O
,    O
this    O
enzyme    O
has    O
one    O
substrate    O
,    O
alpha-D-mannose    B-Organophosphate114969994
1-phosphate    I-Organophosphate114969994
,    O
and    O
one    O
product    O
,    O
D-mannose    B-Organophosphate114969994
6-phosphate    I-Organophosphate114969994
.    O

GlcNAc-1-phosphotransferase    O
catalyzes    O
the    O
N    O
-    O
linked    O
glycosylation    O
of    O
asparagine    O
residues    O
with    O
a    O
molecule    O
called    O
mannose-6-phosphate    B-Organophosphate114969994
(    O
M6P    O
)    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
ATP    O
and    O
D    O
-    O
mannose    O
,    O
whereas    O
its    O
two    O
products    O
are    O
ADP    O
and    O
D-mannose    B-Organophosphate114969994
6-phosphate    I-Organophosphate114969994
.    O

Organophosphate-induced    B-Organophosphate114969994
delayed    I-Organophosphate114969994
neuropathy    I-Organophosphate114969994
,    O
a    O
neuropathy    O
caused    O
by    O
killing    O
of    O
neurons    O
in    O
the    O
central    O
nervous    O
system    O
,    O
especially    O
in    O
the    O
spinal    O
cord    O
,    O
as    O
a    O
result    O
of    O
acute    O
or    O
chronic    O
organophosphate    O
poisoning    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
1-deoxy-D-xylulose    B-Organophosphate114969994
5-phosphate    I-Organophosphate114969994
and    O
3-amino-2-oxopropyl    O
phosphate    O
,    O
whereas    O
its    O
3    O
products    O
are    O
pyridoxine    O
5'-phosphate    O
,    O
phosphate    O
,    O
and    O
H2O.    O

Capsidiol    O
is    O
a    O
bicyclic    O
terpene    O
that    O
is    O
biosynthetically    O
derived    O
from    O
the    O
mevalonate    O
pathway    O
via    O
farnesyl    B-Organophosphate114969994
pyrophosphate    I-Organophosphate114969994
(    O
FPP    O
)    O
.    O

As    O
the    O
nomenclature    O
for    O
terpenes    O
suggests    O
,    O
the    O
first    O
Absinthin    O
precursor    O
farnesyl    B-Organophosphate114969994
diphosphate    I-Organophosphate114969994
[    O
A    O
]    O
contains    O
15    O
carbons    O
,    O
or    O
3    O
isoprene    O
units    O
.    O

#    O
Farnesyl    B-Organophosphate114969994
diphosphate    I-Organophosphate114969994
departure    O
via    O
a    O
generic    O
sesquiterpene    O
synthase    O

Farnesyl    B-Organophosphate114969994
diphosphate    I-Organophosphate114969994
is    O
the    O
universal    O
precursor    O
to    O
a    O
wide    O
variety    O
of    O
linear    O
and    O
cyclized    O
sesquiterpenes    O
.    O

Synthesis    O
of    O
all    O
higher    O
terpenoids    O
proceeds    O
via    O
formation    O
of    O
geranyl    B-Organophosphate114969994
pyrophosphate    I-Organophosphate114969994
(    O
GPP    O
)    O
,    O
farnesyl    B-Organophosphate114969994
pyrophosphate    I-Organophosphate114969994
(    O
FPP    O
)    O
,    O
and    O
geranylgeranyl    B-Organophosphate114969994
pyrophosphate    I-Organophosphate114969994
(    O
GGPP    O
)    O
.    O

The    O
linear    O
triterpene    O
squalene    O
,    O
the    O
major    O
constituent    O
of    O
shark    O
liver    O
oil    O
,    O
is    O
derived    O
from    O
the    O
reductive    O
coupling    O
of    O
two    O
molecules    O
of    O
farnesyl    B-Organophosphate114969994
pyrophosphate    I-Organophosphate114969994
.    O

CVS    O
is    O
a    O
terpene    O
cyclase    O
enzyme    O
responsible    O
for    O
the    O
biosynthesis    O
of    O
valencene    O
,    O
a    O
sesquiterpene    O
,    O
using    O
farnesyl    B-Organophosphate114969994
pyrophosphate    I-Organophosphate114969994
as    O
its    O
substrate    O
.    O

Both    O
isoprenoid    O
chains    O
,    O
geranylgeranyl    B-Organophosphate114969994
pyrophosphate    I-Organophosphate114969994
(    O
GGpp    O
)    O
and    O
farnesyl    B-Organophosphate114969994
pyrophosphate    I-Organophosphate114969994
are    O
products    O
of    O
the    O
HMG    O
-    O
CoA    O
reductase    O
pathway    O
.    O

However    O
,    O
the    O
chemical    O
is    O
not    O
phytotoxic    O
,    O
unlike    O
tetraethyl    B-Organophosphate114969994
pyrophosphate    I-Organophosphate114969994
.    O

Fenamiphos    B-Organophosphate114969994

S-Ethylisothiouronium    B-Organophosphate114969994
diethylphosphate    I-Organophosphate114969994
:    O
an    O
example    O
of    O
an    O
isothiuronium    O
compound    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
serine    O
phosphoethanolamine    O
and    O
H2O    O
,    O
whereas    O
its    O
two    O
products    O
are    O
serine    O
and    O
ethanolamine    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
.    O

Phosphorylethanolamine    B-Organophosphate114969994
or    O
phosphoethanolamine    B-Organophosphate114969994
is    O
an    O
ethanolamine    O
derivative    O
that    O
is    O
used    O
to    O
construct    O
two    O
different    O
categories    O
of    O
phospholipids    O
.    O

6-Phosphogluconic    B-Organophosphate114969994
acid    I-Organophosphate114969994
(    O
6-phosphogluconate    B-Organophosphate114969994
)    O
is    O
an    O
intermediate    O
in    O
the    O
pentose    O
phosphate    O
pathway    O
and    O
the    O
Entnerâ€“    O

denufosol    B-Organophosphate114969994
tetrasodium    I-Organophosphate114969994
(    O
USAN    O
)    O

It    O
is    O
responsible    O
for    O
the    O
hydrolysis    O
of    O
guanosine    B-Organophosphate114969994
triphosphate    I-Organophosphate114969994
(    O
GTP    O
)    O
to    O
form    O
7,8-dihydroneopterin    B-Organophosphate114969994
triphosphate    I-Organophosphate114969994
(    O
7,8-DHNP-3'-TP    O
,    O
7,8-NH2    O
-    O
3'-TP    O
)    O
.    O

After    O
2    O
years    O
with    O
Merck    O
Research    O
Laboratories    O
,    O
Leighton    O
began    O
his    O
graduate    O
studies    O
with    O
Abbott    O
and    O
James    O
Lawrence    O
Professor    O
David    O
A.    O
Evans    O
at    O
Harvard    O
University    O
(    O
Ph.D.    O
1994    O
)    O
,    O
culminating    O
in    O
the    O
total    O
syntheses    O
of    O
both    O
Calyculin    B-Organophosphate114969994
A    O
and    O
Zaragozic    O
acid    O
.    O

fosfestrol    B-Organophosphate114969994
(    O
INN    O
)    O

Fosfestrol    B-Organophosphate114969994

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl-CoA    B-Organophosphate114969994
and    O
L    O
-    O
phenylalanine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    B-Organophosphate114969994
and    O
N    O
-    O
acetyl    O
-    O
L    O
-    O
phenylalanine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
isovaleryl    O
-    O
CoA    O
and    O
malonyl    O
-    O
CoA    O
,    O
whereas    O
its    O
3    O
products    O
are    O
CoASH    B-Organophosphate114969994
,    O
CO2    O
,    O
and    O
3-methyl-1-(2,4,6-trihydroxyphenyl)butan-1-one    O
.    O

The    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl-CoA    B-Organophosphate114969994
and    O
phosphate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    B-Organophosphate114969994
and    O
acetyl    O
phosphate    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
butanoyl    O
-    O
CoA    O
and    O
phosphate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    B-Organophosphate114969994
and    O
butanoyl    O
phosphate    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
malonyl    O
-    O
CoA    O
and    O
cinnamoyl    O
-    O
CoA    O
,    O
whereas    O
its    O
3    O
products    O
are    O
CoA    B-Organophosphate114969994
,    O
pinosylvin    O
,    O
and    O
CO2    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
(    O
E    O
,    O
E)-piperoyl    O
-    O
CoA    O
and    O
piperidine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    B-Organophosphate114969994
and    O
[    O
[    O
N-[(E    O
,    O
E)-piperoyl]-piperidine    O
]    O
]    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
acyl    O
-    O
CoA    O
and    O
1-O    O
-    O
alk-1-enyl    O
-    O
glycero-3-phosphocholine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    B-Organophosphate114969994
and    O
plasmenylcholine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl-CoA    B-Organophosphate114969994
and    O
alpha-2,8-linked    O
polymer    O
of    O
sialic    O
acid    O
,    O
whereas    O
its    O
3    O
products    O
are    O
CoA    B-Organophosphate114969994
,    O
polysialic    O
acid    O
acetylated    O
on    O
O-7    O
,    O
and    O
polysialic    O
acid    O
acetylated    O
on    O
O-9    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
3alpha,7alpha,12alpha    O
-    O
trihydroxy-5beta    O
-    O
cholanoyl    O
-    O
CoA    O
and    O
propanoyl    O
-    O
CoA    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    B-Organophosphate114969994
and    O
3alpha,7alpha,12alpha    O
-    O
trihydroxy-24-oxo-5beta    O
-    O
cholestanoyl    O
-    O
CoA.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
4,8,12-trimethyltridecanoyl    O
-    O
CoA    O
and    O
propanoyl    O
-    O
CoA    O
,    O
whereas    O
its    O
two    O
products    O
are    O
3-oxopristanoyl    O
-    O
CoA    O
and    O
CoA    B-Organophosphate114969994

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
caffeoyl    O
-    O
CoA    O
and    O
putrescine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    B-Organophosphate114969994
and    O
N    O
-    O
caffeoylputrescine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
feruloyl    O
-    O
CoA    O
and    O
quinate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    B-Organophosphate114969994
and    O
O    O
-    O
feruloylquinate    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
acyl    O
-    O
CoA    O
and    O
retinol    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    B-Organophosphate114969994
and    O
retinyl    O
ester    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl-CoA    B-Organophosphate114969994
and    O
ribosomal    O
-    O
protein    O
L    O
-    O
alanine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    B-Organophosphate114969994
and    O
ribosomal    O
-    O
protein    O
N    O
-    O
acetyl    O
-    O
L    O
-    O
alanine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
caffeoyl    O
-    O
CoA    O
and    O
3-(3,4-dihydroxyphenyl)lactate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    B-Organophosphate114969994
and    O
rosmarinate    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl-CoA    B-Organophosphate114969994
and    O
salutaridinol    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    B-Organophosphate114969994
and    O
7-O    O
-    O
acetylsalutaridinol    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
palmitoyl-CoA    B-Organophosphate114969994
and    O
L    O
-    O
serine    O
,    O
whereas    O
its    O
3    O
products    O
are    O
CoA    B-Organophosphate114969994
,    O
3-dehydro    O
-    O
D    O
-    O
sphinganine    O
,    O
and    O
CO2    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl-CoA    B-Organophosphate114969994
and    O
L    O
-    O
serine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    B-Organophosphate114969994
and    O
O    O
-    O
acetyl    O
-    O
L    O
-    O
serine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
4-coumaroyl    O
-    O
CoA    O
and    O
shikimate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    B-Organophosphate114969994
and    O
4-coumaroylshikimate    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
acyl    O
-    O
CoA    O
and    O
sphingosine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    B-Organophosphate114969994
and    O
N    O
-    O
acylsphingosine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
acyl    O
-    O
CoA    O
and    O
cholesterol    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    B-Organophosphate114969994
and    O
cholesteryl    O
ester    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
sinapoyl    O
-    O
CoA    O
and    O
2-hydroxymalonate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    B-Organophosphate114969994
and    O
sinapoyltartronate    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl-CoA    B-Organophosphate114969994
and    O
taxa-4(20),11-dien-5alpha    O
-    O
ol    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    B-Organophosphate114969994
and    O
taxa-4(20),11-dien-5alpha    O
-    O
yl    O
acetate    O
.    O

The    O
3    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl-CoA    B-Organophosphate114969994
,    O
(    O
S)-2,3,4,5-tetrahydropyridine-2,6-dicarboxylate    O
,    O
and    O
H2O    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    B-Organophosphate114969994
and    O
L-2-acetamido-6-oxoheptanedioate    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl-CoA    B-Organophosphate114969994
and    O
2-aminoethanethiol    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    B-Organophosphate114969994
and    O
S-(2-aminoethyl)thioacetate    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
malonyl    O
-    O
CoA    O
and    O
4-coumaroyl    O
-    O
CoA    O
,    O
whereas    O
its    O
3    O
products    O
are    O
CoA    B-Organophosphate114969994
,    O
3,4',5-trihydroxy    O
-    O
stilbene    O
(    O
resveratrol    O
)    O
,    O
and    O
CO2    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
feruloyl    O
-    O
CoA    O
and    O
tyramine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    B-Organophosphate114969994
and    O
N    O
-    O
feruloyltyramine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl-CoA    B-Organophosphate114969994
and    O
16-epivellosimine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    B-Organophosphate114969994
and    O
vinorine    O
.    O

MenH    O
(    O
SHCHC    O
synthase    O
)    O
was    O
previously    O
thought    O
to    O
be    O
a    O
thioesterase    O
involved    O
in    O
hydrolyzing    O
DHNA    O
-    O
CoA    B-Organophosphate114969994
in    O
a    O
later    O
step    O
of    O
menaquinone    O
synthesis    O
.    O

Naringenin    O
-    O
chalcone    O
synthase    O
uses    O
malonyl    O
-    O
CoA    O
and    O
4-coumaroyl    O
-    O
CoA    O
to    O
produce    O
CoA    B-Organophosphate114969994
,    O
naringenin    O
chalcone    O
,    O
and    O
CO2    O
.    O

4-coumaroyl    O
-    O
CoA    O
and    O
three    O
units    O
of    O
malonyl    O
-    O
CoA    O
are    O
converted    O
into    O
three    O
molecules    O
of    O
carbon    O
dioxide    O
,    O
four    O
molecules    O
of    O
coenzyme    B-Organophosphate114969994
A    I-Organophosphate114969994
and    O
one    O
unit    O
of    O
naringenin    O
chalcone    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
(    O
S)-3-hydroxy-3-methylglutaryl    O
-    O
CoA    O
and    O
H2O    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    B-Organophosphate114969994
and    O
3-hydroxy-3-methylglutarate    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
palmitoyl-CoA    B-Organophosphate114969994
and    O
H2O    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    B-Organophosphate114969994
and    O
palmitate    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
phenylglyoxylyl    O
-    O
CoA    O
and    O
H2O    O
,    O
whereas    O
its    O
two    O
products    O
are    O
phenylglyoxylate    O
and    O
CoA    B-Organophosphate114969994

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
(    O
S)-methylmalonyl    O
-    O
CoA    O
and    O
H2O    O
,    O
whereas    O
its    O
two    O
products    O
are    O
methylmalonate    O
and    O
CoA    B-Organophosphate114969994

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
succinyl-CoA    B-Organophosphate114969994
and    O
H2O    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    B-Organophosphate114969994
and    O
succinate    O
.    O

ATP    O
-    O
citrate    O
lyase    O
is    O
responsible    O
for    O
catalyzing    O
the    O
conversion    O
of    O
citrate    O
and    O
CoA    B-Organophosphate114969994
into    O
acetyl-CoA    B-Organophosphate114969994
and    O
oxaloacetate    O
,    O
along    O
with    O
the    O
hydrolysis    O
of    O
ATP    O
.    O

In    O
the    O
presence    O
of    O
ATP    O
and    O
Coenzyme    B-Organophosphate114969994
A    I-Organophosphate114969994
,    O
citrate    O
lyase    O
catalyzes    O
the    O
cleavage    O
of    O
citrate    O
to    O
yield    O
acetyl    B-Organophosphate114969994
CoA    I-Organophosphate114969994
,    O
oxaloacetate    O
,    O
ADP    O
,    O
and    O
orthophosphate    O
:    O

These    O
thioesters    O
are    O
made    O
by    O
conjugating    O
the    O
fatty    O
acid    O
with    O
the    O
free    O
SH    O
group    O
of    O
the    O
pantetheine    O
moiety    O
of    O
either    O
coenzyme    B-Organophosphate114969994
A    I-Organophosphate114969994
(    O
CoA    O
)    O
or    O
acyl    O
carrier    O
protein    O
(    O
ACP    O
)    O
.    O

Long    O
-    O
chain    O
acyl    O
-    O
CoA    O
synthetases    O
such    O
as    O
ACSL6    O
,    O
catalyze    O
the    O
formation    O
of    O
acyl    O
-    O
CoA    O
from    O
fatty    O
acids    O
,    O
ATP    O
,    O
and    O
CoA    B-Organophosphate114969994

The    O
fatty    O
acid    O
is    O
firstly    O
bound    O
to    O
CoA    B-Organophosphate114969994
and    O
may    O
cross    O
the    O
external    O
mitochondrial    O
membrane    O
.    O

First    O
,    O
it    O
is    O
activated    O
by    O
potassium    O
ions    O
binding    O
near    O
the    O
CoA    B-Organophosphate114969994
binding    O
site    O
and    O
the    O
catalytic    O
site    O
.    O

It    O
is    O
a    O
temporary    O
compound    O
formed    O
when    O
coenzyme    B-Organophosphate114969994
A    I-Organophosphate114969994
(    O
CoA    O
)    O
attaches    O
to    O
the    O
end    O
of    O
a    O
long    O
-    O
chain    O
fatty    O
acid    O
inside    O
living    O
cells    O
.    O

Coenzyme    B-Organophosphate114969994
A    I-Organophosphate114969994

Pyruvate    O
dehydrogenase    O
kinase    O
is    O
activated    O
by    O
ATP    O
,    O
NADH    O
and    O
acetyl-CoA    B-Organophosphate114969994
It    O
is    O
inhibited    O
by    O
ADP    O
,    O
NAD+    O
,    O
CoA-SH    B-Organophosphate114969994
and    O
pyruvate    O
.    O

The    O
latter    O
type    O
is    O
called    O
plasmalogen    B-Organophosphate114969994
.    O

Plasmalogen    B-Organophosphate114969994
.    O

This    O
is    O
quickly    O
followed    O
by    O
accumulation    O
of    O
chromatin    O
remodeler    O
Alc1    O
,    O
which    O
has    O
an    O
ADP-ribose    B-Organophosphate114969994
â€“    O
binding    O
domain    O
,    O
allowing    O
it    O
to    O
be    O
quickly    O
attracted    O
to    O
the    O
product    O
of    O
PARP1    O
.    O

:    O
(    O
2    O
)    O
ADP-ribose    B-Organophosphate114969994
+    O
H2O    O
AMP    O
+    O
D    O
-    O
ribose    O
5-phosphate    O

In    O
molecular    O
biology    O
,    O
the    O
Macro    O
domain    O
or    O
A1pp    O
domain    O
is    O
a    O
module    O
of    O
about    O
180    O
amino    O
acids    O
which    O
can    O
bind    O
ADP-ribose    B-Organophosphate114969994
,    O
an    O
NAD    O
metabolite    O
,    O
or    O
related    O
ligands    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
ADP    O
and    O
D-ribose    B-Organophosphate114969994
5-phosphate    I-Organophosphate114969994
,    O
whereas    O
its    O
two    O
products    O
are    O
phosphate    O
and    O
ADP-ribose    B-Organophosphate114969994
.    O

Naled    B-Organophosphate114969994

Acrydite    B-Organophosphate114969994
is    O
a    O
phosphoramidite    O
that    O
allows    O
the    O
synthesis    O
of    O
oligonucleotides    O
with    O
a    O
methacryl    O
group    O
at    O
the    O
5    O
'    O
end    O
(    O
less    O
commonly    O
3    O
'    O
or    O
internal    O
)    O
.    O

FC    O
(    O
fludarabine    B-Organophosphate114969994
with    O
cyclophosphamide    O
)    O

FR    O
(    O
fludarabine    B-Organophosphate114969994
with    O
rituximab    O
)    O

FCR    O
(    O
fludarabine    B-Organophosphate114969994
,    O
cyclophosphamide    O
,    O
and    O
rituximab    O
)    O

Second    O
line    O
treatment    O
may    O
include    O
fludarabine    B-Organophosphate114969994
,    O
combined    O
with    O
cyclophosphamide    O
and/or    O
mitoxantrone    O
,    O
usually    O
with    O
rituximab    O
.    O

It    O
was    O
approved    O
by    O
the    O
US    O
Food    O
and    O
Drug    O
Administration    O
for    O
CLL    O
patients    O
who    O
have    O
been    O
treated    O
with    O
alkylating    O
agents    O
and    O
who    O
have    O
failed    O
fludarabine    B-Organophosphate114969994
therapy    O
.    O

If    O
there    O
is    O
sufficient    O
DNA    O
to    O
measure    O
both    O
mass    O
and    O
average    O
length    O
,    O
it    O
is    O
possible    O
to    O
determine    O
the    O
proper    O
amount    O
of    O
dATP    B-Organophosphate114969994
to    O
be    O
added    O
to    O
generate    O
poly(dA    O
)    O
tails    O
90    O
to    O
200    O
nucleotides    O
long    O
.    O

"    O
EC    O
3.1.14    O
"    O
:    O
Exoribonucleases    O
producing    O
3'-phosphomonoesters    B-Organophosphate114969994

As    O
of    O
2016    O
,    O
several    O
antisense    O
drugs    O
have    O
been    O
approved    O
by    O
the    O
U.S.    O
Food    O
and    O
Drug    O
Administration    O
(    O
FDA    O
)    O
:    O
fomivirsen    B-Organophosphate114969994
as    O
a    O
treatment    O
for    O
cytomegalovirus    O
retinitis    O
,    O
mipomersen    O
for    O
homozygous    O
familial    O
hypercholesterolemia    O
,    O
eteplirsen    O
for    O
Duchenne    O
muscular    O
dystrophy    O
,    O
and    O
nusinersen    O
for    O
spinal    O
muscular    O
atrophy    O
.    O

Fomivirsen    B-Organophosphate114969994
(    O
marketed    O
as    O
Vitravene    O
)    O
,    O
was    O
approved    O
by    O
the    O
U.S.    O
FDA    O
in    O
Aug    O
1998    O
as    O
a    O
treatment    O
for    O
cytomegalovirus    O
retinitis    O
.    O

The    O
loss    O
of    O
this    O
protein    O
in    O
monocytes    O
is    O
one    O
product    O
of    O
organophosphate    B-Organophosphate114969994
poisoning    I-Organophosphate114969994
.    O

Additionally    O
,    O
prolidase    O
could    O
also    O
serve    O
to    O
detect    O
fluorine    O
-    O
containing    O
organophosphorus    O
neurotoxins    O
,    O
like    O
the    O
G    O
-    O
type    O
chemical    O
warfare    O
agents    O
,    O
and    O
could    O
antagonize    O
organophosphorous    O
intoxication    B-Organophosphate114969994
and    O
protect    O
against    O
the    O
effects    O
of    O
diisopropylfluorophosphate    O
when    O
encapsulated    O
in    O
liposomes    O
.    O

Organophosphate-induced    B-Organophosphate114969994
delayed    I-Organophosphate114969994
neuropathy    I-Organophosphate114969994
(    O
OPIDN    B-Organophosphate114969994
)    O
,    O
also    O
called    O
organophosphate-induced    B-Organophosphate114969994
delayed    I-Organophosphate114969994
polyneuropathy    I-Organophosphate114969994
(    O
OPIDP    B-Organophosphate114969994
)    O
,    O
is    O
a    O
neuropathy    O
caused    O
by    O
killing    O
of    O
neurons    O
in    O
the    O
central    O
nervous    O
system    O
,    O
especially    O
in    O
the    O
spinal    O
cord    O
,    O
as    O
a    O
result    O
of    O
acute    O
or    O
chronic    O
organophosphate    B-Organophosphate114969994
poisoning    I-Organophosphate114969994
.    O

Phosphatidylethanolamine    O
is    O
also    O
thought    O
to    O
play    O
a    O
role    O
in    O
blood    O
clotting    O
,    O
as    O
it    O
works    O
with    O
phosphatidylserine    B-Organophosphate114969994
to    O
increase    O
the    O
rate    O
of    O
thrombin    O
formation    O
by    O
promoting    O
binding    O
to    O
Factor    O
V    O
and    O
Factor    O
X    O
,    O
two    O
proteins    O
which    O
catalyze    O
the    O
formation    O
of    O
thrombin    O
from    O
prothrombin    O
.    O

The    O
phosphatidylserine    B-Organophosphate114969994
decarboxylation    O
pathway    O
and    O
the    O
cytidine    O
diphosphate    O
-    O
ethanolamine    O
pathways    O
are    O
used    O
to    O
synthesize    O
phosphatidylethanolamine    O
.    O

Synthesis    O
of    O
Phosphatidylethanolamine    O
through    O
the    O
phosphatidylserine    B-Organophosphate114969994
decarboxylation    O
pathway    O
occurs    O
rapidly    O
in    O
the    O
inner    O
mitochondrial    O
membrane    O
.    O

The    O
major    O
membrane    O
lipidsPtdCho    O
-    O
Phosphatidylcholine    O
;    O
PtdEtn    O
-    O
Phosphatidylethanolamine;PtdIns    O
-Phosphatidylinositol    O
;    O
PtdSer    O
-    O
Phosphatidylserine    B-Organophosphate114969994
.    O

Sphingomyelin    O
(    O
4.42%    O
of    O
the    O
total    O
phospholipids    O
)    O
,    O
phosphatidyl    B-Organophosphate114969994
ethanolamine    I-Organophosphate114969994
(    O
12.8%    O
)    O
,    O
phosphatidyl    O
choline    O
(    O
21.9%    O
)    O
,    O
phosphatidyl    B-Organophosphate114969994
serine    I-Organophosphate114969994
(    O
2.9%    O
)    O
,    O
phosphatidyl    O
inositol    O
(    O
2.7%    O
)    O
,    O
lysophosphatidyl    B-Organophosphate114969994
choline    I-Organophosphate114969994
(    O
5.3%    O
)    O
,    O
phosphatidyl    O
glycerol    O
(    O
8.9%    O
)    O
,    O
phosphatidic    O
acid    O
(    O
4.9%    O
)    O
,    O
and    O
cardiolipin    B-Organophosphate114969994
(    O
3.6%    O
)    O
were    O
identified    O
in    O
the    O
nine    O
genotypes    O
.    O

Upon    O
activation    O
(    O
in    O
platelets    O
)    O
or    O
injury    O
(    O
in    O
erythrocytes    O
,    O
platelets    O
,    O
endothelium    O
,    O
and    O
other    O
cells    O
)    O
,    O
certain    O
cells    O
expose    O
the    O
phospholipid    O
phosphatidylserine    B-Organophosphate114969994
on    O
their    O
surface    O
and    O
act    O
as    O
catalysts    O
to    O
induce    O
the    O
coagulation    O
cascade    O
.    O

An    O
early    O
morphological    O
event    O
in    O
both    O
the    O
extrinsic    O
and    O
the    O
intrinsic    O
apoptotic    O
pathways    O
is    O
the    O
surface    O
exposure    O
of    O
the    O
phospholipid    O
phosphatidylserine    B-Organophosphate114969994
,    O
about    O
96%    O
of    O
which    O
normally    O
reside    O
in    O
the    O
cytosolic    O
leaflet    O
of    O
the    O
plasma    O
membrane    O
.    O

When    O
PAP    O
is    O
active    O
,    O
diacylglycerols    O
formed    O
by    O
PAP    O
can    O
go    O
on    O
to    O
form    O
any    O
of    O
several    O
products    O
,    O
including    O
phosphatidylethanolamine    B-Organophosphate114969994
,    O
phosphatidylcholine    O
,    O
phosphatidylserine    B-Organophosphate114969994
,    O
and    O
triacylglycerol    O
.    O

The    O
major    O
membrane    O
lipidsPtdCho    O
-    O
Phosphatidylcholine    O
;    O
PtdEtn    O
-    O
Phosphatidylethanolamine    B-Organophosphate114969994
;    O
PtdIns    O
-    O
Phosphatidylinositol    O
;    O
PtdSer    O
-    O
Phosphatidylserine    B-Organophosphate114969994
.    O

:    O
(    O
1a    O
)    O
2    O
geranylgeranyl    O
diphosphate    O
diphosphate    O
+    O
prephytoene    B-Organophosphate114969994
diphosphate    I-Organophosphate114969994

It    O
employs    O
one    O
cofactor    O
,    O
pyridoxal    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
.    O

It    O
employs    O
one    O
cofactor    O
,    O
pyridoxal    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
.    O

It    O
employs    O
one    O
cofactor    O
,    O
pyridoxal    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
.    O

It    O
employs    O
one    O
cofactor    O
,    O
pyridoxal    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
.    O

It    O
employs    O
one    O
cofactor    O
,    O
pyridoxal    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
.    O

It    O
employs    O
one    O
cofactor    O
,    O
pyridoxal    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
pyridoxamine    O
5'-phosphate    O
and    O
2-oxoglutarate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
pyridoxal    B-Organophosphate114969994
5'-phosphate    I-Organophosphate114969994
and    O
D    O
-    O
glutamate    O
.    O

It    O
employs    O
one    O
cofactor    O
,    O
pyridoxal    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
.    O

It    O
employs    O
one    O
cofactor    O
,    O
pyridoxal    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
.    O

It    O
employs    O
one    O
cofactor    O
,    O
pyridoxal    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
.    O

It    O
employs    O
one    O
cofactor    O
,    O
pyridoxal    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
.    O

It    O
employs    O
one    O
cofactor    O
,    O
pyridoxal    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
.    O

It    O
employs    O
one    O
cofactor    O
,    O
pyridoxal    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
.    O

It    O
employs    O
one    O
cofactor    O
,    O
pyridoxal    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
ATP    O
and    O
pyridoxal    O
,    O
whereas    O
its    O
two    O
products    O
are    O
ADP    O
and    O
pyridoxal    B-Organophosphate114969994
5'-phosphate    I-Organophosphate114969994
.    O

Papaverine    O
is    O
available    O
as    O
a    O
conjugate    O
of    O
hydrochloride    O
,    O
codecarboxylate    B-Organophosphate114969994
,    O
adenylate    O
,    O
and    O
teprosylate    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
pyridoxal    B-Organophosphate114969994
5'-phosphate    I-Organophosphate114969994
and    O
H2O    O
,    O
whereas    O
its    O
two    O
products    O
are    O
pyridoxal    O
and    O
phosphate    O
.    O

Serine    O
hydroxymethyltransferase    O
(    O
SHMT    O
)    O
is    O
a    O
Pyridoxal    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
(    O
PLP    O
)    O
(    O
Vitamin    O
B6    O
)    O
dependent    O
enzyme    O
which    O
plays    O
an    O
important    O
role    O
in    O
cellular    O
one    O
-    O
carbon    O
pathways    O
by    O
catalyzing    O
the    O
reversible    O
,    O
simultaneous    O
conversions    O
of    O
L    O
-    O
serine    O
to    O
glycine    O
and    O
tetrahydrofolate    O
(    O
THF    O
)    O
to    O
5,10-methylenetetrahydrofolate    O
(    O
5,10-CH2-THF    O
)    O
.    O

Aspartate    O
transaminase    O
(    O
AST    O
)    O
or    O
aspartate    O
aminotransferase    O
,    O
also    O
known    O
as    O
AspAT    O
/    O
ASAT    O
/    O
AAT    O
or    O
serum    O
glutamic    O
oxaloacetic    O
transaminase    O
(    O
SGOT    O
)    O
,    O
is    O
a    O
pyridoxal    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
(    O
PLP)-dependent    O
transaminase    O
enzyme    O
that    O
was    O
first    O
described    O
by    O
Arthur    O
Karmen    O
and    O
colleagues    O
in    O
1954    O
.    O

CBS    O
uses    O
the    O
cofactor    O
pyridoxal-phosphate    B-Organophosphate114969994
(    O
PLP    O
)    O
and    O
can    O
be    O
allosterically    O
regulated    O
by    O
effectors    O
such    O
as    O
the    O
ubiquitous    O
cofactor    O
S    O
-    O
adenosyl    O
-    O
L    O
-    O
methionine    O
(    O
adoMet    O
)    O
.    O

It    O
displays    O
a    O
modular    O
organization    O
of    O
three    O
modules    O
with    O
the    O
N    O
-    O
terminal    O
heme    O
domain    O
followed    O
by    O
a    O
core    O
that    O
contains    O
the    O
PLP    B-Organophosphate114969994
cofactor    O
.    O

The    O
distance    O
of    O
heme    O
from    O
the    O
PLP    B-Organophosphate114969994
binding    O
site    O
suggests    O
its    O
non    O
-    O
role    O
in    O
catalysis    O
,    O
however    O
deletion    O
of    O
the    O
heme    O
domain    O
causes    O
loss    O
of    O
redox    O
sensitivity    O
,    O
therefore    O
it    O
is    O
hypothesized    O
that    O
heme    O
is    O
a    O
redox    O
sensor    O
.    O

The    O
PLP    B-Organophosphate114969994
is    O
an    O
internal    O
aldimine    O
and    O
forms    O
a    O
Schiff    O
base    O
with    O
K119    O
in    O
the    O
active    O
site    O
.    O

The    O
ligands    O
for    O
LPL    O
-    O
R    O
group    O
are    O
the    O
lysophospholipid    O
extracellular    O
signaling    O
molecules    O
,    O
lysophosphatidic    O
acid    O
(    O
LPA    O
)    O
and    O
sphingosine    B-Organophosphate114969994
1-phosphate    I-Organophosphate114969994
(    O
S1P    O
)    O
.    O

Sphingosine    O
kinase    O
1    O
phosphorylates    O
sphingosine    O
to    O
sphingosine-1-phosphate    B-Organophosphate114969994
(    O
S1P    O
)    O
SK1    O
is    O
normally    O
a    O
cytosolic    O
protein    O
but    O
is    O
recruited    O
to    O
membranes    O
rich    O
in    O
phosphatidate    O
(    O
PA    O
)    O
,    O
a    O
product    O
of    O
Phospholipase    O
D    O
(    O
PLD    O
)    O

Sphingosine-1-phosphate    B-Organophosphate114969994
(    O
S1P    O
)    O
is    O
a    O
novel    O
lipid    O
messenger    O
with    O
both    O
intracellular    O
and    O
extracellular    O
functions    O
.    O

It    O
has    O
been    O
proposed    O
that    O
sphingosine    B-Organophosphate114969994
1-phosphate    I-Organophosphate114969994
(    O
S1P    O
)    O
and    O
sphingosylphosphorylcholine    O
(    O
SPC    O
)    O
are    O
GPR3    O
ligands    O
,    O
however    O
this    O
result    O
was    O
not    O
confirmed    O
in    O
a    O
Î²-arrestin    O
recruitment    O
assay    O
.    O

Siponimod    O
(    O
INN    O
,    O
code    O
name    O
BAF312    O
)    O
is    O
a    O
selective    O
sphingosine-1-phosphate    B-Organophosphate114969994
receptor    O
modulator    O
for    O
oral    O
use    O
that    O
is    O
an    O
investigational    O
drug    O
for    O
multiple    O
sclerosis    O
(    O
MS    O
)    O
.    O

Interestingly    O
,    O
however    O
,    O
this    O
catalytic    O
triad    O
is    O
essential    O
for    O
the    O
dephosphorylation    O
of    O
lysophosphatidic    O
acid    O
,    O
phosphatidic    O
acid    O
,    O
and    O
sphingosine-1-phosphate    B-Organophosphate114969994
,    O
but    O
is    O
not    O
essential    O
in    O
its    O
entirety    O
for    O
the    O
enzyme    O
's    O
native    O
substrate    O
,    O
phosphatidylglycerol    O
phosphate    O
;    O
His-207    O
alone    O
is    O
sufficient    O
to    O
hydrolyze    O
PGP    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
ATP    O
and    O
thiamine    O
diphosphate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
ADP    O
and    O
thiamine    B-Organophosphate114969994
triphosphate    I-Organophosphate114969994
.    O

Adenophostin    B-Organophosphate114969994
A    O
is    O
a    O
potent    O
inositol    B-Organophosphate114969994
triphosphate    I-Organophosphate114969994
(    O
IP3    O
)    O
receptor    O
agonist    O
,    O
but    O
is    O
much    O
more    O
potent    O
than    O
IP3    O
.    O

It    O
catalyzes    O
the    O
oxidative    O
decarboxylation    O
of    O
glutaryl    O
-    O
CoA    O
to    O
crotonyl-CoA    B-Organophosphate114969994
and    O
carbon    O
dioxide    O
in    O
the    O
degradative    O
pathway    O
of    O
L    O
-    O
lysine    O
,    O
L    O
-    O
hydroxylysine    O
,    O
and    O
L    O
-    O
tryptophan    O
metabolism    O
.    O

Hence    O
,    O
this    O
enzyme    O
has    O
one    O
substrate    O
,    O
4-diphosphocytidyl-2-C-methyl-D-erythritol    B-Organophosphate114969994
2-phosphate    I-Organophosphate114969994
(    O
CDP    O
-    O
MEP    O
)    O
,    O
and    O
two    O
products    O
,    O
2-C-methyl-D-erythritol    B-Organophosphate114969994
2,4-cyclodiphosphate    I-Organophosphate114969994
(    O
MEcPP    O
)    O
and    O
CMP    O
.    O

Hence    O
,    O
this    O
enzyme    O
has    O
one    O
substrate    O
,    O
UDP-glucuronate    B-Organophosphate114969994
,    O
and    O
one    O
product    O
,    O
UDP    O
-    O
D    O
-    O
galacturonate    O
.    O

Hence    O
,    O
this    O
enzyme    O
has    O
one    O
substrate    O
,    O
UDP-glucuronate    B-Organophosphate114969994
,    O
and    O
one    O
product    O
,    O
UDP    O
-    O
L    O
-    O
iduronate    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
UTP    O
and    O
1-phospho    O
-    O
alpha    O
-    O
D    O
-    O
glucuronate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
diphosphate    O
and    O
UDP-glucuronate    B-Organophosphate114969994
.    O

mifamurtide    B-Organophosphate114969994
(    O
USAN    O
)    O

Syk    O
inhibitor    O
fostamatinib    B-Organophosphate114969994
is    O
in    O
trials    O
.    O

Through    O
the    O
reduction    O
of    O
dihydroxyacetone    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
into    O
glycerol    B-Organophosphate114969994
3-phosphate    I-Organophosphate114969994
,    O
GPDH    O
allows    O
the    O
prompt    O
dephosphorylation    O
of    O
glycerol    B-Organophosphate114969994
3-phosphate    I-Organophosphate114969994
into    O
glycerol    O
.    O

Cytosolic    O
GPDH    O
,    O
or    O
GPD1    O
is    O
located    O
in    O
the    O
mitochondrial    O
inner    O
-    O
membrane    O
space    O
or    O
cytosol    O
,    O
and    O
catalyzes    O
the    O
reduction    O
of    O
dihydroxyacetone    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
into    O
glycerol-3-phosphate    B-Organophosphate114969994
.    O

In    O
conjunction    O
,    O
Mitochondrial    O
GPDH    O
,    O
or    O
GPD2    O
is    O
embedded    O
on    O
the    O
outer    O
surface    O
of    O
the    O
inner    O
mitochondrial    O
membrane    O
,    O
overlooking    O
the    O
cytosol    O
,    O
and    O
catalyzes    O
the    O
oxidation    O
of    O
glycerol-3-phosphate    B-Organophosphate114969994
to    O
dihydroxyacetone    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
.    O

Cytosolic    O
Glycerol-3-phosphate    O
dehydrogenase    O
(    O
GPD1    O
)    O
,    O
is    O
an    O
NAD+-dependent    O
enzyme    O
that    O
reduces    O
dihydroxyacetone    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
to    O
glycerol-3-phosphate    B-Organophosphate114969994
.    O

GPD1    O
consists    O
of    O
two    O
subunits    O
,    O
and    O
reacts    O
with    O
dihydroxyacetone    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
and    O
NAD+    O
though    O
the    O
following    O
interaction    O
:    O

Mitochondrial    O
glycerol-3-phosphate    O
dehydrogenase    O
(    O
GPD2    O
)    O
,    O
catalyzes    O
the    O
irreversible    O
oxidation    O
of    O
glycerol-3-phosphate    B-Organophosphate114969994
to    O
dihydroxyacetone    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
and    O
concomitantly    O
transfers    O
two    O
electrons    O
from    O
FAD    B-Organophosphate114969994
to    O
the    O
electron    O
transport    O
chain    O
.    O

substrate    O
pages    O
:    O
glycerol    B-Organophosphate114969994
3-phosphate    I-Organophosphate114969994
,    O
dihydroxyacetone    B-Organophosphate114969994
phosphate    I-Organophosphate114969994

Tricresyl    B-Organophosphate114969994
phosphate    I-Organophosphate114969994

Tricresyl    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
,    O
abbreviated    O
TCP    B-Organophosphate114969994
,    O
is    O
an    O
organophosphate    O
compound    O
that    O
is    O
used    O
as    O
a    O
plasticizer    O
and    O
diverse    O
other    O
applications    O
.    O

The    O
drink    O
,    O
called    O
"    O
Ginger    O
Jake    O
,    O
"    O
contained    O
an    O
adulterated    O
Jamaican    O
ginger    O
extract    O
containing    O
tri-ortho-cresyl    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
(    O
TOCP    O
)    O
which    O
resulted    O
in    O
partially    O
reversible    O
neurologic    O
damage    O
.    O

The    O
cause    O
of    O
the    O
mysterious    O
explosions    O
was    O
finally    O
traced    O
to    O
the    O
use    O
of    O
Ulmer    O
leather    O
gaskets    O
impregnated    O
with    O
tricresyl    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
(    O
TCP    O
)    O
,    O
a    O
leather    O
treatment    O
,    O
which    O
was    O
used    O
in    O
the    O
liquid    O
oxygen    O
plumbing    O
.    O

Two    O
formylation    O
reactions    O
are    O
required    O
in    O
the    O
eleven    O
step    O
de    O
novo    O
synthesis    O
of    O
inosine    B-Organophosphate114969994
monophosphate    I-Organophosphate114969994
(IMP)    I-Organophosphate114969994
,    O
the    O
precursor    O
of    O
the    O
purine    O
ribonucleotides    O
AMP    O
and    O
GMP    O
.    O

Inosinic    B-Organophosphate114969994
acid    I-Organophosphate114969994
or    O
inosine    B-Organophosphate114969994
monophosphate    I-Organophosphate114969994
(    O
IMP    B-Organophosphate114969994
)    O
is    O
a    O
nucleoside    O
monophosphate    O
.    O

The    O
umami    O
taste    O
is    O
most    O
frequently    O
associated    O
with    O
the    O
food    O
additive    O
monosodium    O
glutamate    O
(    O
MSG    O
)    O
and    O
can    O
be    O
enhanced    O
through    O
the    O
binding    O
of    O
inosine    B-Organophosphate114969994
monophosphate    I-Organophosphate114969994
(    O
IMP    O
)    O
and    O
guanosine    B-Organophosphate114969994
monophosphate    I-Organophosphate114969994
(    O
GMP    O
)    O
molecules    O
.    O

Poly    O
I    O
:    O
C    O
is    O
a    O
mismatched    O
double    O
-    O
stranded    O
RNA    O
with    O
one    O
strand    O
being    O
a    O
polymer    O
of    O
inosinic    B-Organophosphate114969994
acid    I-Organophosphate114969994
,    O
the    O
other    O
a    O
polymer    O
of    O
cytidylic    O
acid    O
.    O

It    O
is    O
produced    O
by    O
combining    O
the    O
sodium    O
salts    O
of    O
the    O
natural    O
compounds    O
guanylic    B-Organophosphate114969994
acid    I-Organophosphate114969994
(    O
E626    O
)    O
and    O
inosinic    B-Organophosphate114969994
acid    I-Organophosphate114969994
(    O
E630    O
)    O
.    O

Disodium    B-Organophosphate114969994
inosinate    I-Organophosphate114969994
(    O
E631    B-Organophosphate114969994
)    O
is    O
the    O
disodium    O
salt    O
of    O
inosinic    B-Organophosphate114969994
acid    I-Organophosphate114969994
with    O
the    O
chemical    O
formula    O
C10H11N4Na2O8P.    O
It    O
is    O
used    O
as    O
a    O
food    O
additive    O
and    O
often    O
found    O
in    O
instant    O
noodles    O
,    O
potato    O
chips    O
,    O
and    O
a    O
variety    O
of    O
other    O
snacks    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
ATP    O
and    O
inosine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
ADP    O
and    O
IMP    B-Organophosphate114969994
.    O

It    O
has    O
3    O
cofactors    O
:    O
D    O
-    O
ribose    O
1,5-bisphosphate    O
,    O
alpha    O
-    O
D    O
-    O
Glucose    B-Organophosphate114969994
1,6-bisphosphate    I-Organophosphate114969994
,    O
and    O
2-Deoxy    O
-    O
D    O
-    O
ribose    O
1,5-bisphosphate    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
CTP    B-Organophosphate114969994
and    O
sn-glycerol    B-Organophosphate114969994
3-phosphate    I-Organophosphate114969994
,    O
whereas    O
its    O
two    O
products    O
are    O
diphosphate    O
and    O
CDP    O
-    O
glycerol    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
CTP    B-Organophosphate114969994
and    O
N    O
-    O
acylneuraminate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
diphosphate    O
and    O
CMP    O
-    O
N    O
-    O
acylneuraminate    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
CTP    B-Organophosphate114969994
and    O
N    O
-    O
methylethanolamine    O
phosphate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
diphosphate    O
and    O
CDP    O
-    O
N    O
-    O
methylethanolamine    O
.    O

Phosphatidate    O
cytidylyltransferase    O
(    O
also    O
known    O
as    O
CDP-    O
diacylglycerol    O
synthase    O
)    O
(    O
CDS    O
)    O
is    O
the    O
enzyme    O
that    O
catalyzes    O
the    O
synthesis    O
of    O
CDP    O
-    O
diacylglycerol    O
from    O
cytidine    B-Organophosphate114969994
triphosphate    I-Organophosphate114969994
and    O
phosphatidate    O
.    O

However    O
,    O
archaeal    O
riboflavin    O
kinases    O
in    O
general    O
utilize    O
CTP    B-Organophosphate114969994
rather    O
than    O
ATP    O
as    O
the    O
donor    O
nucleotide    O
,    O
catalyzing    O
the    O
reaction    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
geranylgeranyl    B-Organophosphate114969994
diphosphate    I-Organophosphate114969994
and    O
sn-3-O-(geranylgeranyl)glycerol    O
1-phosphate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
diphosphate    O
and    O
2,3-bis    O
-    O
O-(geranylgeranyl)glycerol    O
1-phosphate    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
geranylgeranyl    B-Organophosphate114969994
diphosphate    I-Organophosphate114969994
and    O
"    O
sn    O
"-    O
glyceryl    O
1-phosphate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
diphosphate    O
and    O
sn-3-O-(geranylgeranyl)glyceryl    O
1-phosphate    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
geranylgeranyl    B-Organophosphate114969994
diphosphate    I-Organophosphate114969994
and    O
protein    O
-    O
cysteine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S    O
-    O
geranylgeranyl    O
-    O
protein    O
and    O
diphosphate    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
geranylgeranyl    B-Organophosphate114969994
diphosphate    I-Organophosphate114969994
and    O
protein    O
-    O
cysteine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S    O
-    O
geranylgeranyl    O
-    O
protein    O
and    O
diphosphate    O
.    O

Synthesis    O
of    O
all    O
higher    O
terpenoids    O
proceeds    O
via    O
formation    O
of    O
geranyl    B-Organophosphate114969994
pyrophosphate    I-Organophosphate114969994
(    O
GPP    O
)    O
,    O
farnesyl    B-Organophosphate114969994
pyrophosphate    I-Organophosphate114969994
(    O
FPP    O
)    O
,    O
and    O
geranylgeranyl    B-Organophosphate114969994
pyrophosphate    I-Organophosphate114969994
(    O
GGPP    O
)    O
.    O

They    O
derive    O
from    O
geranylgeranyl    B-Organophosphate114969994
pyrophosphate    I-Organophosphate114969994
.    O

Both    O
isoprenoid    O
chains    O
,    O
geranylgeranyl    B-Organophosphate114969994
pyrophosphate    I-Organophosphate114969994
(    O
GGpp    O
)    O
and    O
farnesyl    B-Organophosphate114969994
pyrophosphate    I-Organophosphate114969994
are    O
products    O
of    O
the    O
HMG    O
-    O
CoA    O
reductase    O
pathway    O
.    O

It    O
is    O
formed    O
by    O
6-phosphogluconolactonase    O
,    O
and    O
acted    O
upon    O
by    O
phosphogluconate    O
dehydrogenase    O
to    O
produce    O
ribulose    B-Organophosphate114969994
5-phosphate    I-Organophosphate114969994
.    O

The    O
last    O
step    O
of    O
the    O
oxidative    O
reactions    O
in    O
the    O
pentose    O
phosphate    O
pathway    O
is    O
the    O
production    O
of    O
ribulose    B-Organophosphate114969994
5-phosphate    I-Organophosphate114969994
.    O

It    O
is    O
a    O
ketose    O
sugar    O
formed    O
from    O
ribulose-5-phosphate    B-Organophosphate114969994
.    O

The    O
defect    O
in    O
red    O
cell    O
DNA    O
synthesis    O
is    O
most    O
often    O
due    O
to    O
hypovitaminosis    O
,    O
specifically    O
a    O
deficiency    O
of    O
vitamin    B-Organophosphate114969994
B    I-Organophosphate114969994
and/or    O
folic    O
acid    O
.    O

Selective    O
vitamin    B-Organophosphate114969994
B12    I-Organophosphate114969994
malabsorption    O
(    O
congenital    O
â€”    O
juvenile    O
megaloblastic    O
anemia    O
1â€”and    O
drug    O
-    O
induced    O
)    O

A    O
,    O
D3    O
,    O
E    O
,    O
B6    O
,    O
B12    B-Organophosphate114969994
,    O
folic    O
acid    O
(    O
B9    O
)    O
,    O
ascorbic    O
acid    O
(    O
vitamin    O
C    O
)    O
,    O
along    O
with    O
a    O
vitamin    O
K    O
derivative    O
,    O
menadione    O
sodium    O
bisulfite    O
DVL    O
adds    O
these    O
vitamins    O
to    O
an    O
electrolyte    O
premix    O
that    O
has    O
7    O
mineral    O
salts    O
:    O
magnesium    O
acetate    O
,    O
sodium    O
acetate    O
,    O
calcium    O
acetate    O
,    O
potassium    O
chloride    O
,    O
calcium    O
chloride    O
,    O
sodium    O
chloride    O
and    O
sodium    O
diacetate    O
.    O

vitamins    O
(    O
folic    O
acid    O
,    O
nicotinamide    O
,    O
riboflavin    O
,    O
B12    B-Organophosphate114969994
)    O

Patients    O
should    O
take    O
folic    O
acid    O
and    O
vitamin    B-Organophosphate114969994
B12    I-Organophosphate114969994
supplement    O
even    O
if    O
levels    O
are    O
normal    O
when    O
they    O
are    O
on    O
pemetrexed    O
therapy    O
.    O

Vitamin    B-Organophosphate114969994
B12    I-Organophosphate114969994
,    O
folic    O
acid    O
and    O
other    O
anti    O
-    O
megaloblastic    O
-    O
anaemia    O
preparations    O

Vitamin    B-Organophosphate114969994
B12    I-Organophosphate114969994
deficiency    O
anaemia    O

Vitamin    B-Organophosphate114969994
B12    I-Organophosphate114969994
deficiency    O
anaemia    O
due    O
to    O
intrinsic    O
factor    O
deficiency    O

Vitamin    B-Organophosphate114969994
B    I-Organophosphate114969994
12    I-Organophosphate114969994
deficiency    O
anaemia    O
due    O
to    O
selective    O
vitamin    B-Organophosphate114969994
B    I-Organophosphate114969994
12    I-Organophosphate114969994
malabsorption    O
with    O
proteinuria    O

Other    O
dietary    O
vitamin    B-Organophosphate114969994
B    I-Organophosphate114969994
12    I-Organophosphate114969994
deficiency    O
anaemia    O

Other    O
vitamin    B-Organophosphate114969994
B    I-Organophosphate114969994
12    I-Organophosphate114969994
deficiency    O
anaemias    O

Vitamin    B-Organophosphate114969994
B    I-Organophosphate114969994
12    I-Organophosphate114969994
deficiency    O
anaemia    O
,    O
unspecified    O

It    O
has    O
3    O
cofactors    O
:    O
pyridoxal    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
,    O
Cobamide    B-Organophosphate114969994
coenzyme    I-Organophosphate114969994
,    O
and    O
Dithiothreitol    O
.    O

Vitamin    B-Organophosphate114969994
B12    I-Organophosphate114969994

Vitamin    B-Organophosphate114969994
B12    I-Organophosphate114969994

One    O
study    O
in    O
2014    O
pointed    O
to    O
certain    O
species    O
of    O
seaweed    O
as    O
being    O
a    O
possible    O
vegan    O
source    O
of    O
biologically    O
-    O
active    O
Vitamin    B-Organophosphate114969994
B-12    I-Organophosphate114969994
.    O

Diseases    O
that    O
may    O
present    O
similar    O
to    O
an    O
anxiety    O
disorder    O
,    O
including    O
certain    O
endocrine    O
diseases    O
(    O
hypo-    O
and    O
hyperthyroidism    O
,    O
hyperprolactinemia    O
)    O
,    O
metabolic    O
disorders    O
(    O
diabetes    O
)    O
,    O
deficiency    O
states    O
(    O
low    O
levels    O
of    O
vitamin    O
D    O
,    O
B2    O
,    O
B12    B-Organophosphate114969994
,    O
folic    O
acid    O
)    O
,    O
gastrointestinal    O
diseases    O
(    O
celiac    O
disease    O
,    O
non    O
-    O
celiac    O
gluten    O
sensitivity    O
,    O
inflammatory    O
bowel    O
disease    O
)    O
,    O
heart    O
diseases    O
,    O
blood    O
diseases    O
(    O
anemia    O
)    O
,    O
and    O
brain    O
degenerative    O
diseases    O
(    O
Parkinson    O
's    O
disease    O
,    O
dementia    O
,    O
multiple    O
sclerosis    O
,    O
Huntington    O
's    O
disease    O
)    O
.    O

Vitamin    B-Organophosphate114969994
B12    I-Organophosphate114969994
,    O
or    O
cobalamin    O
,    O
acts    O
as    O
a    O
cofactor    O
for    O
the    O
enzyme    O
methionine    O
synthase    O
(    O
which    O
forms    O
part    O
of    O
the    O
S    O
-    O
adenosylmethionine    O
(    O
SAMe    O
)    O
biosynthesis    O
and    O
regeneration    O
cycle    O
)    O
.    O

The    O
"    O
FIGLU    O
"    O
test    O
is    O
used    O
to    O
identify    O
deficiency    O
of    O
vitamin    B-Organophosphate114969994
B12    I-Organophosphate114969994
or    O
folate    O
deficiency    O
or    O
liver    O
disease    O
.    O

Indomie    O
is    O
made    O
from    O
flour    O
supplied    O
by    O
Bogasari    O
flour    O
mills    O
,    O
and    O
fortified    O
with    O
vitamin    O
A    O
,    O
B1    O
,    O
B6    O
,    O
B12    B-Organophosphate114969994
,    O
niacin    O
,    O
folic    O
acid    O
and    O
iron    O
.    O

He    O
is    O
best    O
known    O
for    O
his    O
development    O
of    O
rapid    O
-    O
reaction    O
techniques    O
,    O
including    O
stopped    O
flow    O
and    O
rapid    O
freeze    O
-    O
quench    O
EPR    O
methods    O
,    O
as    O
tools    O
to    O
study    O
the    O
mechanisms    O
of    O
enzymes    O
containing    O
flavin    O
,    O
iron    O
,    O
cobalamin    B-Organophosphate114969994
,    O
or    O
pyridoxal    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
cofactors    O
.    O

Vitamin    B-Organophosphate114969994
B12    I-Organophosphate114969994
,    O
vitamin    O
C    O
and    O
thiamin    O

Vitamin    B-Organophosphate114969994
B12    I-Organophosphate114969994
deficiency    O
can    O
cause    O
demyelination    O
.    O

Hyperhomocysteine    O
,    O
a    O
condition    O
known    O
to    O
promote    O
clots    O
,    O
can    O
be    O
caused    O
by    O
a    O
combination    O
of    O
genetic    O
factors    O
and    O
vitamin    O
B6    O
,    O
vitamin    B-Organophosphate114969994
b12    I-Organophosphate114969994
and    O
folic    O
acid    O
deficiency    O
.    O

This    O
vitamin    B-Organophosphate114969994
B12    I-Organophosphate114969994
enzyme    O
catalyzes    O
the    O
isomerization    O
of    O
methylmalonyl    O
-    O
CoA    O
to    O
succinyl    O
-    O
CoA    O
in    O
humans    O
.    O

Regarding    O
autism    O
,    O
James    O
'    O
view    O
is    O
that    O
the    O
transsulfuration    O
pathway    O
is    O
disrupted    O
in    O
autistic    O
children    O
,    O
resulting    O
in    O
these    O
children    O
being    O
deficient    O
in    O
glutathione    O
,    O
as    O
well    O
as    O
vitamins    O
such    O
as    O
vitamin    O
B6    O
and    O
vitamin    B-Organophosphate114969994
B12    I-Organophosphate114969994
,    O
and    O
that    O
maternal    O
glutathione    O
deficiency    O
may    O
also    O
be    O
a    O
risk    O
factor    O
for    O
autism    O
.    O

Nitrous    O
oxide    O
is    O
thought    O
to    O
be    O
particularly    O
non    O
-    O
toxic    O
,    O
though    O
heavy    O
long    O
-    O
term    O
use    O
can    O
lead    O
to    O
a    O
variety    O
of    O
serious    O
health    O
problems    O
linked    O
to    O
destruction    O
of    O
vitamin    B-Organophosphate114969994
B12    I-Organophosphate114969994
and    O
folic    O
acid    O
.    O

Vitamin    B-Organophosphate114969994
B12    I-Organophosphate114969994

The    O
rings    O
of    O
porphyrin    O
are    O
components    O
of    O
hemoglobin    O
,    O
myoglobin    O
,    O
vitamin    B-Organophosphate114969994
B12    I-Organophosphate114969994
,    O
chlorophyll    O
,    O
and    O
cytochromes    O
.    O

H.    O
Boyd    O
Woodruff    O
(    O
1917    O
-    O
2017    O
)    O
,    O
soil    O
microbiologist    O
who    O
discovered    O
actinomycin    O
and    O
developed    O
industrial    O
production    O
by    O
fermentation    O
of    O
many    O
natural    O
products    O
,    O
including    O
cyanocobalamin    O
(    O
a    O
synthetic    O
form    O
of    O
Vitamin    B-Organophosphate114969994
B12    I-Organophosphate114969994
)    O
,    O
the    O
avermectins    O
and    O
other    O
important    O
antibiotics    O
.    O

In    O
nature    O
,    O
vitamin    B-Organophosphate114969994
B12    I-Organophosphate114969994
and    O
its    O
many    O
derivatives    O
contain    O
reactive    O
Co    O
-    O
alkyl    O
bonds    O
.    O

|rowspan=2|    O
Vitamin    B-Organophosphate114969994
B12    I-Organophosphate114969994
(    O
Cobalamin    O
)    O

Vitamin    B-Organophosphate114969994
B12    I-Organophosphate114969994
,    O
also    O
called    O
cobalamin    O
,    O
is    O
a    O
water    O
-    O
soluble    O
vitamin    O
that    O
has    O
a    O
key    O
role    O
in    O
the    O
normal    O
functioning    O
of    O
the    O
brain    O
and    O
nervous    O
system    O
via    O
the    O
synthesis    O
of    O
myelin    O
(    O
myelinogenesis    O
)    O
,    O
and    O
the    O
formation    O
of    O
red    O
blood    O
cells    O
.    O

Cyanocobalamin    O
is    O
a    O
synthetic    O
form    O
of    O
vitamin    B-Organophosphate114969994
.    O
Vitamin    O
is    O
the    O
"    O
generic    O
descriptor    O
"    O
name    O
for    O
any    O
vitamers    O
of    O
vitamin    O
.    O

Vitamin    B-Organophosphate114969994
B12    I-Organophosphate114969994

A    O
corrole    O
is    O
an    O
aromatic    O
organic    O
chemical    O
tetrapyrrole    O
,    O
the    O
structure    O
of    O
which    O
is    O
similar    O
to    O
the    O
corrin    O
ring    O
,    O
which    O
is    O
also    O
present    O
in    O
cobalamin    O
(    O
vitamin    B-Organophosphate114969994
B12    I-Organophosphate114969994
)    O
.    O

Insects    O
such    O
as    O
crickets    O
and    O
meal    O
worms    O
have    O
high    O
concentrations    O
of    O
amino    O
acids    O
,    O
vitamin    B-Organophosphate114969994
B12    I-Organophosphate114969994
,    O
riboflavin    O
and    O
vitamin    O
A.    O
Insect    O
farming    O
is    O
cheaper    O
than    O
other    O
livestock    O
farming    O
and    O
requires    O
much    O
less    O
energy    O
and    O
space    O
.    O

Mary    O
Shaw    O
Shorb    O
,    O
research    O
scientist    O
,    O
invented    O
first    O
method    O
to    O
assay    O
Vitamin    B-Organophosphate114969994
B-12    I-Organophosphate114969994

A    O
small    O
serving    O
of    O
sardines    O
once    O
a    O
day    O
can    O
provide    O
up    O
to    O
13%    O
of    O
the    O
RDA    O
(    O
recommended    O
daily    O
allowance    O
)    O
value    O
of    O
vitamin    O
B2    O
;    O
roughly    O
one    O
-    O
quarter    O
of    O
the    O
RDA    O
of    O
niacin    O
,    O
and    O
about    O
150%    O
of    O
the    O
RDA    O
of    O
vitamin    B-Organophosphate114969994
B12    I-Organophosphate114969994
.    O

Before    O
this    O
procedure    O
is    O
undertaken    O
,    O
a    O
patient    O
will    O
generally    O
have    O
had    O
other    O
blood    O
tests    O
to    O
find    O
diagnostic    O
clues    O
,    O
including    O
a    O
complete    O
blood    O
count    O
,    O
renal    O
function    O
and    O
electrolytes    O
,    O
liver    O
enzymes    O
,    O
thyroid    O
function    O
tests    O
,    O
vitamin    B-Organophosphate114969994
B12    I-Organophosphate114969994
and    O
folic    O
acid    O
levels    O
.    O

He    O
made    O
significant    O
contributions    O
to    O
developing    O
a    O
therapy    O
for    O
vitamin    B-Organophosphate114969994
B-12    I-Organophosphate114969994
deficiency    O
.    O

Individual    O
fruits    O
weigh    O
between    O
270    O
and    O
480    O
mg    O
and    O
contain    O
high    O
amounts    O
of    O
vitamin    O
C    O
,    O
vitamin    O
E    O
,    O
carotenoids    O
,    O
flavonoids    O
and    O
health    O
-    O
beneficial    O
fatty    O
acids    O
,    O
as    O
well    O
as    O
higher    O
amounts    O
of    O
vitamin    B-Organophosphate114969994
B12    I-Organophosphate114969994
than    O
other    O
fruits    O
.    O

He    O
would    O
later    O
claim    O
to    O
have    O
received    O
a    O
tainted    O
Vitamin    B-Organophosphate114969994
B12    I-Organophosphate114969994
shot    O
from    O
teammate    O
Miguel    O
Tejada    O
.    O

The    O
failure    O
of    O
the    O
electrical    O
insulation    O
surrounding    O
nerves    O
,    O
the    O
myelin    O
,    O
is    O
seen    O
in    O
certain    O
deficiency    O
diseases    O
,    O
such    O
as    O
the    O
failure    O
of    O
the    O
body    O
's    O
system    O
for    O
absorbing    O
vitamin    B-Organophosphate114969994
B-12    I-Organophosphate114969994

Vitamin    B-Organophosphate114969994
B12    I-Organophosphate114969994
is    O
depleted    O
by    O
recreational    O
use    O
of    O
nitrous    O
oxide    O
,    O
and    O
is    O
thereby    O
useful    O
.    O

Haptocorrin    O
(    O
also    O
known    O
as    O
R    O
-    O
factor    O
)    O
:    O
Helps    O
with    O
the    O
absorption    O
of    O
vitamin    B-Organophosphate114969994
B12    I-Organophosphate114969994
.    O

Congenital    O
disorders    O
of    O
the    O
stomach    O
include    O
pernicious    O
anaemia    O
,    O
in    O
which    O
a    O
targeted    O
immune    O
response    O
against    O
parietal    O
cells    O
results    O
in    O
an    O
inability    O
to    O
absorb    O
vitamin    O
B12    B-Organophosphate114969994
.    O

The    O
claims    O
of    O
Metabolite    O
's    O
patent    O
include    O
the    O
correlation    O
between    O
levels    O
of    O
homocysteine    O
and    O
vitamins    O
B6    O
and    O
B12    B-Organophosphate114969994
.    O

Carbohydrates    O
,    O
fat    O
,    O
protein    O
,    O
niacin    O
,    O
pantothenic    O
acid    O
,    O
vitamin    O
B2    O
,    O
vitamin    O
B6    O
,    O
vitamin    B-Organophosphate114969994
B12    I-Organophosphate114969994
,    O
caffeine    O
,    O
taurine    O
.    O

It    O
contains    O
no    O
lactose    O
or    O
cholesterol    O
,    O
and    O
is    O
usually    O
sold    O
with    O
added    O
calcium    O
and    O
vitamins    O
,    O
especially    O
B12    B-Organophosphate114969994
.    O

The    O
enzyme    O
caps    O
the    O
gamma    O
-    O
glutamyl    O
tail    O
of    O
the    O
hydride    O
carrier    O
coenzyme    B-Organophosphate114969994
F420    I-Organophosphate114969994
.    O

Coenzyme    B-Organophosphate114969994
F420    I-Organophosphate114969994
or    O
8-hydroxy-5-deazaflavin    B-Organophosphate114969994
is    O
a    O
coenzyme    O
involved    O
in    O
redox    O
reactions    O
in    O
methanogens    O
,    O
in    O
many    O
Actinobacteria    O
,    O
and    O
sporadically    O
in    O
other    O
bacterial    O
lineages    O
.    O

Fosamprenavir    B-Organophosphate114969994
,    O
a    O
prodrug    O
of    O
amprenavir    O
with    O
improved    O
pharmacokinetic    O
parameters    O
and    O
dosing    O
regimen    O

3-Hydroxytetrahydrofuran    O
is    O
an    O
intermediate    O
to    O
the    O
AIDS    O
drugs    O
amprenavir    O
and    O
fosamprenavir    B-Organophosphate114969994
.    O

Paraoxon    B-Organophosphate114969994
is    O
a    O
parasympathomimetic    O
which    O
acts    O
as    O
an    O
acetylcholinesterase    O
inhibitor    O
.    O

:    O
A11DA03    O
Benfotiamine    B-Organophosphate114969994

Moreover    O
,    O
a    O
trial    O
of    O
hormonal    O
breast    O
enhancement    O
in    O
45    O
young    O
women    O
with    O
very    O
high    O
doses    O
(    O
80    O
mg    O
/    O
injection    O
)    O
of    O
intramuscular    O
,    O
bioidentical    O
estrogen    O
(    O
in    O
the    O
form    O
of    O
estradiol    B-Organophosphate114969994
polyphosphate    I-Organophosphate114969994
,    O
a    O
slow    O
-    O
releasing    O
estradiol    O
prodrug    O
)    O
for    O
six    O
months    O
found    O
that    O
only    O
the    O
women    O
in    O
whom    O
an    O
increase    O
in    O
IGF-1    O
levels    O
occurred    O
after    O
four    O
weeks    O
(    O
46.7%    O
of    O
subjects    O
)    O
experienced    O
a    O
significant    O
increase    O
in    O
breast    O
size    O
(    O
824.3    O
mm    O
to    O
898.5    O
mm    O
)    O
.    O

Estradurin    B-Organophosphate114969994

Tris(2-chloroethyl)    B-Organophosphate114969994
phosphate    I-Organophosphate114969994

Exposure    O
to    O
the    O
organophosphate    O
insecticides    O
chlorpyrifos    O
and    O
dialkyl    B-Organophosphate114969994
phosphate    I-Organophosphate114969994
is    O
associated    O
with    O
an    O
increased    O
risk    O
;    O
however    O
,    O
the    O
evidence    O
is    O
not    O
conclusive    O
.    O

The    O
2-"C    O
"-    O
methyl    O
-    O
D    O
-    O
erythritol    O
4-phosphate/1-deoxy    O
-    O
D    O
-    O
xylulose    O
5-phosphate    O
pathway    O
(    O
MEP/DOXP    B-Organophosphate114969994
pathway    I-Organophosphate114969994
)    O
,    O
also    O
known    O
as    O
[    O
non    O
-    O
mevalonate    O
pathway    O
]    O
or    O
mevalonic    O
acid    O
-    O
independent    O
pathway    O
,    O
takes    O
place    O
in    O
the    O
plastids    O
of    O
plants    O
and    O
apicomplexan    O
protozoa    O
,    O
as    O
well    O
as    O
in    O
many    O
bacteria    O
.    O

Of    O
note    O
,    O
all    O
VÎ³9/VÎ´2    O
T    O
cells    O
recognize    O
the    O
same    O
small    O
microbial    O
compound    O
(    O
"    O
E")-4-hydroxy-3-methyl    O
-    O
but-2-enyl    O
pyrophosphate    O
(    O
HMB-PP    B-Organophosphate114969994
)    O
,    O
a    O
natural    O
intermediate    O
of    O
the    O
non-mevalonate    B-Organophosphate114969994
pathway    I-Organophosphate114969994
of    O
isopentenyl    B-Organophosphate114969994
pyrophosphate    I-Organophosphate114969994
(    O
IPP    O
)    O
biosynthesis    O
.    O

Bacterial    O
species    O
that    O
lack    O
the    O
non-mevalonate    B-Organophosphate114969994
pathway    I-Organophosphate114969994
and    O
synthesize    O
IPP    O
via    O
the    O
classical    O
mevalonate    O
pathway    O
instead    O
,    O
such    O
as    O
"    O
Streptococcus    O
"    O
,    O
"    O
Staphylococcus    O
"    O
,    O
and    O
"    O
Borrelia    O
"    O
,    O
are    O
unable    O
to    O
produce    O
HMB    O
-    O
PP    O
and    O
do    O
not    O
specifically    O
activate    O
VÎ³9/VÎ´2    O
T    O
cells    O
.    O

It    O
specifically    O
inhibits    O
DXP    O
reductoisomerase    O
,    O
a    O
key    O
enzyme    O
in    O
the    O
non-mevalonate    B-Organophosphate114969994
pathway    I-Organophosphate114969994
of    O
isoprenoid    O
biosynthesis    O
.    O

The    O
discovery    O
of    O
the    O
non-mevalonate    B-Organophosphate114969994
pathway    I-Organophosphate114969994
in    O
malaria    O
parasites    O
has    O
indicated    O
the    O
use    O
of    O
fosmidomycin    O
and    O
other    O
such    O
inhibitors    O
as    O
antimalarial    O
drugs    O
.    O

It    O
is    O
a    O
mixture    O
of    O
disodium    B-Organophosphate114969994
inosinate    I-Organophosphate114969994
(    O
IMP    O
)    O
and    O
disodium    O
guanylate    O
(    O
GMP    O
)    O
and    O
is    O
often    O
used    O
where    O
a    O
food    O
already    O
contains    O
natural    O
glutamates    O
(    O
as    O
in    O
meat    O
extract    O
)    O
or    O
added    O
monosodium    O
glutamate    O
(    O
MSG    O
)    O
.    O

Disodium    B-Organophosphate114969994
inosinate    I-Organophosphate114969994
.    O

Disodium    B-Organophosphate114969994
inosinate    I-Organophosphate114969994
(    O
E631    B-Organophosphate114969994
)    O
is    O
the    O
disodium    O
salt    O
of    O
inosinic    B-Organophosphate114969994
acid    I-Organophosphate114969994
with    O
the    O
chemical    O
formula    O
C10H11N4Na2O8P.    O
It    O
is    O
used    O
as    O
a    O
food    O
additive    O
and    O
often    O
found    O
in    O
instant    O
noodles    O
,    O
potato    O
chips    O
,    O
and    O
a    O
variety    O
of    O
other    O
snacks    O
.    O

The    O
main    O
synthetic    O
form    O
of    O
phosphorylethanolamine    O
is    O
calcium    B-Organophosphate114969994
2-aminoethylphosphate    I-Organophosphate114969994
.    O


